var title_f15_54_16224="Mgmt algorithm ABRS";
var content_f15_54_16224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Algorithm for the management of acute bacterial rhinosinusitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 604px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for the management of acute bacterial rhinosinusitis.",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     From: Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72. By permission of the Infectious Diseases Society of America. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16224=[""].join("\n");
var outline_f15_54_16224=null;
var title_f15_54_16225="Calculator: Mangled Extremity Severity Score (MESS)";
var content_f15_54_16225=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MESS_form\" name=\"MESS_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Mangled Extremity Severity Score (MESS)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Patient age",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 30 years old (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         30-50 years old (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than 50 years old (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Extremity injury type",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Low energy wounds such as stab, civilian gunshot or simple fracture (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Medium energy wounds with dislocations, multiple or open fractures (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High energy wounds such as crush, close-range shotgun or military gunshot wound (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Very high energy wounds such as above, but with gross contamination or soft tissue avulsion (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Ischemia of wounded limb",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Reduced pulse but normal perfusion, less than 6 hours (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Reduced pulse but normal perfusion, more than 6 hours (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No pulse with poor capillary refill and parasthesias for less than 6 hour (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No pulse with poor capillary refill and parasthesias for more than 6 hour (4 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Cool, numb extremity for less than 6 hours (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Cool, numb extremity for more than 6 hours (6 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Hypotension and Shock",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Systolic BP greater than 90 mm Hg (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Transient hypotension (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"MESS_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Persistent hypotension (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        MESS Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         7-14 Points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Amputation will likely be required",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         0-6 Points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Limb will likely be salvaged",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div class=\"references\">",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Johansen K, Daines M, Howey T, et. al. Objective criteria accurately predict amputation following lower extremity trauma.",
"       <i>",
"        J Trauma",
"       </i>",
"       . 1990 May;30(5):568-72; discussion 572-3.",
"      </span>",
"     </li>",
"    </ol>",
"   </div>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"MESS_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16225=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function MESS_fx() {",
"with(document.MESS_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[0].checked){",
"Score = Score + 1;",
"}",
"if (cc2[1].checked){",
"Score = Score + 2;",
"}",
"if (cc2[2].checked){",
"Score = Score + 3;",
"}",
"if (cc2[3].checked){",
"Score = Score + 4;",
"}",
"if (cc3[0].checked){",
"Score = Score + 1;",
"}",
"if (cc3[1].checked){",
"Score = Score + 2;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 4;",
"}",
"if (cc3[4].checked){",
"Score = Score + 3;",
"}",
"if (cc3[5].checked){",
"Score = Score + 6;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 7) && (Score <= 14)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 0) && (Score <= 6)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f15_54_16225=null;
var title_f15_54_16226="Medullary sponge kidney CT";
var content_f15_54_16226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcifications in medullary sponge kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAVYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5jNFKaO9ACUUoGaSgAoFLR39qACgUfjRQAd6BRS0AIP1pR0oAp2OM0ANpcVPZWlzfSmKyt5biQDJWNCxA9/Sus0X4beKNXtluLfTwkDDcGlcKcZxnHWgDjMUuK9jsfgPrjLFJd3ETRuwXEKtkH3JA4rrR+z9psVuN19cPOhJkJfgj0Ax1570AfN3A5pMjH3h+dfX+nfBLwpBHbyyQwSwhlQmSQkMxGeTx3p8HgTwHYyxTXCaaWMrQzoAMoQrcAZ46fmKAPj9ULk7Edsf3VJpTG4AJRwPXaa+m4vFfw98OxwRxKZyttIjmGFSSc9efb615hqvjyxeORNO0lRIqIiSPjA29Tj3oA8xYFThlZT6EEU3K+tdXJ4o1GRy7pA+ZfM+eJSfZenT2+lS6V4qubElzY6dMGDqVe3XgEYOP8KAOQyCcAijFdUdWSS02TaPaNGFXkLjoc5yOcmrGmL4Y1CcLe232DM65IZigQg55z29O9AHG44oxXsNj8KtK1WwtrjS9TlYz+aM+ajgFPYDNc/qvwt1qxjMkc9vMvlRyBcMrHecY6du9AHn2OeKSuiv/AAb4gsTKJ9KnJify2EWJCGxnoOelYBG3G7K+m4YzQAylxTiCKT60AN7UUuKCKAEooooAKSlo9f8AGgBKKXjPSkoAKKKDQAUUUUAH4UUUUAOpDSnrSUAFFFFAB+NFFFABS0Yrb8M+F9W8S3Aj0q1aSMMFedhiOPPct/hQBiYq7pmlX+qTCLTbO4upD2iQnp1r2/w18JdG0nULWbxDcjVItxDoAUiQ56kA5I/GvTre20/TLL/iWSR7LVmaARKI1CHnZkDpx1oA8S8M/BPVb2aP+27pbOKXAjFviRi5PQnoMV6rpPwO8P6fZW88tqbiW3mIuWuZMlxjAOBwPXFa+rfErwrY2k/nXcHnLGrC0hO5hJ1Izj864rV/jjCLZm0qzLXG4bkm+UMCvJGc9/5UAeg6XpGgaIhEflhWVkV+FwOuG9eal1Dx94X8N29rLcyJEdq70VMu3boP5V8q674m1TWJHF9cyGNiSsQb5VGc4ArHkmkkGCWb5QPm5oA+gL/9oErcywWGlhoN2FmlPLrk9u3Y1yPiL4qeJNVmjaKaO1tipVhEPmb1Oe/FeUxnByBkjg1sRvttgF2kEcgjpzQB2LeMb2SxkhlupWDbQqo3CkdcDt+PNcqurKJ5C671lfe5cnOSD+vPNZ1wCsIkyVbO3YB2/wAKp7WuJmLPsUnJJFADbuQS3IEZ46dMVK3yIqxqNxGDnt64qIQqJNqYOB1xnNSopcjadoY457YoAfaQG4YgsFIbIz34JP8AKr+h6dFNI005Bhi3NgHG4joPcZ6+1VYJ4V80MCxdcbAMjjNTXMltbacGgdy8rA+UTwnOf8mgCK5vPLd1TCDhVVBnCqTjn6VDcyLcrjyUWQvuBQYB/Cq+HnkG0M5JOQOTTI3eFwVGGXB9uD3oAuWl3cac0c9nLJDMj7t6MRtPpj3rqNH+KPiLTWfe9teBohEPPTkAeh9a5u6u7WXTIR5ZF6Dh2HQjPH447VkuCTyMZ6AUAe72Hxe0a5nSTUrSS1dLhfm27gVKEEnHp/hXS6TpHhjxNb2ksiWt4SJ3YMgJQt2HsDXzHtI5x061b0zU77S51msLiSB85O1iAe3I70Ae0eJPgraSs8mjO9oy2kdwyK/mJuOcjn12/hXn/iT4WeJNFieYQJexKwUiBsuMjIyvX8q3/C3xavrNzFqUYkDRLGJkJ3fKxIz7HJ/OvW9E8eaR4qW4Nu0DTzSKBG68oFHUD8+aAPkyWJ4pDHMjRyDqrDBH4UwivrfWPBuia3Yrp5t4biVpJdzuvzBiTgBuoI+teXeJvgndQQSS6FdeZJFD50kFwwxjdghWA7ehoA8YxRWlrmi6jod81prFnNZ3C/wyDg9+GHB/Cs4jFADaSndvakxxQAlFKRzSUABoPWiigAxSxgMdrHaP7x7Gko7UAJRQelFADvWkpe1FACUUtGKACpba3mup44LaGWadzhI4kLMx9gOtX/DWh3viPWIdN0xA08p+8xwqAclmPYV9B+GPC9j8PJYII4477V7hMtelcdslUz90D9aAOU+H/wAIoXje88XPiZF3DS1bay8cNIc/+Ojn1xXo41hIdNtdI021itWgyI5oowsK4GQp9enJJzVHVNTE9pc6zqFwLaeEBRATiRl/iAHdTzgfjXn+teLLi5iSwtWMOiElhD1dHPcn09hQB2A1S10e9urm7n/tOSdCsgLHbEwOQuAOh/8A115r4v8AEGr6pcSbJpYLcsAsMZwpxnrjryf1pMtJErxTFJIcAZPMnPJx3PtVqQx3MyQXiiHz2DAKOY2GOo9D1/GgDgVjklcFATISc4HNShZdvOQFOPmHFdrZRol5C3lxrJI3l7mYFcZ/z9Kp3QhYu7wFMYZAOfoCPw/KgDnU024kgWRYnZDxuxxnsCe2a0HsFaygmiQhmBViQThh2NdWLiC3uDLEHk0yfZ58C4+UkDds+uK6hNK01yjaeDPYEmSQKMsCOM470AeKeTjp164zUYYgEg8npjNeha54Vt1ia4sLj92qrnI6g989hxXn+qywxXDRW7bwrctQBHPcEtneTnr9areawbqcEdqgJJPUmgHFAF+GVUOQQG/z+dIrF9q7jgGq6oWQt2FSLbyMARnbuwW7A0AIWUEkcEjsenNKd8i53enU9KgfCnAO4/pTGO7qeKANjTVWO5V3uY0jDEH5uRx/Ktq18NXF8pa3kt5Ikt3meWN8qgU9M+vQY964zipY55oonjimkjjkG10RiAwznn8h+VAHTNo9ha3FxDfahbrLFtACvkMT97Hpj3rRki0WG0gWGOJnzKGlWUMSdo2rj1zjp6nmuEwMdKOM8cUAdYNGL6Ub10FtbiIsZZG4Yg8gfnjFYDi3MzgTDZ0DFTzj/Gqpll8sRmWQxjkIWyo/D8BUfHegC15YA+WRGznvUttLNC4a2maKUDO9G2n8DVDH4U5GZSCpwfagD2XwN8SbjMWl6yi3CzyjdcFtrA544HPTHPtXtWj6zYXhew0zUYLwgO1ycgtgYIU/984x9etfHVu5eTcj7WGD9Per9nql1p9/9q025ltrlWPzoeSff9fzoA+stX0LSvENiIbqG1mt5JS720xzsUcAKw5XPSvEvHfwbvNOa5uPDYubiKHJfT7hc3KD/YI/1h5zgDOO3et34e/Eq3v1t9N1zdbXyxsqXnG1xnIXnpxxXtGpywTQvczA3UkbRiCeNjt5VeQfyP40AfDs0TxSPHKjxyIdrowIZT6EdjURr6l+IfgKy8bQvdG4hg8QqfLjuUTCTc8LMOgHX5uufavmzXtG1DQdUuNN1e1e1vYG2vHIP1HqD6igDMopTSUAJRS0lABQOlFFAB9OaKPxooAWlooxQAd62PC/h3UPEupCz01AW6vI5wsY9Sf5Cq+haRea3qUVjp0TSTycnA4Re7E9hXsmlaG3h60Froxm3XACrK8ZO6Q9Scfl14oAVLzSvCmi2mk6fpsrSSkiedTiRm6MWYc/QDAAzWtr93L4VlOo3V2uqLewo0O8g7Mev8h0/Gm6ppcXhu1/tG+uxLNIVRwAHKyeuew46fWvNrvVZp9TeeYmaOXKmNRkLnpjPAoAut4ivr3UZ7yYxutwPLCMM4Un7vPT8KoWwikuNvzqyBvKDdQRzgn096hLpvR4o8PGPmwp59/rUipGCHUMJVUswOSGB7j3oAtWUcZYQM27edykMOPcelOv5JrV7m0uI98mVZJSeAOevqTx+tU4Y7eS983cY5Ew+OuSPpWkthd3mnT6lD++RDlmZgPc5/T86AK1tMpQQzyyMJH/AHbZHyN6evJ/KtKF1u7OXT5Ej85FZo+eNmegJ/CqJRofmeFihUsyqv3AeSRT47VPJWRmaVVHysvUZ6Z/z2oAmW3kGoWtmH8iMlcmVcdMc5rX0++k03U/KX90kEjZOMFlPb05rP1EBirRh7iPywVbH3WGAPqPU+w4qj4l1/7HpdvFCyteSDMiuuQv9aANbx3dNp3htXtVBS/Ty2bbhos8lffoK8irVn1m6uUMd3I0kWchT/Cfas50IGR9zPWgCI9TRS0YoA3/AAfo8+uX5s7bHmMvJP8ACPWk8UXdokp0vRnLaZA+7zT96Z+5J9B0A9queFrl9I0XV9RiYR3DQtbxMDhhvUg4/OuWA2jAHFADcUU7FGKAG/gaKdijHFADaWlxRigBtGOKdijHFADaT/P1p2KMUAIpIOR1rU0lLe7uQkrmOYsAg7PweM9jnH51mYp8LGKaOQdUcMPwOaAO+8P6LpuprNBqcwg8q3kZAGwzv1A9CPf0rpvBvxDufDLTaFqEkcukvJEguNm5otpAOB/ukjPoorD0zRLa80+HWGkEtsLfc8aj59+OBweOa5jWFaUyXHkFIiAqqehXHX+VAH1Y1r5EiaroWLqzS8IjUEkTZXG5j1OA2cVQ8R+ENJ+IXhaCLVJ0tNRt7Z2guAozbSA/dPdos9snrng15D8HfiTeaDf22m39wP7Ikud+985hYoVzn0Py/lXst3Db2t/Bqlmz3MDW0pTyG++d3UHoVx1oA+SvE2gal4a1ifS9btHtL+HBeJ/QjIYEcEH1FZFfYvxK8K23xR0F4LCOCLxBZxRyWUsnysxIJeEt/dbJIz0I+tfIl/Zz2N3Pa3kLwXMDmOWJ1wyMDyDQBUoPWlNJigBKKXFJQAf54oo70UAOp6IzuqIpZ2OFUDkk9AKaK9H+EfhS41a9XU/ISRElEVujpuDP1Jx7AYHufagDvfhH8OtRt76BRAY9QOJnnEvysP7nHYd/WvfRpOl+GtKlhuTCBOGlcSuBsk65U+mc1s+D9EsfDehDCCDf+/lMnBVj169q8Z+PXiyC509YbcRG7jJAdG4dM9Md6APIfiHffa9fvHtpT5SsoaOFsjOMk/r/ACrm7B4nu1Vp0t3J+9IuVzjjA9af9umFzLISwnICEleHH+eKhyrRt58K/Ix3KCR+tAFt1ZEn3kA4Dghcg5P9aWyv47OSMyWsc8LnDo4xtP8AdHtUEF0TKkVyziBlO/byxPPX9PzpZGlFuUkiDRLg7wO/YfT39aANqxRJVlX7O6o74Vk5bI7DFUrWW40e8mMQeS227XDAgMp+UnH1qxpetLaSA28rIrsd0bAHI6ckCtq/v4tQjVYnjWFlywkGCuOuD3PPvQBk22qmz1KT7JCJbWSLYAwJyPX8D0FWtMgni123kMJ/0gmJ0KZD+w/z0qpI0sNzLahl3oF+UHhlP17/AE4rd07xPdC+SEwwKijCuV5iyMHGefpQBdi+02t7LYeR5yTA7FZeDjPy57V5F4kna51q5d0Ee1/LCAY2gcYrtJ/EFxBqRVXZWhBw578k5+vX86ksNO0bxTe241J1sJLlgWuoz79CCcAn1oA8zxUtoyeZtlGUPWvQfGnwr1zQ7lrjTrR9S0V32Q3cHzfgw/PkccGuMuNJuLOfy7qCSJ+u1gRmgBlxpgEPnQyqynBx35qtHbDI8x1C1cu9yReWQSBgZ6gVn4JIJPAoA39G0xtXEljDeRQs6lkEp+UsoJA9s4xn3rI1TTrvSbtrbUraS2nAB2uvUEZBB7gipbVmjkSSJiHVuDnFfU/w5tbfXdEtbm+trK5dbSOLE0ayYOAcLn60AfJGU6k/oaUFdv3vyr77tPA2lLfRj+ytNNtuEgkFshDMPbHXk8dODQPh1oX2s3U2k2RnUuE2WyYwe+3px9KAPgU7QeTj8KTK9iPwr70Pws8ORRhYdIs5J/LVXeSEZcAnv0B/Wp4PAGkwPc/ZtG01TJIj82qjpgY+mM/WgD4GVC+NiO3+6hNTRWV1MT5VpcydvliJr7cv/AiLbxrp9nBb2sHm7jCgDuTnPOOAa57TNJnVIhZyARC0jjJkXGSrZOD3PNAHyTJpOoxorSadfKrNsUtAwy3p9apshVtrI4f+6UIP5V9y3cF9PJKGVp1gvo22OOJBt+97H1rAtbS1ZIp7/SIPtaSzypI8fJL8gdO3146UAfHz2V0gUvaXIDDcpMR5B7ioSpBOVceuVPH19K+w7rRtS1KB7sQACG1X93jHzBgSOB8vr7Vbn8F3F0tw5aEG91CNiRCCdqgH6YP4UAfGC4chVy7HgBVJzW9ZeDPEt6Fa08P6pKpAIYW5AwTwSew4Nfa2jeGLTT3s5n0uzae3E8pdLZcgdgCABzyM4z/OuvjDz6O0zKsLz24wjZIUc4DA9vm5FAHxhDpPiDwp4dlsLjTmkm8/Mqsdyxbhnisl9Ujm8NvbXNkWY8LMcD7ue/419KeNbC9XVL2JEit1aWECRed4K46Hp/kV87eItHubWNobx/8ARFEh+VcZ2uR90duBx70AeeEkHKj5evpXvvwC8b3FxZ/8Ixc20M5jSQQzynJVWJ459BwBXhc8TOjyKP3ajjtT9F1CbS9St7q3llieJwxMbFTjPINAH1NPf3XhzWpIrKJXR4rcTTyZAbaQOvbg/pXCftBeFYNZtpPGWhWjfaIyF1YRJ8jDos49+zfXPrXrPhCG18aaIbmRki89Q5mL5LIpU4I6dSPyrVu7S40qeSxjtjd6TNkTtJEFjkjIwYyvRgQTQB8IMuDTDXZ/FDwdL4K8US2ALSWEy/aLKYjG+I9uvVTlT7rXHGgBtJ2paSgA70UGigC5ptnJqGoW9pADvmcLwM4Hc/lX2d8A/D9rb6TFeQ71jt91vHGybTkYy/4188fBXw82o6mLhHQ3Msgt4Is5Yrn52A/DFfZ9oi6VYQ2rRbkijwr7fzH1oA5D4u+Ov+EaFtZTWjyW1whaaTjawxwvPTJ718la/qb3961xEgEC5EcRPEak5xn6k123xU8anVNZv4Ud5oGfbJFKPun2HbHvXmbFVYSKAFJ+ZBzs/wARQBYju5Aj7920kHjr/wDrqRVVmE8AWSNPv4BBUn2qpMHUIxJCYwHA4Az1xSIZYpDGJShkBDcYDD3oAuiIvNGlu+1tpIYDB288c1aiZI/MgkLQs21kBwMjPXJ6/wAqyop45mBZzGycL8vBHPSrD3TSoqsqyBCDkqMgCgCxKPs0sjqivGzEkH6df/rUxZhAuYGQ+YrKUflUJ9+3H86lvG8qUBRuDIDJkZ6nP8qz53QyMIHxEDwSBn3+tAGohW4tRDcK32tAqxylsbvb6e9QRSeY7JdkZ42SAc8cYH5VnExyABHaNiOQen51Xmv5bbAIzLweaAN3UEdLZI3gzMwJ56kf4/4UaP4Z1bVrS4mitpRFCucMpG4eqjuMVjWmulNQju72AzlW3bFbaO/T86948J/GTSdRsks9StVtbrHlhnHylT1we1AHnXg/4k634bhWxaZ73TQc+RIeV46A/wCepra8UfELRtcsra6m0Vk1NcxlcgKq46571yXj+y0+DxJcy6Q2+wmJkG3+Eknj2HtXOgR/Z3LEiZW4XHBFAEN5cNK7FslWYkgDGKhjTDcHI+vWlQM8m3uTjGOpruNG8O3MVmst7ZkI8ZIcrleWABP/ANagDi3nhaFflKsDyw6Eelex/B3xIEjSGJJQI1WIKG4yABj2HFcZq/gnypliilYOZgjOOQcj07Guw8EaCvhaaR53aVJWeJriPPBAHIHpmgD6v0DVbW/toI4iwk8rftbqOcH/APXWxtBwSASO9fOcc88Okxym7mtSts0jEd1L4+6Oce31rrbX4lXem6ybbUEW7gHlLJJCpAUtgcfSgD2Dg80VxWlfETSdT1OO1t2xGzyJ5rsAPlAOfpWhD440Ce5SCK/Qs0Rm3YwoUNtOT6+1AHSAcYrOm063DFhbrt6bE4GMD8jwPyrHufGVpbtcvKC0MOz/AFWGYBj1Pp9Kx7r4h2c3ltZcwtLJCWYZOVAPT+f1oA6XV1SOL7oD71SPyznoCfm/DNQwabI2otPeRoI0dpI1HO0Nxmuas/FsZsllClkS0M7HPz8HG73/AJ4rrba8tLvTBKLhVtdqOsmeqlR69P8A69AE9paQtHJFC7eWSUkBH3uB09KsQ2MMfmLGpVGkDsCeuP6VFpuow3LskSOnzMPnGPmHUVekG4bd+04zx1oAiWCO3XKBgemQCx5P8hmpVjAA3fMwABY9TiqesHy7KSdGIeEErg4Gfeq2iat9tsXlmwWQtuKKQOBn86AOK+It3BZ3VzuaUytcW5wB8qjvn614L4xvojqICwO7RiYAx8gAnse5x3/rXtPxM1WOUxyM9uLfzUfazfNgdCfT6V4P4i1RWvvOllj3EtshThckA84oA5TUlhS0crbEZt1KZAwBuHX9ea5C6AimcIcc8gGu9V4dWjkJhnkbyQV5wpGcZJ7dx+Vch4h06ey1B45YPKP3tg5AH1oA9p/Zr1pXumsb2ZzHbmSQRZwvKqoJPTjb/KvrC4gt9QsjFKqyQSr09RXwp8I7/wCwa2jShljYsMqMkfKc5/Svr/wBrFvO/wDZ1tFOUjtklE7D5W7Yz680Aec/HHwo/inwreWUMdode0tzd27NJ87R7cyIP94YIHqDXx4cEBl6HkV+i3jIPZLb38PlxgTxiR9mT+PtXxl8d/Cw8P8AjWe8s4WTR9YZ7uzcnIZs/vVHcYYg4PYigDzM0lOI9qbigBMUUUUAfW37OHhOJrhNSJt3WwjWFGjHKyAfNn65zXs3j3U00Hwvf6hIyeVEhPzsQBxkcj6Y/GnfD/RINE8N2cMMSJNLGsszqMF2I715/wDtP6wmn+BobUYknvJ9qx54IA5J9cZBoA+UtXvzqF9LPOiRSSNuJRcDr0xVWOWOOUjyC0OCMrxk4/yacJYX3tIm07QMdMH1qMhVOyOTcpYcd2x6UAPikEasIS5RgQUcZ4xV6G/dkhhNuqyx8hnXLOOwb27VVjZVnYsFikIwqDnn1P8AWnzCYMspkYsFG85ywH+GKAJ1ltpMxSDyJw+QWHB9v8KrxsgAfcqy7/mxwCBTvPDiaF2VowwZUb7wP19apwfMz5KAKThW6fj70AXmunj3kMjxuu10IqpNbKsJMLAjcvGMdRnNRzRt5hGQhYDGTwfX/wDXTzLLESs0YCNjkdOMYoAkcsoijuY0ZpR8j4qxeeDPFDW5vBoGpzWgUOJYYDIuD34r0H9nvwtL4l8Xg3MKz6XafPMsik7W/hwexzzX1tLYT6bpKW+hBVZBtCnGD788cUAfnNc281qxS6guLdl5KywspH1yKjBjYffQ57bhX6Srab4wk9rbySjHmM0YKv7j/CsXVvhz4P1di2o+G9KmdvvN9nCn8xg0AfAFpdSwgIWLQHgr149qtX3OSo/dEgj8q+w9Z/Z/8B3LfaLXSZYJUU4ihnYIx7ZBNfPPxd8JW/g/xTJpVrI0scarOqdwCOB+ff3oA6b4CeALPxDCdT1NdyJKyxIMFj8vGQfevZLHwN9gZbS4nNxE1qyxxEcghudp6Z5qt8E9CTS9JsXVJIfNLy7HBG4t3x6DtXrYiia4V2H72NOB/dB6/nj9KAPJbXwqbVryyc77UPG5DIDKmecE+nHUVK/hC3s4YbvZLG5uJUVWQZXrg/Q9foa9ZMUe8v5alm4LY6j3qC/tYrqJIpThQ27A7nBoA8A1Oe40WFZ7GOK4nayeO4Ln5VJbp3wMf5zXH65C0NxeS3FwkYZoiIg2doIz2/nXrmo2EV/bXkEaxfaLeJhHJu+UnORuHt1/GuE1GyOr292klvFbzqkUrlzg5Cn7pPFAHly6sNMmP3pZXlYhQ2AR0A44znJ4wK131O4g0KCDEGx7VnyAS5JbjJ7Hg8fSqmt6ZDfXg8qBLWSJQSwf5RxnIHYHNTWirBpsgIjDmFkJYkg57A/hQBfto54ZLqSe4uHtWeH7RBbsFmmX/YY5Ue+QfbmrP9pF7xDawFB9olURIcAZTgnJz+PUk/hWe9o1/dzIySQR7Y43ckhocdz/APWqxqNtaukqW+7yYHLSMp5Y5IyD70AZD6tfw2gs4JfNeaBvNCuSUO7rn+n+Nax8a6npEIs7i4aRk8psP0AHr6D2zWT9mskjP2W1lt7mS3ceYWzk5HHpmsfXrJXjd5JNl2xjXaWzgDrkdzmgD07wX8TLm61pYpHIuGuZDGNxHzMp6Hn0x37eteg6D8SGutRvDdweYfsckoP8YxzhfbjnHSvkvT72TTtZinUElJslQ3XnHUfU13vhjX1OpRSyv9ngjtZUxIT8xOfxwTigD6L8R+KLi50e4t2urWBN0AYdWdGAOBz19656XXxpju82oTGFnkjW3j7HHBOD2PPWvIdZ8Twz3TtHMRhoVVlGCduM57YzzxVm01aPUtRWeWfyoVumAUjcHBX5j+g/OgDb1XWDfQW0DRwT3EULy7XGNuT1PqR9K80u5LaXVGZEVpVcb1jOQBtGQD1688+uK6DXfESRww2mmRIsqwMr3RbDcnkr9KzdO1K3t9S82aNDb7YmD7fvnAOW/HNAHW6VpDXgSG6l8iHyQEiChWYZzj2+lUtQ8OxXun3b2cLXL4BVt53ZHG4g9TXYeE7RtRlt7xNyRzTOPMc/MzAE9D0XoMelaS6glvBHFbiK4k8l8xQIQWYHuT6dqAPDbDQ73StXRrmN4YU3u2crngjHr3r6J+F/iI3en6e8Xl29nYRBZvmIAXeCST1OMelcJ4tmEqs0dqRMsvAijILgqQSCfrg/TNU/BsxsdQljKPbWtwGEcEcmCoA7nuvXnvQB9bOkV1AVdVkiccg9CK+bfjV4dGs+GtRs/soGradLcXlq33fkBDOoHvGM577RXvXg3UY9S0OKWEsygsNxUgH5j0PesP4jacHNveC3M0eyWKb5sYDKAfzUMPpQB+fDYIBHQ89Kaa6Lx3oy6D4r1HT4k2WyyGS3+bdmJuVIP0rnTQAh6+lFBooA++PCHjVjuttQiMNvEOJ5MKhT+8D0x/Ovnv45fEa38ceIY7SwieLTNPLxxysOZicBiPb5Rj61yPi7VdQi8zRHubsQgL5kDyHGR0x6D2rmQi8o7OoHcdv88UASuJnL7yJjtGGHG0Dt70yPBkxLn5Rjjj/IqNIXBcqzLtHLZ4xT3IBRZELoME5PJzQAsm3axDIzH16//XqTzJCCGXkIDvHGPr60x1ijcbwxXqMfez/9aljBiuQyyEgjhs5/MUATx7WWRGiRLgsNpJx9f8abbQh5WRvLA5UluucUuwSorQAyE9c/eH+faqjzHzimxcZ5OevtmgCVWEkZR1EiJkdeRz1qFlYxAq/AIwucn/8AVUrIysJNm0Z25PrV/S4Y7zVrWAbR5zhWDHr34P8AntQB6b+z342i8Ja+9rejdY6jhcjgxH+8fbNfXlpd2t7F5lncQ3Ef96Jw4/MV89eF/gbFqOlzPqjCC5AP2dkJwc9Cfb2rZ0L4aeJvh/BNqPhvU1u7g5V7IZEbR8ngN3FAHudFeW6P8W7dPJh8T6beafcSNgOkRZB2JIzuHPfGK9D0rWNO1e0W6029guYGXcHjcHA9/T8aAL+ecd6+TvjFdQ6t8YzEZI1jtniQOvIbG0sD69xive/HHxE0Tw3azxHUbc6lszHFywzjPOOP1rwj4ReFX8Z+Lp9Xvo0+yxF3/dyYbeScH6gkUAfSvheNU0Sx+XGIl6jpxnitYffPy9hz69eP8+tR2tultaQ26FmSNAgLHJIAxzU1ABVa/uoLWMNOepwB3J9qnLqNuTjd0BrmfH13BZaNcTShUk2BY5m6K2ePpQBwfizUlmuLi1soY5Alz5cZhwHJwGPpk8dOleStrCeItcEE926NDGdoH3mVc5Rj2NVvG3ix5dbji+S28q9JMsLYVxtAznsc59hnmq8l3DZS2Wq28MRZ4JVmXGd/OCfqM/j24oAfaw22r3EkMP8AooECSATPhWYkdD/npVS8s4Zm8qznlFvFP5ZG/bvODwT9c8+1XNMstMvLHfKxVzBFIxjfGcHBC9dp6Z4PtWlb6GmsXtylukK6ZFegOd/bb6Z9uc0AQ6fBeXcfkkosc1u2F5yAvb/9VZFuLXRdXnt72SOUTqk0TN+8ABBGD3D8Hjtwa6rSPChje2ntNRlwY5BKJnyX9No+npVXxFoLW+l3M5tUnzDCySk4ZDuIx+QoA5eGVxfCN7iS7SRiFjVthRcjHzUlzpcN8l65mjE0MX7r1UgnOAOKpap5jskLS4i88K7BcFPlPBPBP5Uac9sqbZnbJjkAY5GACeMjt79aAOAdTBOTxlTkd/8AP/1q6nwpcQwJLPOWlYwui/7O7jB9j0rDniEmolUjaGPK/fH3Vx1rvrHw9aro0TCVnUSATRqeXyMjbxyc0AcrJILiRmeZI1I+5jhcfwgfpxTDdzBogMw2+4tnjrjB/SrkWks80ct1avBZgDd5h5IHoR7YqO7KyXiSW8CDDgIFBC7exGf6+lAD7eKF7a1OGLBJNnqTnv6ip7q9+yeIreOdzIFSIDy2BUA7TjGORVa6c2ttHLO0jyjcsEStwvqT6ADp61lW7z31wwMkSyy4LMeMYI6H8aAPobT4vKv7GeXUInaW9JVEbaAm3k8DsCePetuaSG2jhntIkMi28kYj67yDgH3+tY3hnRpYbXTBfXMLIbreJEHzr8nUAfStaa4TT4YIbK6RmWKVWklQBshjwM85oAl1KWO21BzfWPkPsinDnB8sMCPlI75z/OvO9R0qCO7e5nb5Jrh+kpG4YztzwSf9npiu+1K6ee6km+Sby47YndnYEPDL9ecntnPTis3xxpsuoXUU9zaoyJcrGkEQAVlxwx5AB9T9OaAPQPgfr0N/oj6eLtJnt/mQDuCxJI/MV6VcQpcQSQyDKSKVP0Iwa+YPBeuXvh/XLDUI7a3FlFBIJdp+YrvO5QOhY4Br6DHiazu9CTU7CRZLd0VizY+TOOCM8nnoCenegD5L/aP0M2+p2mqxxNHGG/s7LcNKFBKsR244rxRq+vPinpdt4s8F65BaQSXeqswe2mIIBdGzhTxg7cjB7V8iE7gGAxkcUAM4ooNFAHSX6vLqF03mGZVc7mzk4zULCPeRJuPYNnhvrTAfNZypILE8DNG4K3zKAMctjgj3oAk2Kit/rG4x8p/LNPjjklfCklMDlR1/Co1YA5kjXPYjp9TU8sZgT93PlRkbgCc89qAENuWch0cygnnuPwpZmgV1AXzFAwxAxlu+D3xTYLt4vmjTMw7PyR9M1MZIpowVReCQQOntj3oArxyICHUMyxYx83Oeev6VnzTFrku3yknJAFaSiJSd7AoRg7QQf/11QuoULkxt5gPfGMe1AGxazLJZiJjvmcZORnI+nY10nwyghn8U2EU0MJEsgKySfdQgE5/PFcfpixrKBIRGW6Ejv6f/AF629J1W90i+s74wxM8GfKLDI3YIJI/H+VAH3/ZKyW0YckuFAOfpU9eTfDn4x+HtbtYrXUb6GxvVSMbZm27yeOvTOe1eo2t3BdAmCaGUZwDHIGz+VAFXUdJtby3kSeJZCykBnGff+dfLXxz02Hwne2X9nSJbyTRB3SB9oPzdwO9fU2s6jbWWn3Mk13DCEjZizOARgV8Z/GzxZY+JdXi+yAObVfL3+vrn1oA4aLUXudQaWYlnlYZ3c55619k/AGz0218C2radueSRnaSVhyWJ5Gfw4r4qsiJJo1BAJYc/jX2J+znrEMnga10/yykkUkik44Y7uv69aAPXiMjg496KRmCglmAA6kmuR8UeOtF0YGKa+AuGJVFjG7LDHy/XnvQBq+JtShs9Hnd7uK1kaN9nmc5IBHT64r5y+Kvi/UNdkDw3Mdvtt0Sa2Q/K/wA2d361m63rlxeaz/xOPtRt2J8ohzhSSeD+OKjt9JvI5pFv5YoVMStvkXeM9QM/TvQBT8J/CzxB4yuZDNH5Nmk53zS8FSwySB36qce9ejeBfgjJPoF3a+I5ykTmVbV4/wDWKpOAx9iOcVY8NeK9f0GKONIEmhmcMokU7WQ/xqQfYcn0P4exeEtb/wCEh0SDURayWyS/dV+cj1HtQB55c/BbT08Ox2dveyvcwQLGj7QnmMpJ5x65xXF6RaWOhxvZuki3ragjSRO+QQARyepIyDj3r6Qrzr4q+Cxq9q2radKLfULYB9gQbZsEfePXOABn0GKAOEFzbyWum/2rctGLeGeOJlUHAJIycVg6pIsPh+eytZUuJ1tYSbl+j/N0Uds9c+9cHp0mo2viRIbmcyzIzBraX5lx/eBz26kd63PESCfw+yR20rPLGiF43ODt53HPTA9O1AGBObO+v57cRBJJ7xPOf+JBjBx/P8Kr6Gtvp+p29kDHPFIZQs/3m9sZ4rH0+8aLUi0yzK3mpiNeQw7H9K6HSGgOoWqXVsJYszf7WGI68c570Aa11Zm5iuJIrZpLMQQruYBdg3Dr6j3qnrUMmk2mYhJc3ENyiLMDu2HGcY9O1dLYjTnsJrW5vJURbSMIsp6kMOPr35qK80gajq0sVpG1zEt3GrFGwOxO0HnbQBymiaHf3S28kss0k/lyuYpMgALwfbmqnifREsGjRS9tvgWXygPvE+h9PavdtP0K0XT7cyTOnlG6QNJ3wTnn8uKh1vQ4LnRUmkhgcpYIQ/lghfm/M8d+1AHyvcmQTyq+5E3EEN1OOmfektshjLkxBCGzjoM10XjO0i0vxXqEc6F4fPLICMrj/PvWdYzG4kjSaWHyC5JjHVu+M/SgD23wZLZzaBbPptxeXE73AkMqjO047Z/yav8AiW8skn027lUmUM8ZEny7/m5z6kH0qPwxFZWulRLpblLeaFXOBhYzvAJx156dql1S6kt9StlmkW6tYpsJbbdygd2I43Z7mgDor29tLuwkkIEYKQkqhA+6y7h7nHauS8aXNtePjSZmgjaYfeJyHbg5J49OK7EJBcQxzrHalZVAZSOu1uATwcjAH9TXP+O7rRkOzUZFjjkkWVEiULvAI5c9N2aAOC02x1N9HHmS28Yt4JS24/Oo3cnHY84HtXUeEtUu7S3k8PwKHlkgilhN0uVJLZLD6dj2rkoL3Q2lRLK4YDB4u8kKeuVP48Cn6pqr2moadqEk8aGExbjCPMDKGzt4xyQMUAe4+GZNRi1WW11LUbdZxc5dFQZA2c5+g6etfF3iTR5NA17UtInJaSxuZLctjG7axwce4wa+xbm2tbq8stQsUVftLgtEUBJJXJPPQg182fH2yltPijq8kzI63my5RkAAIKgEcY6MCM+1AHnHeilPWigDaVgsYL5wFPfB+tKpw4BXK8H5j19qXzSsKgJkAYyR+lDYYMCFxjccjB7fpQA8j95nypCCceWD1p3nnzNzABtuAP8ACm/vxhEYbeTn/D3psrBV/ew/Njrnt7UAWBdRMT5kTM5x32kUnlRvMPs2ASc5Y4C01CPLdmjRmx94/eA+lJFEJGEaKFJJ3K38zQBJcR+SiYmR3ZeApyQM9Dx1pIgQfJEfyMcnNNiT5xGAVO0kMeh/z0q1Ywi4Egy7YUF1DcnnovvQBWuYh5n+inzFVsDPU+9ILm6RhhwQBtIYdO5qyAsUpBkCN1UqOT/hTfJijwfNBJOGwckHHX6YxQBLarHdyf6UEC8EsB09/wAa2bVvEWkyzS6Rf3SR7yS1vKfm45Pp0rmowsYfzMNkZHPT8KWe7a3Gy3mfy3GXVj09qAL97rmqSI63Go3FxFuIKySE9f1rDuZTKd+SxPUkYJ+tI03Byep7mmoQTzwDxQAsTmN1YcfNkV7d8B/H1loGpC21BysU+5lLMNqkEHJ9DjP6V4mynOAu0DuaaXZCRkk88j6UAfbviH4i6Ze6JdQ2rp+8iYF2cZUf3sdTXiEtvf6lHNe2U6TRYLrLJhQeQSR19+vPNYmnukmi2U9pB5M0ZIaWRtwPoSop9tevdaW1hZWzIcF5Qv8AfBGCpHoP50ATanLdyXMEMl38ikbwwHDH0buOlak97/adha6fdBxGjMzIoxuA6DcexHNZsKtfXTpfLMkcUkasJBvUtnnr+ma0YIbmDU/LSOGRJ5XURSHceOw7ZoA14davYreCzspUEccQeESIfkTnC8+pz+Vd98PfHtzpl9Fo/iFIo7OUqlvLG4xC5P3DnGFA5znI9K8+0py1hdS3toFe0tDtdD1Yv94/7VcpcSLDcSXcUqyYuI2UMSWBPcn09MUAfVUfxA8MvrR0ptUijvN2xVkBUOcZ4J49fyrmfjjd2N5o1roo1Wax1GZjdwPBJtyEGPmOcEEyLx35x0rwjxLeW2p6y17czGCdZHSRUIzgAYyfy/Go/F9smo21hOZ72OG2sllQFuwdcY9wefbFAGeukXem61Fd3M5cB8pdL84JI4z29q2tS8T3ltZvavatdq8bQjaAMYx0PqeMflzWTorvdWV/ZzakfsrSxsoJ6/Nxk1Jdabcy3cUMErC3WSYA+ZudeBx/47QBoaZ4etJdDkuL50guGkV8b/mYBTx7MM1b8O6PEt2v2V42ltmYuWcgHIwDiuZ0TT5GmJ1K6nkhEQMTgEt359wO9ei6StlZsDqKllby0VcjMpI4H1HegCCPSbZ4J/OFq05gyJDJjcwZsYz346+1WvDyXN9qF0xeCC4hmj3JHxlcgYFTjSZrPfJ9ijFyPNWMyNhfXAA7nHH+7VLw+tsviaVlt5PtroZCZThM7eVY/wAqAPRr+yVtMhQQy/amMhQxjemCThj9ev8AjWVc3tzbaLNDfwvHcm0WMFcYkRXAOPzxx61rGS5NqHmc27SzEDzX+4pyQB7c4x7Vl30zTxeTLcRTpDaHLY+6ysDt+nTHpQB4N8WEsU1u6VI5SXlBUk52Lj+IjjOe1cboOmxX17DExJJYkbRgnAzwPwr0Xx/eQX8t2YWTzXlVwJFzjtk+n0rzWL7VpdzDMflkXOzac4GMcenegD3vSNQgtNGitYfJmWS0UO+wq5YN0J6D6d/WtObTlj1Ka5dZp9l0jGGPIKgrn73b6fhXG+D9TM+k+TJND5pt1Hz8bxnOSD/ED+lek3U80sT3S30kb+dE7w7V+fCgbTnt+tAGfaaiGgMdsUjuMyuN4/1ZXHBHbPGPpmvMPiX4iuItUSO9toZmktkIBG0KM9vXPT8a9Z1zUbDTbKO4gt4YJ2ad/NkcfOAOSQPfoK+b/Gt/Jqmqm6cMA0SKewYjPOOw5FAFyG4fUoBlY0jQ5KIecn7ueOPbnmmzuI/D1xHGpSUHjDcJjdk4xwQcfjWfYPMiCPyizM2AVPJ9v89K6/QLWL+zL1beeCG5nhlSVZuEACNkE9c8/jigD1XwB4jk1f4d2N0yp/aFu5tgI8kEJ3J7kj16V5f+0vHNJ4h8P388oka509iXUADcJnyBjr1rq/2eZb260bW9PQRzLbv5yor4bJ46env2qp+1Zp7WieE5WlBDpcoI8fcO4N1/4FQB89nk8UUp60UAbo+4MgkEYIHQ0M0bE749pGMHnkUx9u1QQwI7/j6UoMZfhi/TtigCRfL+R4sht3y+xqSJGOHyhTbscHr19KhCSM25UwTwMd/SkIBLM7EOOCFGehoAlEUJkLyeZsBHTjipIXVnGxDLEoJ2Zxj2ye1NlEqoGYqxfkEnbxjpSShgDJORGin/AFa9/TFAEqxM8LyFAFPzKg7UwQbXDxyLGxGCHP8AUVE7Y3SRuQCR8p6n8Pap1xHEjSQFmPdvTvkelABJ5bSqS+ZeuCvB9ie/1qQ2kiRiZFUIO4O/rzmkiieaUpEisoA+9/U1YFtKb12ik27JEVlIOASO4+uaAK4t2l2wrGVYA4wc7mrOvI+dy5wOp6810EMflvMJ5Y4vLDYHJ8z2X0qD7K7W8pIysq/Ii9c8UAcyOuMVZt4yzBQcsfWo5l2Sso5IPXFaVpB5sWImUybsg98Y54oAW5ifCKwGAvBGME0y4szglSi8gbuxOKtJLNY4RUjkV125ZchQT29KU7ZkeBmCqCH27eh6dfXBNAHrHhuXSkis1tbaVLqd23lTujQgY3gentW1NYww6a0VtcwwSR25d2UEbvmxxjGOR+Ga8p0LVLyyaFbVylvFKTGCOc4/lXU6TeXuvQpDPtjQQMDJGcYy2TjPUevvQAuq3CJdszzO0rvFKHUZ+Yeo7/561tQwrfiG5v8AzIVhuJFk2tgvxxg9RznjNOs7OCXV57axt3a5VU8x5OXwBnIHpU1xrllbakskkT3Ji3qYQMblxgEg/wAXGQaAMrUbbWJYoYorMGE2hkDKefK3dx3Oce/NUvFmjRnD3odIC8IV42GQMd627C/1DxLZyRabC9lHHGY2uJGydgOSB75/QU3UzFY3QsZriG6mkaE+ex+72yB3Ge9AHD3l3ZRLIb6OZGNw+yRR1GBgn0OfWtoan5+jJHHI1xJHYsjjb8oG7GPfg/niuoXw9bOW8uVJ7z7VIZiy5QDaOF7E81UvvC9rNpZjtnlV4rZzIU4DHdwPboc/hQBxJis3kuk8+K0CvHgBiCOemO49K0rO5uEeBTcQTWwuZSrL1bIA57Y44696wvGmhDTLzznd23gAbhjbxn5hVfR9QMV9HBLMm/zCuUHHAIxj86APV/Ccdxf6TJHDaRSl7R26YJQN2yfvZx9enFbX9j2FpG01tJLc33lxqkco4j34+oBI6HtXCeGtSVIJZIr9oJI7V1ESg8ncMn2JFelahfm406We0+zpIFtw4B+8M9fYfyoAz9Xab7Hb29+krXYubgAFhiRVUnJJ9AT+Xeuc8E6hLdoYbWVZJSj9VXd9OTzxx2q54hOpPovn2arerLc3H7reCQQp4Hcc5+teS+GHutK123nu4JIBJHIfmBG4FSP58A9qAPqGxZb3S7iG7ZknjaMRozgqWYdPf2NYusaFf31nbx+TDDAqvE6I21zzw2T1BPbrV6LF3A88MflSztayRkjIDEdDjirLGWzvFj1IPNfyXDxo/JWMFfTv/TvQB4H4v066jv7iHTrNpXRNztwxB989TXJT6TqqW7TtbNIsbYdMZ28A/lyD+NfSt9oEUlgkwBWV4mMpiYHcoPP+Rms7UfCh16wmttDl25MSuSw+RSAfxxg/hQB8/wDh6eZL+HzISzBdibyVA9OnT8a9Y0l7a6jL21+IIjLCzo7FgTjHGc/4fjXJap8PfEmh6rFFKhuIWYhJUHyuuc/Lnlj/APqroNMsJNJkmvd6u7FQ0YG8r7AepoAzvE80VpG0lxdmeMSXBDw5BYNgAZ6jnr7GvNnkSaU/unXKZA9G7j/PrXtWrR215YSxQTeXkyyj7Yig57Aj1P8AhXjeqQ+XcOryuXXCBDgnjnkigDa0ue3tHjAV0kLxmTdgqq45weuc/TtXQQX+n3ayFALiIi4G3OH+4eW4xjnIx79c8ec3F/gPFlwpwSRzx61r+GrloQTC4DEkDaQWGeDx+J5oA93/AGSfCqwwav4kZ3KTObOJGGAQpzu/Gsn9sW3+yweFI1x5bT3TrhemVj4r234JxrH8KPC4QDLWSMxwBlj1Jx3rxb9tFgZfCSg/MPtJI9BhKAPmButFDdaKAOo1m0Njq2o2sqYNtdSxE46FXI5/KqJBYbkU4PQkd67f4x2EGm/FvxPbxHfE135/LfxSKHIz7FiK5CUurKWCgc4CngZ4oAhIckh3JAGAM805VUjldoz0Pel+cIxZgcY+WnCU7CxLBcgEADp2+tAE10iKqnzlkZhnaFwFH+f5VEZD5e1I+CMEOM/j/wDXpYrmLdtjUr1BYDJP40+Z43YCB9pKgZfofxoAeMzEqUjKLjhRgrjr+dPG/wC8++UgHYpILL9acyYuAvnBCNoeVGyDSxWwt4zcOfMViyBw2Cc9j9aAGRzLtaNC4dlGRjLN7H6VM4jkmeK13RlSBIGJw5Hr696aj2qGMeVJHlMGRuTn1Ht/SppluYYnkK/6OzDEnByO2PT6UAMs4rXyJBdCaOVG3IOqMMd/akAk2LJbs5DKcbeQQeoq4dSlNogmMQhUsERk5APXHHf3pkCy3IknikVUQZKIAvU9cdu+aAObvYsTvsDDB5Ddav2aqYEilUCMEnzFbDVej0+4u3acFJNpzyfvKP1/Sql9azNIPsKSvnkhR83vkelAELzssLJET5bAg5/pVUzp3+YZBwDUM6yRZE4ZHPO09qiQd26GgDasblp7sSvIsSk7WfOMA1p2urPYX0MMZW5hjBQuh+8Ccn9T+nvXLTSI5VYk2gAcA9TWrZRw2NxbreO/zEGRU64ODg/hQB60bpr6+Q6cVivlB3So3OwrjafWtCHSIH1sjUUladCN2c5z05/2a53wFp0mteKQ2nwlLKONpCBncRj0HcfXmvebTwRq0t7dyRyJErQIkcs5yx5JI6Z9OvIoA8r1/ULbQi1nbTwNOCyrFHwXOOAT26frXNaLcRx6s7yhZWuI8m2LkMD1ABHvXsdx8DYb6Y3F5dxC4aXexj3YC4HA/Hn8KzdZ+Acy/ZbzTNVE99C+9hKmwccgA89wBzQBjh7W1tUuNSbyAyfKGJIzxgcdeTjJ6cUjNFdWnmjdK5RkAHy7Seje5BzXVWHhdrW3kh1OFEne3RgkuE+YdcZ4JJFcr4h13S9BtXuL1WFyspU2wGAeOAO+Op49KAOE+Il+0rxwXenkyiEhFj54Axv9TXm+lB4dVtjHtdi4ALDgcda9DHi1pdQi1KS0lcDeiWzLu8tT/Dn+VcpqNlbt4kWOHa0E+zKIxxkjpn04oA9B0SGKaIR6hbwmSGJ23g/PIcjkY/LFdX5kOo2Nzc2MxRVSFHgKbWbsFrmPDaw2FxBZXtzHb3kL7EkLcqh5weMcehrs70i1iE99bxMkCBI5I2wsvP3j/hQBi6lBHpen2bXKypZm7MhOTuHy4JyOw/KuU8Y+JdC1XQdPtLNYFms4fLicAbvvZO73967DxXrUJ02NIn85CCzIMAICuCDnt16fh614FfyI08yxosUYY4RRwPbmgD6S8LTalcaRDDezRKphtSkictGoAw2enYZrq7ESy6ml9Pi4l+3vDFz8r/uzhj6d6+a/Cvjl9KjitbpJGsgkaECTJwuOn5V7t8O/Gun6nqkkVreJDFcXZEJYLuUlAc+3Rh9SKANt1hW0S4isnjItZVt1ydrHOTx71JoOlLHGWurkJNcfZzIeBtbaOo/ID6VX1FhssdrO7eRMrSRtkluxA7j1Oalmv5EWZ1l07aq24mjdhnPdt35UAReLIWS8jknElykUrIfn3dvlI9K8vbUbKVri2tFMLTwMyzOMGPB6t6nNQ/FHxOkV80enX9xFOl1JKyq4ZThfl9sZ/wAmvG4dRuI7kyGd3kJ6liQT70Ae5xPBLewwPGmpyYDBOWVtwPOR0A7jpXHa5oc8recLeBfLl8khs7goBI6cZz+lbXgrUtP1CyWaKA213HtDiJsBuSCM55zjpgV0y8i4jiuYlRp3U/KMBSvJI/hOcCgDwrW7EwsB5iMSNy4GO9VrC3JhlmUFgh52HBHT9K9L+IOn202kW3kgtfGJiwbjndyeP6V5rc7rS3NuchzJls5BPvj8KAPuL4GAr8IfCoPaxT+tfOP7XV6JvH9jbIBtSyE5bOcluOR24WvavAPiMWPhGz0u/tZrNY4NjFMFUJGRk89a+Zvj/qsOqfFHVjaFmgtRHaBmbJJRRu/UkfhQB5waKQ0UAehfFe+Go+N9W1OMcT3T4B9BwK5+1nkyDbuA7Z6jPbkfl0rovF1hcTjUDgNtlaRiwAII449BxXE2FwUO0nAPQ/hQBp7mLklWdsD5l5xVlboo5B6qwOGHIOMflxVbDs+ck/L0J4/Gp49yg7ZNxDDCYyD2xQAXEtzcSqFdck4IRQM+9PuIo7d0Do5dkDE5yKbJDsulKHBH38cbfb9aWSG3Ls8lxI5xztHA9vegBJVjjlkitx8xYEbTkEdvw5pYRsul86Q4X5hs4AFWVhJACRsiPtIyMEjpkn3p5iRGMckLmUZ5YYwMHHHpQBWF1iRikJkUrlWJzyeScdj6ipYJJJonZpido+6/Tvj/APVTI3jwESFy8RI4bA6Y4qeWSB4AJjtfAykfBXnqx/OgCO+uZVCJeW8RZAGG3BwD0BrR8K6Nd6tNPdacohgtvmkZmzhfp3qLTNITVdRSyS+EMBAJmcDAGen1r1ax+yaTbWml+HoINWbzPskpA27SP4mPr7/WgDDm0sJLbX1rp6bHOA7NlNwxk8dR1P0NN094ba1mN0iSbpAT5Y2sATjA9fpXWa9pOr2JgfU7mGzjlzhZz+7iHA4+vHtXG+NvFWgW16kOmSfa54VVXMa7UD5yxz/LFAHN+P8A7Jeb5I0MbxSGOIlMMVwOG9PbPNcA2QeBj1rvNb1az1dULeZ9qcnEajg/KO3fJ6elc7LpiW+mtcXTMkrA7YiORyBk/nQBk2ihZQ7glV54PetPS7WS9ncqC00kiome7OSBn8cVmxtgFcdeM17J+z74Om8ReMYJndY9N01luZ1xkyttOFHpyVP0zQB9FfB7wKng/wANWv26NTrksebuQHOCTnaMcYGBXcpcwyTtCkgMqgMV7gU9nCuq92zVNVkS/wAxInktGoLt97IJ49aALzNgqPU4/T/61LUEO4TSDyyqsdwYnrwB0p8oypXeVLZAI60AV9W0y11W0e2vYhJG34Ecg8HtyBXyB8X9NvLL4lz2d08kitch7V2HG0hOnbqSK+yImLDJBAIBAPb2rxj9pLwr/a2m6ZqdtJsvIrmOADA+Zdshx+JxQB83S61NpgjjSSOZSJFlTAOCTj+Vc7NeSR6gl5AxV0KsmexAxTL6GS1u5YpVCOCcqO3tTLFftFykGDukG1cdj/hQB6J4YjufFGuxTGJ2YyovnKOrHHBHfoea78+G5ZYPsV5fSD/WlCpJ2EHBGPwqDwjpv9ipZWFpPujS5jZ2OCN+3cB7A8jIrrY9NN3bWd5JJ5ZuDcM5hOV4+Ye2OefegDzHWfAd7d3QNtqPmyIiNskbbjJ4z26k/wCRXMa34N1mwfN7ACisEZ0Gcn6f1r3Cz8PTppFxrhhe0s4oY5VndwSxDYwB7e3HPrStfT6hYu+pwrJALtUjeHhwCMliPT2NAHgH9m2F3bRBIvIfy/nkBzlwB09R7day1KaarmOSRZAQ0ckfBJ6EZ7D/ABr0Dx74Vt4bVNQsFKgtKZD3yCONo6AZrzm5tbyF1int32yqvlk9Cueo9u1AGt4f8WanZXcIFy7QosiFHYkYYfw+hrsrzxAz28sv2PdJKsJy5zkDPXHBrgbGwMWpSRkBdgIPGSoIr13wRo9tc6UZLdFuY4iG2Hkvg4yT2xQB5Prwvr258/yjI4dsYTGCecEfy9Kw7izngUG4jZCVz06fWvqK6xbpJB9jihVJf3sqHG3I4PqSMjFZWp6BY61o8MN3bm1aNJhBPFgqz5JywxwCeaAPHPhpdPFqE9t5LSRSojP6KQ64NempGjSyv586P9qLHzCUEikd8jkgge2K5eHQrTSbyQgMJvLjDoFBIJ2tkH34+uRXRWNvfS3EX2z99Al4C+wlCAfb16UARXNpHe2SQyOrTG3kKujFXIDHJB6N7iuD0fw0da8aR2cMM9zp8EiNcEH5tmF3DP411Xi1YtM8IrL5zFZoXjhKjawbecDJ5XI9Petv9njQSNI1PXpZJFFzttowp6oXG8Y9flH9KAPZdHk07SI5ZZJks7K1eRvKlO5TCi9ST0x618MaxqEmrapfalOoWa9nkuXVegZ2LED25r6x/aD1yPQvhvfW8YElxq8o0+FiOUQDMjEdegxx+NfITew46AYoAaf0oo+n8qKAPVNW1G2udI0/VbM7mnYvIki7gDjlT6gHPJx+Nef61YvZ3YIK7ZAJFwc4Bzwffiuj+HniK208T6RqcSyWd42Y5CM+TJ0OfVWAA+ta3iLTrS6ia0EYsmDb4XcHaPVCfXjpQBx9nJ59qF2gsMZIPJx61c/dk53jIOdi+/GawkElrOyNuRgSD25raiuVUblcEr2cYx+NAEzFo5QYwPQgLgfn/ntSyNJlUhRDIcEBgMYFQ+YwTBwST26Z9/ep7aDzZh5yF93Unn+XagCeYyTR73MaNj5Sp5AGOCPXv+VV4hIzNIZZ5FRc5GeOwBP1NCJE6N5MmQin535C89BU8ckqzCG3YxBwCTn7/wD9f2oAmiMv2gNM4UFssAAMnGc+mP1qhcXMbDIiQNnhee57+uKkunmLZupc+VIQVAxj1Jro/Dml2FyiXjW3mSRIzeXIcL6Dk8E8n9KAO08LaTZ2XhuIskMl/MqSOCAAuT79B3Jz+tacUj21zFCjpDBJeF7h408tcL6N6cZ+lLpmlrcPeQWMu9xBFJClwu3qfu+4FYHjpNR0e3mk1EH7O8xCSY25YgFlXsRz+tAFD4+/ESPxrqen2mlArpdjEybs8zuxXJ+g2DH1rykQOVDY+UY5rUmuYUnSRYc/IVCHt1/lVd3mnlRVXO7CqqDOaAH2bG2mUKSZdwwRyQe2Kk1h7u4CPcljtBXJGP07V12maBHpEsV9qEIWRJBsBOduRySPxqbU9Ls7+N/LmWXcjAyuduGHPHqe1AHma/eGMk8V9Y/srWKRWeu3O5WczJGDu5A8tD0x0zmvmfw5pb3mpsnlNLHFneMHnnFfRv7Lk8sGseItOktyqn9+JCc/3Fx7f/WoA94trp7jUpo0EZig+RjnLBuD/jV4juAN2MZIqNbdFxsG35txxxk+/rUoGCTzzQAkhZUJRdzDoKSF2dFZ0KEjlSeRT6KAEGckH865v4iWUV94VuUmcx7HR1cDJU7gM9Pc10tcD8YNdOk6NY20GJLi8ulQwqfnaIZ3MB7Hb+YoA+LvGVq9nrc6y7fMOCwHOPSqeizSWks1xGFLrEdqsMk/MD/Suq+K1vB/ba3NrFtSQbXJPzbh/eHb+tc3penTzI8sUiAgAbWOCQT/AJ/MUAe76DMup2VvdHym33qCSUnaRlPugdvrVrQLvTbLULaHUr6WOwF3NHKMsI1zwd3Iwp557V5doOtNDI1rEzBopVlc5/dkbSPz6811UWv2NtsluP8ASYmMqzq2CpQjjjuR60AfTetWFhd+DWsLWeG3sJIY47eVCDGFyuzB6FT8vPoa858ReFholzEls6MryxMSJMMDgk5B/h446/hXzlH4kWK4uljur8WLwmOO3MpYLhhhRngDqfrXqHhzVLe60Rmv7uS5ke4Ty5MklSBwD/smgDfe23WEUsentGojuDKrHJlUHng9hx2rhfGfhxr3TYtQ0/Y3kWqSrFty2CcY5PHBPavV7LQtSi02x1GWF4IAlwzgtvBVskFvQH/Csq8+zX2mhneSORrGLIAxwZMbsdD2x+FAHgH22UapJcLHsuY5Ak0TjgHGDx1/Cvc/DiJp1hZz29wim5WbzIo1BWYbjlhj6V5X8SPDS2niCa4gnkSaWcbgfm35Gciu18BarawwWtuLuORoROroy4AXjBTPIXpQBu6zq9vbXEk5AntmIZsAsi9MZPUN1GMEfTFW9F1aaSXFtZpLp8gZNwkAK5ORjsCP8iqf2e1FtdrlQdiSHGdo+YE4H5cGtpLKy+yJ5LMsZuMghQMkjn6EelAGb40W5fw5NeSi0jCJCNxiG7IPI4749+3FcVpepXLXhWe3YwvcpNudyAu3pkED9TT/ABD4vmOqLoFo8Xkbsb2O6OTnhs+ueMHuKx/H2sGyg/smC28zUJoQC8S42huBjH3iRnpQBxXjbV7jX9bisrcCRYm8i3CEnzGJJzjp1JFfS3wz0J/Dvg2z0WRZEmKRzOqYJeR2yyfQfLn+fp4f4R0G48LajZalq1lHcapdKfsls67vJVgP3jf7XpXo/wASfFs3gnwbHdWrFdf1VDbxeZJtkiTad06r7cAHplvagDyH48+Lo/FPjmVLFlbTNLT7FbMucSEH55APc15oeRT2OSSTknkk9z60w0AIaKDRQAp5r03wXqsGr6a9tdTuNVgXhW/5eE6ZHuOBj8c8V5keafbzzW08c9tK0U0Z3I6nlTQB69ruhR+JIovtBjGqKxgjuFYKrY/gIxz9a83vrC80K+MF7HsZSRnqjYJUkN6ZHWvRfDGtWniJIVggRdYL/wCkRyuFQDH30PbPeutu9Tis9DSBtOguEFsYSkqBiqgnkceuTn6UAeOWzQyWm0cOSCARnJzyc/SpBvJKiX584yTgfjX0snwC8La7odrfaVe3dlPcQxybonEkYOOQB2yTzz2rxz4g/DDxF4HR7jU7M32mBji+tQXQL1y6jlPqRj3NAHDROyxO25SrJtwOmM+nep2upVMZDDagUkKcjI7/AK9Ko3WpNMUUrGka/dVBx16571XuL3cpWIBF64A6n1oA0rNnvNVit0i+/J0HJ/8Ar17HoMfk6QFlgWNy2EaSQbVyeAeM9TmvCtFvjZata3W3d5UgcKWxnHbNe4297He20M6YX7SrGQ8OytnoR+vagDq/Cx+w+MIbnWruCTc8QZYSSSQ2Rkd/8K6r453Ok+JvCbaTHBJPfh0mgYxlDHxnIJHocYrzvwpcx6drsRs5lnkg2TOLpepU55J5zxXQ+J/F7eINd8+yna3RLYxuhXcMkc4/HvQBxPgj4Lar4i065u7ua2tIVVlXfkliOhwOg4/Wqen6Xa6QL60s2i/tC1PlGUfMNydQB3+tdlYeI9QsvD7RS3MqW24qPJOCVxyfUk8/h2rIlntEiS9aL7FH86424Ziec5Pb1PWgDnraxe/uCYjG05CP5kxGG/TGKj8X2LW1u4WaBixVd0J4UfXuPf3qS71S2t7iG1j2PJOgBRTgKT1OfbHb1qHVNM1OeeR4dOeazkdY44rf5xI3HQdef89aAKvhtJ/Deh/2rtSS5lcq6uPmKDrge5r6H+A0Ukllq2oPZG2ju3jeJscONvOD6ZGPwrmfAnwn1PU2srvxq3l2cBYrYK3LjsGI/h9jz9K9w037FFbpaaeYlht1CLHH0QdB/I0AWJ5Y4IZJpnVIo1LuzHAUAZJNeW+LPi7bWRkj8P266g0UpjkkY4UEdcev1r0PxLpv9r6De2O5laaMhSGx83UZ9sgZ9q+W77w/d6V4gbS9TtRDcJITkMfLdQMhgR1yMH2GM4oA7RfjHrkcaXs9tbNHJGdkaKcId3U9+wH516H4M+JdhrkyWepINPv3KKiM2VlZuAF989q8btrKKSO5+1yKto9gdsg5CfPxwO3Q/nVvwN4futV8VOmkKZ/7PvIJJb6RDsRQRnaTwXA5AFAH0xXzl8ZdTutS+MOl6arfZo9Nt38uRD80nmhXOfQDyx+dfRteP/HHwNqWqTQ+I/DcUcmoWdvIssIH7yYEpgr6lVEnHUkjGelAHlPjjRm1dLvy1DSxqkhViQZG/wBn1x7149p9tdXeoCztlcyyOU2qM98H+tex2+qXGs6o8F2q2mpboY51kOD5nc+w9PXvWff+FbvQfFK6lptwTNb3MnmqygDBAO4Y9ctmgDY0bw3Zafp0aC2jmd9pd2HyydRz3yKi8QeApdQtVmt7AokPMZQBTLxnaD0JOevauks47yewjvUG4G3MjE4bCnPI9F9O46muqv8AxRdzaRYWTbEZ1RdyIpCnAGM56e4oA8f+BXhXQ/Eni7U9J8TQpMka5S0lLIzkFwwBUg8YBNa3xU0C0+F3jHTZtDilGi3JSY27uZPKkV+i5OduAeD3r0HwdpsV14ttLy9tfI1NpJkW5UYLYVgCD34H+etafxI8O2eoarIurTGdmQywMRymB938ME0Abml+N7HWPB6z21rcF5LfYYtgQA4KkA56ZBxXD2/nN4eMF4FWGOzjQNGcn765Ge5wF4+lWtJgt9KeaylgESSsdq78bGOQBjPbvSzTJYWckZVpIxb7X2AHJDDJA7cZ5/woA84+I17aRy7kuZAwuUwrqCANvUZHavMtH1XGuRyTSPFKN+xmOSMgnGT9TXTfF+ZL7VRe2k2+1kAePIwRjj8COmK8tYvNJySS3Gc/1oA9Pm+ISR6b9jNu0rrbiMowAUPk/njg5rR03xbqeqRStDaxxWPnR5XIwjY4BHv+VeY2Fn9omjEykLsyzZxkev8AKvffhN4Dn8TLLM9i1hoaTxlpZD894FHO3jp7+uaAMfwj4VTVPNXw9YySa0ru0sMn+oQAjneeM/N09x712lh8O5fAthN4h1u7tb7VFUtE0oLeST0Ueo5wcete3aJpGm+HtLSx0q2is7KLcwRScDJJJJPJ+przbxdqh1W8m1YzxJ4cs7Ny0j/Jn5gWLbu2VAGOueMk4oA830CzuLPUNe8X+NJ4o7CzG5kjf5unEaDGMtxgfWvB/Hnii88YeJrvWb4FDLhIYc5EEI+4g/mT3JJrp/jH8Q/+E11SK30yN7bw7Yki0hYYaZj1lkHr6DsPxrzdu/UmgBCT2pvNKaT0oASil9qKABv8mjvS02gCW2nltriK4t5GiniYOjr1BFd34f8AE8mpXItrkpDeSgxq+cKc+np3475rz+l4IwelAH058M/iVceC9Qu7DXLiS+0d2T7g3fYz0JB6FT1I/wBmvpLR9V03xBpq3el3UF7ZSgrujYMp7EEf0Nfn74Z8UrbLHZa5G1zpxYEyKP3seP8A0Iex59DXrPh3Xp9Cmm1Two8dtZSgvG0bZSX13jpn0BHFAHQfHH4F2tvZ3Ov+CLcxCFd9zpcS5Vhnl4h/CfUdMDNfNV1bSRcsrAEkZI/zmvqT/heurafp6HWvDy3kEvyG5t32DBHXBBB6jiuCWHR/ETXGoxaSyQSs4ET5YBseoxgdemKAPE1UoQcc9q2NL1280u4ikgmAZPmVW5H5V6lp/wANrG7s0nRLi5nlQMAqFQg9ce9ezfDrTvCnhlG03UtJsbe+JUefLCrll25GWOcc7qAPnnRvGMZEU19Z3MkuSZZoImJkz1J469vpWlYeOdNjv45vsZjmjh8pA556D7w9Pevs+xNo1vGbHyDBg7DDjbjvjHFcp438P+CbqzuF8TWOlRmWM5lZFSbHqrD5qAPmKTxkJrwT26+ZctINsWwkgEEEqOmQcY+tSmN2soIbmSMF5HwZWwSMc8n+VTw6VZweILmHRJPN06B1Kys2HcYzjjocH17ZqyPDj6hHPGzh52mbLHkKpHX3/CgCz4V0S11G50210OxGoySx4acD5Imz83XoP/r19K+G9Bh8P6e6RbridjuZmxknGAo9hXL/AAwvNC0DwXYWg2WbwR7XMg+Z/mJLZxkjcx+lbOueNILGCVrO0mu5FkES87ULnpz6e9AGlf6Vc6nd2slzdyQ2cRLPaR9JDjjc3t1xV7TtMs9ODCygWIMADt74yf6mvDvGt18RtZFp9g1M6YCZHeCyIBC4yMtjJ4rtvhx4tluvh/E+pXJuNYtYykgfCu+CQhP1A698UAej1Q1nSLHWbU2+o26TJg7SR8yEjGVPY14R8TNV+Id/JJPoGryWVijgeRaqiMpx/eIyRnt0ra+BPirXrrU73R/E99cX07bnhacKGjCAZ6AZBLfhigDe0b4R2dpO66hql5e2fk+QIM7NwyfvEdeP5mvR7GztrC1jtrKCOC3jGFjjXAArJ8b6+nhrwvqOqMu+SCItGgGSzkhV4yOMsM+1fLUnxi+JOoarK9jqMMCNIpW0jso2SMZxt3MCxHrk59MUAfYVc94uTXxa+f4dkiM0aN+5ccOeMfljpXn3gP4ieIdU1Eadr1tBG6uVNxDGV3DAwdpzjkkfgKtfHPxV4n8NnR4/CzIpuUnMrGJZCCuwggN25I/4F7UAdfqnhHSvE1ukuvaXFHeZUl4mw3y8j5h+Vcv4p0hdIKRS3BS0uJ3MbBATt2D5SfQHP1rZ0Hxhdx6RFceJbeOJiiM0lsrEAtxgqeRz9a6xJrHUoAQ0FxFk4DAHBGQeD+IoA8DCyacrwIz2+bU8KgKMu7+IDuQePrWi8T31vdPaxhZ7QwbIxgKy4HX1xV7XbJLa/urXS3kns5bCYKpA3j5uecevQjt781R1u1S2Uz2Nw0cLpAI1JyCeAcsOQeOmKAIhHeRXMNzDOsURuJUVSuSDgnAP58e9JdzXNxNDdyxRyo9u0u7kFcfxfgfzrpvCPhW81lRqN3dC2tfPl8uOJAcr0BXPA5yM9eD610k3gSJI1Onand20yQSQo7BZMbuc4wO9AHIy+Re21y0ucwtEzgj5mDZ+YEchgeorn/EusaX4bth9vu1mfYyqiJzIOvXucA/lXocfw/mubdY9U1iUqVjEqWsYj3bRyN3Xk965Tx38HdF1C0iWDULpL2EMV34dihHIAwB2BH0PXNAHyl4h1GTUtTmug7mKRiyq5+4D2pdF0DUtXu4otOtJrjeTyiEgAda9t8PfBmGGGK91a9gkVkMqRsmF4OBu7DNdRoUlnpWrz6Y1pJYtCQS0MQU42gjB6dfzoAq/C74RWF3dLNq5a80+OCN/JlHDOTkr7rhSpB67q94v9V0/SYQkskabCqLDHgsM9BtHQV55p3id9O0t1CSISm85H7zgnJJ78fTFcN4+8YaNpA/ta9mla8m2GO2ZsTzgKOnXaP8AaP4UAd14s8aZ0ya41gDStDjMomkaX5pVA2hMerEkYHfFfK3xG+INz4qkSzsY20/QIUWOOzVifO2nh5fU9OOgrF8YeLdV8VXvnatcu0KOzwWocmKDPoD1PucmudJyetACMc8000vtSHpQAh+lFH8qKAEPBooPWigBT1ptPNNI/KgBPx4opfpRjrQAD61paJrN3pE2+2YSQk5ktpCTHIPcetZtLQB7v4e8U6d4oguIre0YSDY8tluAYjoWT1A54HqM4rttIFtp9nBA4dLYM+YQnzOwwRx1yK+VYZJIZkmhd4pkIZHRtrKR0IIrvfDPxM1LTZQdUD6gQGCzFsSAnufWgD6OvtYhlUnSZmTZDgRRruIG7jkdFxxVLVoJbnUpobUh5LhokeRuSMA5A98Z6cdfWvLNE8baVJAEttWW3n258uWLyyHzySw4P0rr7PxXc3qTLaXsDCSaEIDhjwDkkdj1wff2oAzL3wymm30KaBqOpRXccrFpknZQnsvbB71NPot3qWuwnxBqd3fk24y8p+cqOdrHsf8AGtOw8QW2nyWrvcBk/eZZ1Bbfn5mJ7elJ/aD3U9rD5i+fIo8t+xAJ4YeuOlAF7TdO0l45hpFsRF9ojXdO+3gYz+HI/KumsrOytpobfR1ie2EjSSzJk7zjkA1hXl3bm1nWWSASb4/LXIzMcjr6YweO+BV9NTNtDHHbPEbudgEVG+VVJ7emTxQBo2cVvHMzraSzpPBmMhsleeh9OMVJLNLcy3TXqbLUSRr22/LzjPQH69eazLfXop7u2sxKOjb5sZCngEH1A/wq/aXvni7kt5Unt4XGVOCM9GP5Z/l3oA2rWSQT2bx4jTDBFDbmPy4Jbjv0rnV0yS3uw8MPkhwI2Gf4c/d2+qnJznkMBjitKC8S2vp4o2AjfE0ezk4brgnp6kVbv7jdPZu2QizESBiFU56Y79wfwoArXbJazzW00glibLg8HZhenvz61n+CpraD4n2NtBIJXltJn39ePlPB/Ck8WXyaNeN9rWOSzuAWD87Vbrg/lz9azPCcElt491PVIB9pNlZCSHb1fzAQD7jigDU+Jd7JrPjiCyRo5tNsIdropwwmZiHDeoCiP6H1qvZ+HLV757q2jhigjCqQowSw6/8A6ziuR8NGZftU9zzqF3d+aZH5+bjLE/gK664nmsNOPm38MJuIvOUbslsKT09Djp2oA2J1WwgeWCKOSJpRMCjZyxAz83pxVVmu9cuIb/U5leSKGU28TAbAvUnbx1AGf90etZ/hjxLbXOn+beyorRxqZShAV2YAZA6DoKZaa1AgKiTzFSV8xnDH5hyAe3GaAOz1E21xCxZ2USRKybfvZUcj8+lUljZJIHhi2MJXWUKcbiQdufXODxVKLWbKeIW3miKVkJOQACeu0f40llqCx3c7DJdJVeZEA4Qls47cDjPoaALd4jCKOWyKzI9tIvl4wVXI3Y989utc34i00T2lzHZSSJBOkDEOeEcHGAR+da8FxDPvubOZ/PtlcKjt8rxk7jkdjhQKdJdwqjy28RdLhFV4w+eQcMCO/tQB57Y+PfF/g25gs0h+36bJcukaNFluOMdiCcg/XNek+Efijqus2wa78MSW7tG7K3ngKxHQYIyM9qoLcaTNcQ+VGpuYbjLEvwH29MfiRVYana21qJBOtuk0TuhTkI/IHPagDrrnWdZvvOi+0Q2xRoG8u3BLjcASmT9ajsN63stxHKzyxXMiSlyWKfKPTPHbiueu9bSKV03lL1kh/i+Vm4Oc/SsuTxC2n6jLPEzqjXDicIMoxxySD06DpQB0t5cQtp6GaMrDNA+IfvZfd1yDgDPSueSzFu19PfSNLqTyRKqK4YrhRyD3Bz7dK5PxN8StC02wRBeb7xrV4xbW67myTkDPRQf0rx7xl8QdT8RPNFAo02wmVEkghPzyhR/G3pnsOKAO68d/FH7JdLBpbwXuowviVyM28ZU8DP8AGc44HHvXjWqajd6pfzX2pXMl1ezndJPIcsx/oPYVVyMccAdhTT6UADHmm+tFBoAKSj6UUAJRSmk7UAHWijv6UUAONNNOak70AJ3opaT1oAKUUUUAAFFFFADuDwRkU6MmM5iZkOf4SVP6U3vS0AWoL66gOY55Ax4yWJ/nWgnibVkZHN47MgwpI6Vi0Z6c0AdP/wAJhftGEljif1I4Y/ic1ojx9cyEGa0UMCOYZCvHcD61xGee1ANAHodv48s45EkOn3YbneEmyDz1Gec/zq1Z+P8ATozIgt7+GN12hkIz15zggen5V5nml3UAey23xE0dY126nfxToFIaaDIJ9sGtu08a6Rc/Z8eIbYhpCG81XUqMHkAjA6/zrwAN+NHykcgH8KAPpew1eDVPDa2TXtpd4WVztlBK+hznhv6V2uh69Do2iNGlssrrHGsjFcHBAH4jrXxouBypKeu0kVL9pnK4a7uiMAY85ug6UAfTWt39tZ3TxW9xaW5S9yzTyAYXaOeDgYx0964rWdc0d9TRrjXbB1jjcbkLsPYDA/nXirEMcsWcnn5mJyaT5R2A/CgD18eK/DVtFCYdRQOEj3xpbnBYcntjueKgHjXQIrq+lW8vCJJd0ZSHkjHXJ/z+VeUb+nb6UBvegD02Xx7pfkwKqXkkkYfazIBsz0xz+lK/xFs4LpZ7GC+LBFBD4AY4OT1P4f5FeY7vek3df60AekP8RYlkQ21teKocsQZB0OM/j2+hqD/hY90lyZYLeVQMbT5p3Dnua8+3e9ICcdRQB2114+u55Y5ltEjuEYtvErc8foaqSeN9Uks/spjt/K7/AHvr6+tcmTS596AOln8aa7LDBF9rRFhAVCkY3AAccnNYtzqN7dBhcXt1KCSxDSnBJ68VTzSZ5oAcCFGEAAPXAppNIT/9aigAPakozxSUALSfWjrSUAKetIaKKACk496KKADv6UUd+PzooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan demonstrates bilateral calcifications at the corticomedullary junction in both kidneys as is typically seen with medullary sponge kidney. There is an absence of interstitial calcifications as may be seen with nephrocalcinosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16226=[""].join("\n");
var outline_f15_54_16226=null;
var title_f15_54_16227="Wheat dextrin: Drug information";
var content_f15_54_16227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Wheat dextrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11560705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benefiber&reg; Plus Calcium [OTC];",
"     </li>",
"     <li>",
"      Benefiber&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11305957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Fiber Supplement;",
"     </li>",
"     <li>",
"      Laxative, Bulk-Producing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11306039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake for total fiber:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The definition of &ldquo;fiber&rdquo; varies; however, the soluble fiber in wheat dextrin is only one type of fiber which makes up the daily recommended intake of total fiber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults 19-50 years: Males: 38 g/day; Females: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults &ge;51 years: Males: 30 g/day; Females: 21 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pregnancy: 28 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lactation: 29 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11306038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake for total fiber:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The definition of &ldquo;fiber&rdquo; varies; however, the soluble fiber in wheat dextrin is only one type of fiber which makes up the daily recommended intake of total fiber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-3 years: 19 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 4-8 years: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 9-13 years: Males: 31 g/day; Females: 26 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 14-18 years: Males: 38 g/day; Females: 26 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11306040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11368325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 1.3 g [gluten free, sugar free; provides dietary fiber 3 g and soluble fiber 3 g per 3 caplets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;:  (80 g, 155 g, 245 g, 350 g, 477 g) [gluten free, sugar free; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;:  (161 g, 267 g, 529 g) [gluten free, sugar free; contains phenylalanine; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 3.5 g/packet (28s) [gluten free, sugar free; original flavor; provides dietary fiber 3 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 3.5 g/packet (16s) [sugar free; contains phenylalanine; kiwi-strawberry flavor; provides dietary fiber 3 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 3.5 g/packet (8s) [sugar free; contains phenylalanine; raspberry tea flavor; provides dietary fiber 3 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 3.5 g/packet (8s) [sugar free; contains phenylalanine, sodium 20 mg/packet; cherry-pomegranate flavor; provides dietary fiber 3 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 3.5 g/packet (16s) [sugar free; contains phenylalanine, soy; citrus punch flavor; provides dietary fiber 3 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg; Plus Calcium:  (424 g) [gluten free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 2.7 g [gluten free, sugar free; contains phenylalanine, soy; assorted fruit flavor; provides dietary fiber 3 g and soluble fiber 3 g per 3 tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg;: 2.7 g [gluten free, sugar free; contains phenylalanine, soy; orange cr&eacute;me flavor; provides dietary fiber 3 g and soluble fiber 3 g per 3 tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benefiber&reg; Plus Calcium: 2.7 g [gluten free, sugar free; contains calcium 100 mg/tablet, phenylalanine, soy; wildberry flavor; provides dietary fiber 3 g and soluble fiber 3 g per 3 tablets]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11305955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11306042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Powder can be mixed into hot or cold beverages (eg, water, coffee, juice), soft foods (eg, applesauce, pudding, yogurt), or cooked into recipes for foods; not recommended for use in carbonated beverages. Caplets should be swallowed with liquid.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11305994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     OTC labeling: Dietary fiber supplement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11305995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of constipation; aid to enhance LDL lowering to reduce the risk of coronary heart disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11306029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Bloating, flatulence, GI discomfort",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11305996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coronary heart disease (CHD): To aid in reducing the risk of CHD, the soluble fiber from wheat dextrin should be used in conjunction with a diet low in saturated fat and cholesterol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with esophageal strictures, ulcers, stenosis, or intestinal adhesions, GI obstruction, fecal impaction, or difficulty swallowing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aspartame: Some products may contain aspartame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Calcium: Some products may contain calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Potassium: Some products may contain potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sodium: Some products may contain sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in the elderly; may have insufficient fluid intake which may predispose them to fecal impaction and bowel obstruction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11358733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11306041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine, potassium, and/or sodium, as well as additional ingredients. Check individual product information for caloric and nutritional value.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11306034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wheat dextrin is a soluble fiber. It absorbs water in the intestine to form a viscous liquid which promotes peristalsis and reduces transit time.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)",
"      </i>",
"      , Washington, DC: The National Academies Press, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James SL, Muir JG, Curtis SL, et al, &ldquo;Dietary Fibre: A Roughage Guide,&rdquo;",
"      <i>",
"       Intern Med J",
"      </i>",
"      , 2003, 33(7):291-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16227/abstract-text/12823674/pubmed\" id=\"12823674\" target=\"_blank\">",
"        12823674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slavin JL, Savarino V, Paredes-Diaz A, et al, &ldquo;A Review of the Role of Soluble Fiber in Health With Specific Reference to Wheat Dextrin,&rdquo;",
"      <i>",
"       J Int Med Res",
"      </i>",
"      , 2009, 37(1):1-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16227/abstract-text/19215668/pubmed\" id=\"19215668\" target=\"_blank\">",
"        19215668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16098 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-1A9BDA5540-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16227=[""].join("\n");
var outline_f15_54_16227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11560705\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305957\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306039\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306038\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306040\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368325\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306042\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305994\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305995\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306029\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11305996\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300226\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358733\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306041\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11306034\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16228="2D TEE and M mode images parasternal short axis aortic valve";
var content_f15_54_16228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) and M mode echocardiographic images along with a phonocardiogram of the normal aortic root from the parasternal short axis position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 225px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADhAh0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pormvibcz2fw38WXVpNJBcwaTdyRSxMUeN1hchlYcgggEEV8B2Hjr4hajeRWen+KfFd1dzNsjhg1C4d3Poqhsk/SgD9IaK/N298e/ECwvJrW98VeKbe6hcpLDNqNwjxsOCrKWyCPQ1F/wsjxvjjxj4kznP8AyFJ//iqAP0nor81/+FjeOMZPjLxIB/2FJ/8A4qnf8LI8cKMHxh4kB6jOpzd/+BUAfpNRX5tf8LK8b/8AQ4eI/f8A4mc3/wAVQfiT44wAfGHiMHt/xM5v/iqAP0lor82R8SvHCrx4x8Rcn/oJzH/2ag/EjxsSMeMfEg9f+JpP/wDFUAfpNRX5sD4k+Nxj/isfEfHH/ITnP/s1J/wsjxx1/wCEx8R/+DOf/wCKoA/SiivzZHxJ8b4H/FY+I93vqc2P/Qq9h+A+q6p4wtdUg8ReKfFL3bzRwWLw6zcRtv8ALlkZQN2CSI+4PTjFAH2LRXxv+0Rqet+CtQ0CPw54l8UW8VzbO8pk1m5l3srlc/M5xkc4GBXkA+JHjccHxl4kx/2E5s/+hUAfpPRX5sN8SfG5Of8AhMfEY+mpzf8AxVIfiR43JJPjLxJ+Gpz/APxVAH6UUV+bI+JXjfBz4x8SZP8A1Epv/iqT/hZPjjOf+Ex8R/8Agzm/+KoA/SeivzYf4keN2Of+Ex8SD/uJzf8AxVOHxH8bDBHjHxGSex1Oc/8As1AH6S0V8/8A7NWuajr3wf1m78QavqN3NHq7Ri4uL2QyKgjgIUSZyBknjpyeuTXp2m+IfC19Mmnw+JLSbUk3KbNNZDTBgeVIV85GO/SgDsqK5q8EcEv7u7JQkbmbVHUr15xg9xjA79utc8+tQC3PmXdwAzlEe31lHJxx/Fgg+2O4oA9Gory+/wBZgslV01a5nJDbkOtRKF6/Lkr14/DjnrjDj10TnnV9dUb87Y9WhYrx7KcjI5+vTqaAPbKK8otrq6nmCpqGuF9iqub0be2S+E4PPbn3rStZpis3napqiKuQc3WeMjJzs479+n5UAei0VwF9N5McOdXvo8Et+8uHU4xnn5fp2I5rNe8ujeHybnWJW2tlUvsAdcYBUc8HsePpyAeo0V5cJbsPKo1y5WRWJJbUgAFx6MuODwemfbvsmDVFiil/tO/mRV2kWkwky34x8kk9zwB60AdxRXm8tzexJMft/iQyMADkx7c8cr+544+mfxzVC3kvZCXGt+IZHDOwPnKiZ6Bf9R+PTHbHoAer0V5aF1SSRI11PXBH5ZDYufm69/3HHfoc+/aq00uoKMTa3q0EAXdk3q5yVIzlo1OPbocAgjsAet0V4/PftDJEZvEupoEG5g+rQr2J6CHcf89gMRJquoTMRFrGqMFQAiK8DsADjdxbnHXqRQB7LRXiE+r3TQFW1zX4WxuWSO6yeSDgg2/bv7fWq1lfXMk4a58QeJWiwzt5epR4G0Z4/dgkcDoO/SgD3iivAXv7jBMXiXxRJs2gf8TKBSTk/LhgMn9T79KoXOpahEyRDXvF8Dbsb31GByc8fMCOPQY/nigD6NorzPwTqE03w01+5/tDUZ5ovtG24urxJ5FIhU5V0ACjPIHUEnk153Zax4vujCLN9dvR1la2nlkEJOMbgDk5BY/8B981LdhN2PpCivly/wDHPiK0j1CFdUBvrW4SHyZ9TaM7SM/Oc/K5w2F9s+1dfBrmqSMMarfsT8vFw3P60ucTke6UV4zBrOpYBfUL9t3/AE3f/GtJNV1Akf6ddEY/57NRzhzHqlFeaR6hfEEvfXAXHeVhn8c1d+3XeObufA7+Yw/rRzhzHfUVxCXd0xB+1zlf+uh5NZWteO9G0OKGXWNdW0Eq741kkYM4xnIXqfy68daOdDv2PTKK4TQ/ElnrcMUul6vHdJIrSJ5U+SUDbS2OvBIH4ityN7n+KWX2O4n86OdDN+isJQ/2gztcXGdgQp5h2AZznHrz19MVN5so/wCWpII4BJ/xo5xXNeishpJSwAlcEdRu5rC8UeNNH8LwLNrWpGEGTyQqBpGLYDEbVBIwCDk+o9RRzoZ2lFYGmaxa6pD5thdmZdiPlSR8roHQ/irA1b8x8/6x/wDvqnzAalFZjtJxmRvXhiKgmknI+SSTJx0YjFHMBtUVgXE0iFFE8hJH98jFRWd47X4t2nkaQMjMA5PBPp6cGjmQHSUUUVQHK/Fj/klnjL/sC3v/AKIevhv4K6zofhnVtW8Qa5eTQ3NnYvHp0dum6Zp5f3fmJn5copZuSO1fcnxY/wCSWeMv+wLe/wDoh6/NWgD0j466voPiXxbb+IvDl0Zf7TtI5L2F49jw3CjawYD5eQFPBIyTXnFHakoAU9qOMd+lAJGcHFGTQAoGfrSUA4OR1pRjvnFADaWkooAKKKWgAr2/4F30CeIFk022uLO2tYZL1t8yyjzkhkQOPlB6Owx7mvHtQmsZTELC1ltwExJ5k2/c3qOBgV698J9YtoI79WtFlFrpVw5kUFSV8sgg/XOKAKPxN8Q2mp6rpza6k2pW1tE8awrMIGQFt3DYPfPBrySYxvNI0KGOIsSqM2So7DPeuw8XTaHqW2SxmniuM4xKSwA9M9gK5zTmtLWffqFqbyFlICRz7CD65waAM8UUsn3zxgE5AznFIBnoKACj9aKUkkc80AIaUfgfbNJS5zgfhQB9efstR+f8C9fjEsNuRrL4eVtqgiO3PJyOvT36Vn+F/AvjH/hYMep2+lyYXxTd6l9omMB08W0nytIgDeaZODhc4Hy9Dk10X7G8Ky/CTV4mCkHWZNwccf6mDNe3abKtta+WrgiPJ29WPQk5+hzzz+FAHMeLL3V7ho0sdy7CTNF5YmQ46MpG0kDIyGx2x0zWSsl20FvLfwWspwUKx6f93PLd8Dtz06E4rrWsLYW4imZpEDAsudud2PvAYyDjj07CmLp9sAqIm0g/MOTgZyP0/H9KAONmu/Imf+ytOtrmfHymS1WEtkZxkRtzkjk9fxrno4PE1w0vk6b4YiWIrIh2OgkAHTjBYg5GcYOD9K9cMZViIy5JwMozDB/TIyPqTUdrBbwi5kWOEF5P3sik/Nxj69eMZ7UAeUyxeJoprfdFoEQiwWWMOD07uzjaCdp6ZypwR94dJp8+sxxMz3PhgMx3q0cpQAA8Egtk9+MjGOPQd89ojArNG5ibgEOMAZ44Pc57fXripVtLI5la1tiwH32QZ9+3XBH1oA4GSy8TXIjP2LRh5m5leOUuHP8Au7cAcepo0LS/EFhfvJcHTLe3AfcEgdGkOCAu9z9eR6555r0SS2hMagRRLkjgADgHgY79uOlWNqtGQjYHI6ZH/wCqgDyu6uPEVwrGW/0iSOFg0pitl2wn0JlDEnDHngfnis7U7a81OzjlVLGX7OEMsVzJJGrcnCoI9gPBPO3HtXrJ0yFgSJZc8Elm3ZwCOQeCME8dKiOk2/2yOW32xkJtJVByvYdMfnn+oAPLrO1sYbQO+nL9rfjdE6yQJ2yGCl88kep5P1l/s3w/NEI7qxlldCdyxCYBG9OE7bhyBjkHjmvTU0+1iaS5n8oyH5mcKFUbeg/DGPwpzwWrxGMybowDgADj8ce4+nHtQB4tqdjFazTLa6WgWZHCFrx23+qnkYxxzj86h0m1+1StHbadpfmKwkxI8rMFxwwGTu7dMYz617DfW0M8cccdxFiHKqGt/MCDbjHGMdjUENlEYZBM8TDIQulk0QABPHOenPrznp2APLpJ9XtbtAuiaTeRRheVnjDKF7bZAw46ccjtjinXOia5Na/aodK02Pzn3OreYh3E5xujPzAH+XSvWZbSCNCjQwkvyQiBdwJOcHHXHfI7c1BOITbKHVtqLuCZC/Njgt04HNAHiUPhnU7sCO9sdFtLbZJJJNE0twysdu1SGkXaWDA+vQHHeqnh2WCY3Lpp0caDagupoFDgglRgNxnB49F4Fe3TWguFYWwiJ3FgzA8nPOSvU5I/HHOcVEdPtS7FldHkCgllj4wMBs7c9PrgZC4zQB47Fody4uBqXhjR7q3C72ntrdHdTnr87jPGTvBGMHrWNr3h+7jmSaz0PSHto0V2aWCSDaFGSx3NggYOTzwOuBz7lcaUlvDDDaywQxNMcCddwdSDwFBG49OOnynIpiafbJeja7AsqA4YbgoBKgeo49O59aAOd8AySp8HPFUl/HplsqLdnNqCIdgt1yzZY575IPQfWvOPCmp6P4h8Cr4cS81Pw3LYXLXDyRxziK6V1wxEiA5IJJG7ngHsa9o8WwQ2Pwh8Z/ZeUGl3kgDfMoP2c8AdAOOlfCVtfWNvBOr3OsWfnEhreLaUaNgQeDjsW/zzUslo9w+0aLc+JvsNmbW/T7VLczyPA0gkmXaN27OEfHJBzgDoM1oeFtaGq/brCLUVEqjCSooDpwgJw2Q3LD5sYJOBxXzM97dW8ipBJPbLES0aByCmee2OcY59hXoOheLLmXVLfV9OO7UY4fKu7cqqrKpYrH0wCNxiUnrz7ZqWiXGx7npGuaZLfX8Ca1YXHlEO8SfK0OCELMxYjlig4wAfXNdPpV7bX0Hm2tzDMFYq3lOGCkEgg+hzXlnjXW7LSNC1GSwshb/brZZo7rylImWQruB4OONp5wM7ec12HgDWNG137S+i3eWb78YQISQFG8KR04x070rdRI7K7t5LizniguTDO6MFk5wCehwCCPqK8slHiHU9Z1eysvFN9atpkggYWcUt4swOSvCjKPjgjv2r0zU9STQ9OW6uY5rmJGCs6BNwH95vujr/APWq5pNrZIW1HyIbe8v9ksnzfM2QAoPvjaMY4zjrSsuqBHk154a8fG1tE0TXtavL65LGd50ktIbZMDpvwxbJPXnA6V3/AIe8Ma62iQ6d4hSCS5d3iN/CYXlRduQ43Rc5IA7sckmuh1/xJp/hyK2+2zTTXF1IscFrCqvK5JA+UDGVHUk9K6qLIGCSW9c801ZbIq1zk9C17w/pml2qt4hs5lYOULGKLdtAZsKqr0GD+vpXWXN8iaNJqVqj3SeSZY0t1Mhm4yoUDOS3HPv7VyI8MeFtDNlbyvFbszyR2ySz7CWaNlO0Z5O0nnqeT1rfXXNMj0iNrC9ivFjZYwLd97EZIIXb3AVv++TSb6DRp6XPLNpVnNeIIrmSGOSSNQfkYqCwweeDn8qp67d2VrEJNRv4rO2ZkKGQbN7g7sZP3sjA24zwfw8G8X+OvEN14tl0bT5/tN6LryLO3svkmC44edskZ3YBXjADZAByfQvCHhrUl8U2Oo+OdXttR11Vd7OHeD9m3qSyxJ0BBJ+c54UAetGoXHadeaxdapq017LqGnmG8eOylbTSiyROSgAIHzkkoQWBxtHqav6X4Pkt4Jr6a/WzvAHjjljUXAhtwxZsNJn53PzMxzjoOmaxPifq0mv6FJd+BPEVhHqekmV7tS6vKkJVldtoDFWGOOBwT0ryS5+MWsaXocNlaW8ttaSNK9vsWMF7dmVVUblYjhZSWYEsx445Au6FuezaJDa+D/EaS3usrLZarERHcSxqgabzSdkeAeDvYntjG37teoRkE5JFeAeHPFGleOvDdrpV5NP/AGqGFxpTz26xmOeMfuvnB2N8ytkY5GRjOK9G+Gur3mv6XYarNrxvFePbLaG0SMpKvDgsOQwbjHfHvkMZ3hQdt3NRPgZO7j/OahlhnjxI9+8cQ+8DGoBz0AJ6f1qoQWuONaYiQgRIBFkYPODjn0xRoFywSk6krIr44wjZ5wDj64wce9Q/Z8ahDNbhGfeine235dwzyAe2cD14yOtVNM07VbdJRe6rHPvdipjt1QKOwI7nGMnPWqeLk6/aKPE9sm2ZN1oLeMmQAruG4tkE57dM9KFoFzvKKKK1KOV+LH/JLPGX/YFvf/RD1+atfpV8WP8AklnjL/sC3v8A6IevzVoAKKKKAFzxjtSUUUAKOtJRRQAppKU9qcEYoWCsVHU44FADKuXF8ZrCC1NvaoISSJY4gsj5/vN1NNN45sha+Vb7Qc7xEvmf99YzVY+npQBPZxSSyr5aqxzjDdK9Q8GNBaaF4uLzxwzLoskbkjAy0sSgD1Jzge5rgW8N6/b6UuqSaNqsWmMocXhtJFiKnoQ+MYPrmut8JWOtanpfjDRbm2vmv00hJYbVoGMpAubd+Fxu5Xn6c0AcDdOshwMALnBx15qvWkmhavLpR1RNLvm0wEg3gt38kHOD8+NvX3qaXwv4ghs5buXQtVS1iTzJJms5AiL/AHi2MAcjn3oAr6VqUlg0oS3tJhKAh+0QLLt/3d3Q1QcEMdwwfStOVtLhRDZm4lkI+bz1ChT7bSavprEUdpLb28ViqXC4kMtokjqfZmGV/A0Ac3SjrVlLG6lhlmitppIYvvyJGSq/UjgVWoAKBRRQB9qfsYvGnwr1MsQqnWpFyx6kwwD9Sa9tt1VLxmcgFhtIbox6cEceg/D8vEP2Lm2fCnVmwWxrMpwvJP7iCvUtS8RacmrmK1Fzd3ivsMcEecshORuOF4ye+ePxoA07cYmTepHLHOcb/mY5Ax6Hn69+71JS5VRFI0GMtIQGU9sdc5yAegHbk157beJtV1DV7hLf+zniWRo/sKiSTftbp5yrsD56quQCTz0Nd/Y3kd7Ck0Dt5uCGB+YoRkYI6jGef0oAkEPy7QhZc4DDI9Dk+vOePpimJBDEJ1XcI2bdtJ6g4zj0GR+nerca+uByWwOh46d+e9Ro7AghQ/HK/geev0HT8+tACpEMZhj7ktjnJJH9CT1yOKlB2pJmNm8tdwDADcck9T9BzXlXxm0i71vUfBllp1lpl7KdRlcx6rC8toFFtJzMi/QkEkZIXqM45bwymo+G/CNprUFvey3vhnxJd2mq2kayNELKRgkqWkeNxgUeRKqngFGJJxQB9CLHtQMgl+UfKm7Pr6n3/l6UFSquUEm4nHPOOOvWvDNT0rR/DukaDfeNbZrrSb77dqWovc2T3McepTvAYjLEgcbkjM0SnGBjtmuZ8ceGLy8+BesXN/pcl1PHq5bw5FNG0lza6bLcRCKLGC6gqCNnUKQOMbQAfTW3Dqq5C5ycLQ6YRARvwwIzjrx7fWqGkaNZ6Jp8Wn6NaxWVjFuEVvCoVEBYscADjJLH3zVoyskih5GAOMbhtzk4xzx26dee1AEc6B8KyDeflbgc8djjk1XmgaTfhdwIzhB944weM/Tr7VaZzycluQepGc4HOB71GYydxydzdMYxjPtzyeaAKzaejTJlNojcMrE4IbBHH58en85I7cKxAABIyOhPIOT06dSOfyqcRyEsVYiTBGQgOTng/l6+g6dKHaUk48zBAxxgD1/OgCo8bjY8a7gMucAAnpge/b8uOoppjkJA2jcSGG3uQMYGe/A+nNWmWZlwPnZeUx1HGOnTqDyemT6UzDMuQxAwPlyNowcEfQ56dRgUAUGVTO6sBsypAJ5yQenbH9DUu2Mr0Q7hwm7j6ZHc9fxp8ih3jOcuxxkkkgYzkDr0Hf8AoKashkZP9WAMnO7rweoI4zigCJolUSFSingAtg49z9ecY5x6VXu1KI4xkqmTnHPJAyAPf8+O9S+cQ7Mm5uWUkghUI79PaoEkLRJIpYRbQ6sFz8p79enze46UAVvGUUzfCzxgluGaV9NvBEF5YnyGA/X+gr4uj+GurvbWt7caiyzsGMoRWkkh4ztUA5duTkDpz1r7Y16R7f4c+JZFlWOSOyunE0/CgiIkMf8AZH8q+YPDd3dHV713vX1CRAxaEwrH9m2kBPm3bAzYZcAA5ckgYIqZNomTMPwl8Np7nT9QSWE2rmFDaz3UKNvkK5fchBIAPyjPucV5jrWmXOh3z2OowTQssg8xSNrAcjK5/hYcgnrjvjJ9itvGGrTiJvD0IuRbXD3d5bRQ5BtnIcjexyXVvMHy8ZOBwBTPiZo48YaFb61bQiO7tWMUzDhWic5jbJ69VJHbcc0k9dRLcd4U8Yy6NqF3out/YHtIBLJb3Fw3lpctgFM8H5jxkc43dOBXcWvxK0K3it5WvbJYpLeKSSRdzAOXAljUKmW2Dnr3WvDJtNvvEvh5dPs9PebWtJcLKqHLzQ8qGCn0OxTjrweal0vR/FGt6VJaoq2wuQICLhIrWIRR4bAJAJO5lJ2jtznsWFY+l/C3j3w3q1i0ttq8RVWcf6Q22TA5+YYAHXj1wfrWf4o8beB5pnt7yS11S5gkwVMRcxgZyFYDkcHoSATk9K8QuPDeq+ENGttUSzhkMV4C15aXHnWxQFlDMp5UhuOeDg9Mc+3+BNR8MavZTx6JoNqdacF7m2eMRlnYYkKyEEAHLEAEcGp2Bmh4F8S+CtY1e1GgaasephmCA2hEkYC5JDYIHbnPGcnipo/FHil1ubeG3006pBOLYWiyq7ksDteTBIjHQhTgnIzjmpIbHwx8O7SWe0s7exnZIzM7TcxBiEyGc4xz0B+bBqG+8Vp4Rs9RheWyn1wRrcX81rD5cce44WSQgZLEEYXk4HvQg2F8Y2mieJMpr2rSrO0oSzgt7fdNFOqhmVMLmQY74x8x5rz7xB4tuPAfhG0t9HW3tPEgcrHbNErS2dsMgF8DBZsq21s43N1rW1rxOPCFsNY166uf+EnvojHDBsGbCB5PMCIMY3+pP0HAGfOLy01maP8A4TbVYoXu9Suz5L3MSypgKM/IOWOABtI2gAk9KEB6L4K0/Tfhlol74h8QX0174j1WHcLSOQFhIcSBGPUN8ysxPHI6kV5Vc6t4k1nVkS1WaybdIyfZ9+7bjaMvncfl65OD1I5zXrVr4N0vxNoVi6SxtqcqpeXEsl7hkknnYHcm7ALKgAwuMr8o4wPQ/Cvww0nRVkluZDF8rBmiZkYjnlpcBugPQjHToOWPU+WtH07x54V1G4n0rS9QtrmZfJ817ZW+XIP8QIXOO+M1u6B4Am1aYp9k/ti+SJTLHHKyxR5+XDMBnHykD/aBwMDNfTF74B8F6kbciKFNuFVobgpvzkjOD8x4J5znnrWhBY+G/BLTXcKNA08QEshcnMcI4OM4yA3YZPfpTv1Cz6nyf4s0PUfCMdsLQX1uFy5hfepjyAMAkAgEkrnGOhy2QK7jwxqtlHrbXf8AaU9p4Y1+3eeK7kkZbe11HGJVcdAC28844Yc45r2v4geFYPGGgm506QyXYXdE0cg2yjjcmT0zt4PGGwfWvBPCemadd3Oq+E/FVyljpt+PtsEjMoFvdBT+8HOAroSSp4B44pO1rhrse739v4WutAjuvEF5FHGm93aS+I8qR9quAQwGc7cDnk9Mnmr4X8OfD68a0m8PCxu57aTzYjHdtIyMpGW27vXaTx6ZzXnvg74J22n32rz+NkSTT4vnglS8IWQ5JaRsYKnAXv3PWs2L4dXUEVzPHZwaFDdxgWWq6bdSzGOOTrHINzM+5TgFQOe/Ipa9w06n0uwBj4bgY5x9KzY9NsnuIJZbCxa5WVZS4hU4fP3gSM5689ayfBniKLWNFMc9wqalZh7W+RsAxypwxx0K55B6dfQiue8Pa74p/wCEilbWLaRdI+1RxxM9uI2xLLsTLdG4dDkY6EHkimnpcr1PWKKKK0Gcr8WP+SWeMv8AsC3v/oh6/NWv0q+LH/JLPGX/AGBb3/0Q9fmsMZ56UAFJRRQAvGPekopaACjFJUsMEs2/yYnk2Dc21Sdo9TQARwSyxySRRSOkYBdlUkL9T2rbsPF2r2Ph2fRLeaMWEzbmVowW6dj1rJtr+7tLe4gtrmaGG4XbMiOQJB6MB1H1qBY2ckKCT6CgBtKBx26UhyOvFOCFyNvOeOfWgD6OtviP4XXRdK0n7c0N6/hAae2otJK8ME+wjyXt9uxumN5zjIqro/jixn+G2peI9NuTb+N7DQhpF3gEO8Xnwok4bGCdpC565x6V5Xonw68Ra0pOn2LAKu5nlbYpBA6Ejmup074ceItP8LeIIoRbST3sMEbx7mBEYnViOQBncsf4A0AdXpPjzRIfFWm6tc+JU/4Q6HR10+fQNkpdj9n2NCIdmwgvzuLbffPFcR4m8aXV98IPD+lv4gu7jUWvLn7Rbm5d2FvhFjSTnkZBwp7V55qumXmlXTW9/C0Mo7H/ABos7yWwIltmRZjwd0avx+IOKAKeMdRSqdpBxn29aWR2kkZ3OWY5PGOabjPSgDb07xTrGm6FdaPZXZi0+6bdLEI1O44x1IzVGfS763sYb24s7iOzm/1czIdrfQ0vlxPYwBd32gsR7e1V5Li4eBIJJpWhjOVjZiVX6DtQBDQMcZq7daTqFrYW97c2dxFaXH+qmeMhX+hqlQB9hfsoNcJ8E9a+xWz3E7a2VWNJniPMdsC25MsAASxx2B9a9JHhVppI4tSke6kWFVZjhGbbheNv+rBI4UHj1JzXnn7IV1LZfB3WLi3h8501tyyA8lfKt92PcLkgdyAK9L0xPEcWsyzau9q8BLbYo25BO0rghQeATkd935AG1BoeniwjsltlSGKNVVNnCDOPl7DPOAOB6VzIlvPCurXCuk9zYEeex6nazADaSRuK/Kp5yQy+1dtZzOz/AHCpUbgozyv8u4xUGp2tpqMawXQOVydpBww7jr0Pb6UALY6hZX8BmS8geJuScgHrjBz0PB+n4Vn3HifQ7NWjuNStVydjc5A+UZ6cdxXOy+A7w3FzIuv39tA+SERF3begGQecA/ePvkd6pf8ACsEnjcLrl7O4kbLzuxUkjk4BABGCB1HrnsAeg6drGnXkpWwvLaUhTK6LIAwHqR1xwc571eTcDwzMzDHBz07+3f2ryCLwje6DqS3gvYbkxYQRGWZHMm3+AgcH5ePXp6Cu08PeLrKbTC2ozGK4iGyUFCdzA4OMevp0GeOMUAdaWZGHygFiQvJx364FQzPFbASSsEZsDOeT19fTPXNc9rfjfSNN0yfUDcKyQxh+QwU5OAvQncSegGeD6Zrm9A1a98S3t5qGpK8GgWys0YZCgkxkEZOcc+mCeOOooA6zUb66v7dRp93a2MDSbHnnGXXHQIp+Uk4zk8emetMmsbm98rz7yeG4VsDZIrD89owcDn1OKh07VNI1bUJLS3RruW3UBkMZUr74bgdD09O/bfghuBGNwh8zeCcAgBQecD15J+vtQBmstxp5EkeZoR80ivhZCCSAFxxkYTGeuD04q/Yahbanpy3NjMJYiMhgclSOob0YYPB6GrUyAwmPbvbhlV/XOQfz5+tcbfeHAkrSWKX9m8jySzPp0+1JWOBuaPoGxjJAz9aAOqdzDGWkmCINzCSQhTnnOcnoOPf191sbu1vxKbS6juUBKlo5Q4Xtjg+v41xFx4feF4V1G0g1GSVylu92C21z1ztXA4AHOM+oxz57Nd6v4OvVuoYbK1ClEkS0j2pKSGZQ6kkAHDYIHHJHJxQB77tAKqCXbbnB4zknj6f4VGJEcRyZBjKqQVbg5x931B4wc1zOkeONG1Ozjuo7+JIiQPnlKkMDgjGMEhuMA+vpVfXPHmhaLaXE09wk5heOJli3NmQgnC4X5sAHpnHHsKAN+9vUs4d93LGqEkF2O3A2nk88Y+Ye/H44t/cXM0tpJbyGzsY90kk6nDycHaqAjocnkdO2R15jwxqt/wCIYb3U/EljBZ6ZHEZI03NiRSwKs+/ptAI2gc5PHArpn1Sa4uoXtrNWZgGt5JycNjJ+bA+QEEhTnnPagAkSa6tkWRTJLIBvVbkmJVx/CCcr0xyB39qxvEV+fB2oQ3832mTRZo1W5tY2EjWsmTiaME/dYkhhngDcB1rvmiVk83yVDbRuI+bKenHJxWbqmmWuq2z2t3HHImevBOPcZ4OM/wA+tAGZqes2lx8I/Emq6XPbXkC6ddyqSQyErCx2sB0x0IPPXNfLek3N54t0KW+1KeykiM6rDbQWjz/Nt4RwHB5JXg8ZGa+l9K8MRaf8N/GGk3At1s7oXeGgURkxvAFJY/3xyCxznGTXz3pfhvRfBsGqR6ndXkFq0VveRTqjboJDIwwu3O5lJjzwR0yOtTIiRpeHXFtei5n8Qwi10q3LXsKWi7PKHUKVHAJ2sO+3Zxk5M/h27uZrm0bVdI+yW2swvby20b7U+UKI5VGB98uUOM/8sznHNR6Fpc0AuovEyW0OhPqE8plvVjzewyIzDlejhkQ44wqrgDBFM12C7TXdHSZEklkcXUpMpWK0BURxjj7oLAIcZBIDDaRmo9CTzn4k6VceHfE84RbuEbgFlJ2rLHwA2Txg8Kc8bsZrM18RwR6ab60u9RVohm5vbuTyzkjhRgMAMr0JHSvcvHej2/jjw1paPfQQ6ntmaC4lUGISKoLxScYUMq7vUHGPSuF0r4Ta2lz9ovbHSPC0MET7rye6Fxk9NwViwA7Z46+uKpNDvoZnw5vta8J3d3q1lpMmp+HJ90U4tiZ44wrbgcHOMejgHDe+a3Ft5GliTR9Q/saXU/NtpAr+ZHdWpUyRTR7Bk8oyMMllHHQYqpruoah4H1CTUfAuvLflYLdNQb7MAsgKjbJgDy2iJwoYYYH5Sc4zrWclvoGr29xbnUX8I6irtZXenxq8+mTuUMqqCGON6YwfmAyAeTuGA2+0nxNq9rpypp8niq6huJpHUB0so2LBWw+V8184ztO1AoGPTodHfxDputS2ut+FYP7IguPtMt/qsjEfuSf3gJxvUKSI4xwox1wTVyPxPpt3qttomi+KbpdNjh+zwTSII/Lu3T5PMl4LKSZXdT829TxgZrG8aeANQj1K3+1eJdRvfDckIutTuLh2kW2iAPmSBiApJPmKirk+tLyFc5vwro138XPG2o6rqc8qaWshdridyEiTJO3PsuPlXHXOVAzW3NZWfiDXb6SOW+t/DOl2P2TSrPTyZbu9WOQqzoinKq7qxaTABxjPUVV1PzH+HkRtbWWw0G5uZP7G01ZVhZjyA7thnckCViSQPlCg4zXqHwrvotM07Vdb0bTFttNltI4dMtQm+e5VNwjlkcn93GxBAUkcsxOSaZQvgzQdW0PSNNlu/wCy9Ev7yORbWzW08+e3RdrABcgvcEYJZvlQLjaATS23iC80nUItOvde07VPEbSFZf7Qbba6YoiVWV2yA74AGFwcyMTkGua+JXxVvNcum03w1JJALNJbfUdQjtfNWEOQnyHbuGTlSQOuMNjJrB8M/AXVb3RV1bWbK6OpmEztbzyrmZ/tHMZ/iBMIbkkfM45GCKVrge56DbTayscur6FaaRcTLIEsiEKzPG6uku9OqnuCMjJxkZz0mg6bpU2nm1Z4dWa1upDLJOfP2T5y4y2dpBYgL2GB2qD4d7P+Ea0mKN98NtYwxxhg2fu/e3Hk5G3I7EEV0dlaW9lE0VpDHCjO0rKi4BdiWY/Ukk00tCkZesXVxYSwXEVn59r5ojnKctHGwH73Hfaw5Azxk9sV4h8a/AQuhqNxo9nLJK0omEUMe5iGyZAoGS2CPMAx0lYjOML9BTvBDshlyBM5QZBIYnJI9u9cbc2tzDC+l2BmmutLk+02QZ9rzQhNoVZCNu9SxT5s/Ljdndmh6Az5Y8Ma3471rT30zT7bVNV06zk8zyBF54jkzlSWKnjOSAeM9uK7DSPHnjXRtRtNN8YW955DyB41v4fLcsjb0CMdvzMyqoLZVdwrpNdknsdTuoPhtfX1pqEyM9/YWmlvLMtyrZ3SbztRCzv93j03Dpd8Swad8UdEh0P+1JzrVnbPI8V9bm3lt51AJYADLI2GVgCxG5COhyOJB0HiO6sdM1bTPGWgiGazacWusPGMgLjZvkxyGQM2ffaPSuxuvEkEN5p63UElrBLdx2ytOADK7syosag5blQxPQLk9jjxiDUv7Ge5l1K3/tbQtcsla+UA5jeOENvZBjCqQTuQYZCrDJUku8Na/wCH4PG3hrR2nTUdMmkhurK980yTpdtI2Iz0KoGkkG11zgn2xCKPpWiiitijlfix/wAks8Zf9gW9/wDRD1+atfpV8WP+SWeMv+wLe/8Aoh6/NWgBaSlpKAClpKuaVp76ld/Z4preFtpbfcSiNcD3NADtJ0q81ad4rCNZJEQuwaRUwo75YikstRvtMadbG7ntjINkgikK7x6HHWqki7HZcqdpIypyD9KSgAPrnOakgleCUPC5Rh0IqOigDulsdE8R6NGNLgkttZiGZl/gcYxnJJ7/AEqhoelpaX5XUreaUKRuaDa+0epGa5iCaWF90Lujf7JxXuvwitl1zUCLxYrmJIBv8mM4YnszZ6j0oAh1z4j32ieTbeGdSSayEezLgNgAAAAN3H9Kfp/xP1zV9B1ZL6e3f7O0AR0CxFsyEfM3GMgdu9c18RPAt1pfjGGzRBY2V/ciNLm4j8qGLc2MltxwoHeu51rX/Dnijw1qWmT6u40XRb+yx5lskBFkuImit2Ejb2YJ5o4GeevQAHK2a6T401uO1RHW73HiaXcD0zg5PHFebeKtIk0XXbyyfaRFKyAqwIOD7V6f8S9O0K1fQz4Zl0a21yaadJRoV088CW4IEDuSW2yEZzg89Tiurk/Z/fW9MtblNcmS/kjEs0lwvmAsQMjHBH40AfNxOe2K6zwz8O/FHie2in0TTBcxyo0kf+kRIXAYqcBmBJyrcdTg4ziut8bfBTVPCtuLi41O0uYM8tEjZA9SD+PeofD3xBi8HeC9Os9OtrLUNbtdRnuIm1Cz8xbRHSMBo+cb9yZz25oA4Oz0HV5dP1LUYLG4+xaa6R3s4XiAsxADd+ox7VluAMkZ5PBxxivaPDvxR0DSdBh0Seyv7kXkVz/aeoNs2yS3QXe5tyD5nl7VC5dc7SeM4rxm4SNbiZYJDLCrELIV2llzwcZ4z6UAPmvLqe3jgmuZpIIv9XG8hKp24B4H4VNqOnNYxW7vc2c3nJuCwTiQp7MB0Psao8jkZFHfr+NAH2f+xpGZfhJrCLjLaxKOnT9xBXtsyeZOBGwDb13bupGScD9Dn0rx39kqCLTvhdqqWV5DfA6w+JIgwGWhgGPmA5/SvYfJDOwTaQFwxGF6qecj7vXtz096AIYr7TpXWHzbdpGbKqz85wcHHX1q3LAu4Fx5sIUh1IBxg5/H6flVW20TTrSyjtLaztooMBBGiAE/U9c989c96gh1GbSr+Kw1VkkjnJFrcEFc46Rt1+bHfvz07gGmNgIVEKkAkKeAc8ev+fenMiAgbmg5J+U7fTJ9+TTZEMhTac4PzZH9Mj2+nbtUcN0yqTcMIX+7sz0xx/UHp/8AWAJGtVkKLM7yJx8pwACDnPGCDx2789q8l+Jnh7UNNh3aUxEF9eWlq53OoCy3EURBAIVgd/8AF07Z7euEvIrGJwp5+VTu4z16cf8A1++K5n4ltu8GTcbQt5ZdeSp+1xdv8jpigDz+38GXsd3YWHiATSW1p+8i8x2eF3ABBRf4AOc4x0UDHQ99a+Fp75Yxquo3MyK3mCPhEUcgJswPlHPJ5roZbHzboEuplCKN7Anbgk5A6Z/qMn0rJufF+mWPjfT/AApJNJ/a17aPdwoVJjZRuwC/95gkhAweI26cZANyzsYLGLy7SFIkACjapBwBxk9+n41K+8lXyoCEHrx3Bzx0wf8A9VQR6hay6hNp8VzA9/AFeW3SVTKit912UHIUnPXrjvVlkYRHGS3PAwCeenUcf/WoAVw2GK7VJXGSM/yPp2qO7h3ICAVZPuFeOemD7Y/nSyBkLMMsvfBOcAdv/rdc00MQpJ7YYHBxz3yOMfX/AAoAjWOCUtx85QF1HXaegI9OpxWLr+haVeRst/awBJVWNXVSrDqRuIOMZ9eP0roE++SFG4lsgEEgY4/p19fSq82Z4p4iVVlySHTfx/e255B6f/qoA8G8SfDXXIZPsujXMSpHIGiLXBCg5zjZ6gDOenvUHh3RJdR1OVtajknjsoCYYbhBCZJHdQ52KAAo45ADucZ6nHuttJva4jZo3eNQVTaN6gjg7uhHPBwPfPWq0VgzvJMWJkDuzySLlsE8AHA24HQjJ5PSgDnYvB93rDW0euXIn0yE7zbH5vPbp8wbovBwO2K6y2tbe2WKK0URwxHCRIAAuOwHU9/y+lWI4N1uUkDFMnDK5Xoc44OeOfy6YoYNjdkkHB5wfxx7ent70ANZFcnap3I5JY5HJU459eQM/wBartbRAxoyn5W3E4Lkgcjg9RzjP17mnS2Mf2iWeQyMZdq7XJKrjABVe2e/5isTxBqqeHbNry4RptNSQRzHJ8yEs3DLn7yg/wAPbn6UAXvEaI3gHxKPsz3SvZ3W6CNfmm/dEbAO5PQcc14q9lDquqW6XVvJJZtY3CXENzHtMu2SIAYPIGSSDxnjmvdLmdZfCOpTQjdGbaVo9ik7lKEggYyc9enOa+TfHvxH0u0uJI9PiS/dFW3cSSOBgv5jqcY6FVXg9cjtWcr30Iludt4t8NadZaNdXFvor6rNAY5La1WaVTvDhFWNVyF2qwwQOeT1ya5fVfDt1caei3Ou6jc3IgN1pk0MmxRsOfsxPTOwRMCSMsD1rB0f4heIPFEc0d5Z3MunySKkiWWyHAycrHISGLfcPB7dMGtbw14rW/8ADs2m2Mkv220dgIXiLIgWSR1wB84LNgbcHBIXoyilqLY9M8KizhBk026dbi8dYrpv+WZkig5kSJhzuG3gckY5GDjrryKw1yzUi3tJLlCUifULJigY8Ou1gCQQMeh4rzm0tW1zQdQHkRXsrRM1hCgcPDNsZhvYfdB3hlORxJtPNejG9lgh+33k9xFYWURknNzA8Z2BCeBtyxGASR0IP4gjL8Sie5024XQLeObVNJYBrezYRybSBlNp6q4LELxygOc4ritRsR4clfUNLs7q90C/UXS3GnM8b28ij737s9wCHGACUUnDZNekWqpqytqHh68gGpLEuZWUMJEJV40nGA4ypyCMEDp3FcF46mk+Hmq2zwvLB4Yup/tixeWZBDcZPmIHVg0e5ckDJXO4EYPB0G13My8vdR1Qafpz+EBD4cX94skumfNdTFW+YR7lOTnqpJG45J61ytnLq/xBuzF4g1O5j8P6PGI7lggg3oDxHtwA0jFcAEHGDXc+MvE/iHx9ZWdx4R8P3MumWd0skV7MmJWcAAFF9ix5GRjrisd9J8c+J9F1CTxcwsdFtf8ASpLe8gW0iuWALAsyKGEa4yxz06cmnZvUEdpF4Dt/F6R32r3dxbeEbRVFhYPhYhGiBQ5JwVB5Oc89eh507rRda8dah/ZMgvvD/g6wUeTPABBNfMDtzgY2oRuI+UA5Bwc8aou18RJpuk6LFHefZJEkuZLxCscKqMNujXG4ncwVSNoKn+5x2xaHRdOaaQzyxqQzyM4Ync3qSPX6AcChFJFDwp4S0Hw/btb6PpsVowQQlzGoeZU6MSOW5PU10kTKQQM5yc/UVVlmxdGFpEjbyvNLLjeACM8EHjoP8irfAkHByR6Uxo5Xwvp1/pPirX45p5LjS74x3tqXzmJiCskfoAMI2ABy5rpnm/fbInUlSDICPuqQf8KzdXa3h1Cwe4kmVh5jx7AWJZVBIwAf4Vbj8ucVc+y4uHngLJNMMs78gD5eNuR2H4c+tAy2jq6qVyVYZHFVZbFSmLdzbzbi4lRQcE/e4PGCeSPx681n6XcXcOoOt5fpd2c/Fs6w7NrckruBwwwQAePutnJrc9aYCADOQOTXDfELw1Z+MtHmOl3SW2uafJm1voW2vBMFDBSwOQCCAR7g4NdyMgtk5HbjpVWS2k2SeW8aSPKrs4jGWUEZU+p2jbn/AAoEfLnhvxRD4aSQajh4TcSJcWN1CJTZXSnlFYY2I4D7GH3G3Ag8k9p4M1n4ezapokfhrSptQ1gzQ7I/sIDWqkgNIzBAMKCWzzzgjnmpfjl4ElRLjW/DFiWlvVdNWiRPMWWP5WDbT0IK53Lgjrkck8V8MfEsdvqnhvRPCGlm1v7q7hXVbpYtzzQRupK5LNj5Q5Y8deAOys09COp9V0UUVZocr8WP+SWeMv8AsC3v/oh6/NWv0q+LH/JLPGX/AGBb3/0Q9fmtQAlFFTWkcUtwiTzCCM9ZCpbb+A5oA1PCeiJr+q/YpNRtNOBRnEt0+1SR/CD6ms7UrYWWoXFss8VwsMjIJYjlXwcZB9DUUwVZGVHEiqcBgMZ96ZQAlKOvTNFKAMZyPpQAjDBI4444opQQPXP1oGM4JwPXFAApxngGvRdI8V2fh/w+YbCCO4adNrGTDyRtjkhsD8q4rTtPF3cxhiQjH+Fe3tXo2ifBzUta06W9smYQjhQ4+cn2GOQf0oA80m1K9lLbrq4IbsZGP9a2LPy5fBmrPPLJuF9aDhAefLucDr04Nd5B8DtTu9Ma4stWsTKhKyQTq0bIR24zn9K4+80W/wBL8J6xbXdpLFINTtFHynDbYrncQe45H50AZOjeItU0adJdJmNrKoxujGCfr619KfAjU9S1K5uJtU1aa+d41cM0hYAk9x0r5VeJ49u4YJPAr6D+CdhrVtpX2zSLWRkmAjjcQDaueWY5Ybv0/GgD6B1yKS4t5IbmKJLcjmV2zj14xwa+P/ip4Sh0LUblreUOjkuuRgge/rmvp7WNM1PUPkv9ZaKBcfLDb7CCRnlt3PTGK8F+OKqt3HHfrYAIuyMx5R24+82F5PHrQB4meTmpIpmjBC4Ge+Of880x/vHAwM06NS5VVXJJ7daAJ7KzlvDIsKF2Rd5x1xVVgVYg8EHBrofDUd1LqcdnBFveZtiqABz6n+tdB4q8D3GnXu68u4fNK72WNDhfzA70AfR37GvHwk1cjnGsykZz/wA8YPSvXZF8/ULAW9z+7R/Plj3nLIAVBxn7hKk+mQPWvGf2WYJR8GNcgtQksj62UXLlFIaO2Gcj0Bz74xXq3hjS59EacXr3F7PcyNJLcjCpEmMqqoWJVQCRgDr2oA7ALtQYCtxgYHt+tNvLOC8tpYLyGOaCQYaN1yCKo2d6rXjWpubYzDLeQGBdVH8/ToPx6nQklVArOcJlV6ZyWOAPzIoA4+18GS2ksqW+v668Jc7Ymuv9SD0AY5OMH3/GrEngXSpUY3j387srBne9lJbP48fQccfWurHDE89PXg1ErHLfNkgtkAZC46Djvg/j+VAHOQeDrOC3lt7ae9hBjCxyi6bdHg549OnODzyK5zxjqAbwdfwag6Jqenz2jygtsSfbNG+9R3VsH6cjnGa9FZD5h4O3pjoMd+/61x3xZsIJvBt/cTW1vLPF5e2SRAzIvmJwD1Hf8/rQB2MKLKhlicOjgFCOPlwMDI/P8a8c1v4Pa3qr6xrL+K5YfElxqqapZBIYzbQNCdtsrZj3ttjLKSCB83Ktg7vXrO38i4lEahbcom1c9+cn9R+VW+jdQetAHmfhX4cXmj+INKvJZ7EQ6de394JYUb7Rdi537Y5mIAOzzGO7vtT5RjNekklgMHIzkYB4+vrzWXZ341iFpPKkhswxKzFgPNCk/MMcqOM5446VnS+NfD1omBfJIFITESswPJAxgYI4P1oA6hQfbjsP61ialpN3LKHsLxIyASY5SzIM9SACO2eDxVzRNVtNYsorvT5VnhYlSyjBUjswPQ1dJwhZcsx7dD24FAGBH4ckkk3X2p3kvHMUbeWgHHGF9/UnP61iat4PuPtUVx4d1mW11OMrK0U7lkdeeDjBUHBAPPQ8Hmu8JIbGOD06f5xTWUtHsYMwY4PY4/TGP6UAYGi6zHe2Ucks0ccqfLJEG+dH6FSD1IJxkZ6Zq68E0JjSF12lstuBbAzzt98kc06fS7Z7zz0ggWQqVkkKDew9z+HX2pmnpJBBJB8yqsrbAzcrGSD17Yzj1xx16AE0oKAMW4VdpPqOemep+6SfamqJAp+bJ+ZcYHHJ7j6D2+lNvruO0t5bm5Ajt7dGllZ+MKAWJz7AfpXG2d5d+NLSG7tvtGlaQziKZZ4v31xGQpIU5/drz15PLcDFAHZIm9EkJByQy5Y445HOOmM59c1DOjSoy4QIB846/JnJznjkDqf15rO1XV7HRrCS4vp0tbX5Vy55yRjCr14BXOBjAzzV2CRbmOKaN/Mt5MSK6kbWQ9Np9O+fQjmgCha6Np/h/wAIeIobeSSDT5BcXDJLMStuDGNwUk/KgwSBxjPavmr4k6Hqd3d2lroFs73lnIjxCdYzEy+S29UUjnBKA5ySW9K+pdahhuvB+tQXipLay2s8cij5d0ZjIIJHfHcV4veeLNMuk03UBIqW9rO00j5zsj8q45OPVYmOOvY8jFRJ2ZEjy7Tvgl4m1+6a58R6pBA21XRFUsAe64XAUcDkVxPjfQNd8AeKbSe5kmjEwDRXkTYaQYGQSP41zgnuQG5zmvrLR9Qm1Lw7Y3lncRpNPapKm9MguQG5HpnIOOeeOmawfjN4Xg8XeALhDEDqVqgurQBsEuF+5+K5GPXFCknoxXaMfwbqlhqd7f8An3GnwQakji8TzRHJCwTcAG43KVWRx0IXLA4Neia614NEUaTbXr3oUSQqyEKTuKkMeQTtydp46Zx1HzF8INcvbTWLmOS3iuUaCMNE4CzXFsjbWWPkZmAwgOc4yOcV9iLqFtLaCdGYoyBgUQsecY4Hfnp1qHpoO1jlPDsKQLDHaahGjJcvYmERLK0bIjkKSeQyrhuSfkUD1Jt6Il1YX2p6d4gu7W40+MQy2MkqhR5TMyeWxP3ihCfMe7iq/h2MSag91qMMVhrN2ojmltZMxyCM/KwVhwW3sCMbscZ4FXn1LR9Z0XUftvlXNtHAYL6CGN3lidlUugC/NjnPHsR60XQFLTPFyeILa2XQ4ZbdY9X/ALOnR0AxEpIYqRxyFOADkV02taSNS0wW0UmJCQokkG8AHgsyE4c4zgHIzg44rzvw8/hPStC01NJvLqWysr/7dLazSbp7ZgsjYZVOVwTnaefXPNdfonxC8Nan4cuNWi1GFLS0jMl4G6wYyDkD3B9c0IZs2PhvS4dGawgiJt2iaB1jkKmQcA7mBBLZXls5yW9TWosnlO28KloigZkyDv3Ed+3Ss2HxXoUt5DaQ6raSXEzpFGiSAlnZWZR9SqOffFSW2t6Xc/Z2tdTiuFmlZUZWDqWCeZjPYBAT9KrmRVrGs0cIm+1iNfOC+Xvbg7c9Oe2aakrSCJkkjYZJJUZDDB6c+uPy96rWutafcXDW6Xto1yFRmjSUMQGXcpPsRyD3FX5WXKAy7CWAHI+bvjmndAcd8TPEc/hnTLDUbe2lunluktYoFOP3jq4RiByVzjI9OR054K28G+O/HNlKfFevXujQx8QQwhVLtzlmVccDJAyecA+lemeMpVhi02ZnRHguGdSw4GIZcH8MVr6VqVteaekyXMMm3CSlXBCvgZU+h56e9JNX1FbU8C0iTVPg5rkWm+Iy974b1KYRrdNL8sbbx++5PysASWGM5GQTjJ+gdNuWuYnMhj3q7AbGyCmSUb8VwfrmsXx14a0zxfoEthqKo2MvBKGwYZNpAYf99frXC/BTxnLqFhd6TrMwl8S6Tm3uYQqq0saNhSDnDYyR+v8AEKLpO6Bdmev01zVS11WwuppIre8gkljALxhxuXOcZHUdD+VSTXkEbBWmjBzzlgMf5xT5kMnY464xWPpvh7R9KvHutN021tbiYgO8UYUkZz+WT261ea+tjdC2WeI3DIXEYcFiBt3HHoN6/wDfQpDd26XVvbtcRieYMY4943OFxuwO+MjOOmaLphYvUUUVYHK/Fj/klnjL/sC3v/oh6/NWv0q+LH/JLPGX/YFvf/RD1+cWkW9pdXixX921pARzKI/Mx+GR/OgCGzjgllK3M5gTGQ2wvz6YFRMAGIU5UHg4xmnTqiTSJG/mIrEK+Mbhng4qOgAoopR0Pbj86AAY5zn2oGM80lKCADkA5HftQAdqVM7uM7u2KSpLeQxTI4GSpzj1oA63wrqK+GZXn1LT2mlba0LsR+7x3AIOc+1fQPhf46abJZbG0HUFlQctAqTLx+Kn9K+W9R1CXUpxJcscgYAHIotbl7Rn+y3Mqbl2vsO0sO4+lAH0Nqfx6037UzW/guLzS2fNlMaOfcnYcH3zW5c/Hq1t/Dq30vhqQqbn7PsF2pz8gbdnZ059OcGvl+7W+MEd7cRXAhmJVJpEO2QrwQGxgkcAjtW0PNj+HUzIrtbtqip5jIcAiE8Z9ef0oA9PPxS8FatPJLffD5pLt24eK4RN+fUhR/Wu80X4i2t5LBp9hokOgEKAC9xG4xjqNv4c18miTA5BJ7c/59an0+5W2m3vCJeOBkjB9eOtAH3JpuoWVnphlmvJ2gPPm3MhIz7N3FeE/GnW7HVZI47W5t7m+lbZAll8oQc8sxwOc15vB4mnNqI7u+eWDaAYCzYOB3HQdhXOSXQllI8uMx5yFfj9aAOjl8E3FlZLd6nf2Nuh5KGUM49OAai0xpFuHkt7hYYQMGaVs8evGSKxdSvTcbElMT4wS8a4I7Y96YiKxZImDxp/fOM96ANUztFfwT6ddFXByXxsI6dTxnn1r0/U9C1jxFpAkXe86j5prhht4HY55Hv0ryBLl52t4GRYggwCq8n3PrX1z8N9K0u48HR2LWU89xMvmTF+Q5wMNkcY+npQBT/Zyvrnwx8D/E90bV57i21p0MUZG58x26/LzycHj1rSOj+PPGmqvfS6zd6VYrN+4iV3t1EfbA4LHA5Yj+I8V2PwU0g6D4W121h+X/ibyOC3oY4QT+QrqbbTpJLnzBuhQEtuT5XJxjJOefT279BQBy+mfDQado0Qt9Tum16JvMW/lYyBnIOQyseRgnnIJODx0ro/C3imLWLm60+4gNlqtqQJbeSUEsD0dc9VOPSugV0Y4AYKx2lgcHgZzn/Pr3rgfiFocmqzWt/pLtBqdoT5cuQv2hFI3K3HqAV9e3HBAPQWk5YAdMHgds+34/8A16VGCoGJ4zjIxwK8aXxx4uuGmSDRbeK5jXlhaOdzDjB+f0/nU9oPiNe/6X/afkpKC5j8mNQgPyqqgrkYyTjqeCaAPXshHBJAwDkHsv8AhXLfFIZ+G3iErjiyfrn0/wD1/jXEXt98R9DvxJdNBq9mysCVt03BQM5O3BHPOcEdK3/GGt2mu/BnxDqdjMXRtLuJ2QcmN1jL7GGOMFcfjnvQB0vi7xNZeGbe3uL4MytIIyEGSobOG+nGPxrkLOTUvEFxLrOvfa7bQIDIsWmMhDXrDIBZe68AgdCT+NdT4ps9He3jvfEF1EljBHIpWZhGHBZCOSQeCgxg859Dg8va6VqXjTUrqbXjPHpIVoo7Y4UTIT1UcEAqcAtnPJGOKAKd9pXiHxle4LR2Wj25VolZS8cuAcBYwQGA9WwOBwQRV2x+FmmpdwXWqz32oTIOWlnwgwP7gwFGc4VeB9BW94g1K40rxV4H0yzdYrPULq4gnjManMaWkrqgPYBlU8dcYzjg4Pxm8WX/AIahtDpOs6Xp15DDNqRhvWjP21Ydg+yqGYMGlEj4ZATmPGRnNAFu3sofBnihZrdJv7Nv0MUiKCVVlwVfAOOOc98E9hXfZUpgbWUnae4x3rMt1svEOgxsytJZ3kKyRkPyyMNyMD64P9Oe/I6lr+q+DrNk1OxfU7CIYt7qKXa7dlR1wcMO7Djvx0oA9BcAkhDgv3yew/ShGKgkn2ABz09B614/ZfErxTql+8emeD5MqpWOSRncEnHynAUL0HOeD9akXx14w0e7+0eJ9EVNLJjDtDbuhRTnODuIzyOvGeMigD1wNlSQpDcqN5znr+lcv4q8Tab4ew17KzO3McMLfNkKSARnnI9f8cdDbXUN3bRzwussMqF0kB3KQT0+v+Fc1r+l6VBqcWuXwiZoIkWCN2CAzqTsK5IAOGI59vxAOZhtLnV5m17xWGfSYh5tlpaPkSK6gjzY2wGIxnng9T0JOBrmpeJ/F3idtK8OPFFawqsklyNwgjG3O3cBtkfnuMZPTpnoNI0rWPF+ttq2tSLFokLn7NaXEHmecFIzIqN9xSw43bmIGSF3YHorR8BVLB1CyBlUfMemfc+v8jQB4pY/CK/u2u013xLMyMoZUtoykmT1JPZc5+UDrg9q6Pwp9q8I3Y8P69qSTxXDkadNL8jSKBlo+RtDewPPPXIr0fb5YIRFUKWYNnuTknjvz+HUZrB8V+HrHxTpU2n6pbs6kExNuIZHH3XXHRgfbsexoAt63bx6v4C1+zlla3W5sri3kkGA0eYipbrgEDmvnu6+D2l6JotxNo13qsl4dkRiEgYSRyN5cg246lGY5HIxXtfhe21S+8Aa/pHim3SWaLz7EvuwLyIwriQlQPvBiOOmPXNPt7Vn2MQxdcMCMjB9vzqJPoSzzuX4LeF0lkuA2pzStKPLifUGjSMF8kJtAxjLED1OO+avn4JeEJGOYdUwCMZ1GXnnH970r0COBgwLRjIOQSM1ctJ3kaQ+VLEFbYPMAG7HRhg9P8mldiR8q/Fj4Q6Z4T1i3uoLi7t9Cvj5aXZYv9gn4wZP7yNzz1474wcnTvhlHY2H23xP44sNOsCoKCyuxcSStnHyqGGdpKk45weK+xr7TrPVbGax1K3iuLOQbXjlXKke+a4GL4CfD9F5024kTJOGu5AB69CP1p81wSZ80eB9H0aHxEkPjo30OiX25bDUPPeKPcrhS5OSAO5HbcOxFe7+HvgXoRvWhvLu8jha2jnMFlcNGkm4vwWyWbaQrAk98dMCtu8+DXh3TIxHpdtcf2PKJBe2hdrg4KYDRq2TndgEA9DngqCL3hRfFEkGpeHG1NLO608SxWN49uHaa38tljZs/wAcblM+oAPIYEg7dzK8R+A/D3h0hfDw8maS1azvIVk3Fl8mVkkkBz83EnzdTuPpVS1+ENtpPi+3Z9RiFhd3q3McLEASmNRm3Kn7wZGuGwPT2rutT0G+bws8uqvbXGuG0jSWWFAnmTAFC2eMgrIwAPAzXmn7T3ifVdG1vwkPD+ftOnz/AGxm2blSVwY4Vbt8wEwx3ANF3sHKtzsJPgl4SNsbWCC5WKRGUuJyCjblIcN18xSDtPQbnGOar2nwY8NxSzWMGq3iXAPnSxQXBRljaVivyg8fJvhDd0yMenpPhfWE1zRLa9CNDOygT27ja8EoHzRsOoIORXhOpeLNcsP2hJr3SdNuNS06eIafIIAM3EduuZvKBPzNHI5PBzwV7mm3oOyPQYvgl4ISaWVtPuZZJCTmS7lO0YwoX5uAg+7/AHe1SN8F/A5cN/ZD5AIANzLjPrjd1969CtZ0ubeKeIkxyKHUkEHBHcHkfSpGYAqCQCxwPfv/AEqrhZHjniz4YaP4d0ubUPDMV/FeMUtiv2iSYGOV1jZQGY44ckEcjFb0nwc8I3Mgl1C2uryfaFZ5LlxuI/iIUgbj64zwPSun8bPoS6IF8UXUNtp7zxANLJsDSBgyqD3JK9PrW3bvHJBG8DK8TKCjKcgrjgg96XUOVHnp+C/gcqR/Y7cgj/j5lwOMZA3Yz0/IV5F8VvhdZeEIbHxToek3ptUDJqVnbXDo0fH31dTuVTyp7YI9a+o6ZKiSRukqq8bAhlYZBB6ginvuFux5Fovw28CeILGxvdItNNuLQwg/I7mRmP32kcNlm6YBAw3PtW3cfBzwNIhUaIiluCRNJkZz0O6rWh/Cvwzod/Nc6ZHfW6yushgS8kWIMM4OAefvHgkjpxXa3AcbHQFthLFQOWG08DPfJFSnJbhyo4eb4SeDjaCK10xrGUMHW5s55Ip1YbsESA7v4jx04HoKntfht4Z06S2k0vS47SaG4huEljJ3gxsDgMScA8gjvk12w64Hb2o4NMLIWiiimM5b4qlR8L/GBcEp/Y15kA4JHkP37V+b9vbm7dltFIYDo8g59ugr9H/ix/ySzxl/2Bb3/wBEPX5z6LLHDcF5CSAOFAz+lAFCSN42KyKysOzDFNq/q95PczFZzkJ93jnFUD24xQAlFLR60AJS0UUAB5PTFJTlOCGGMjnkZpDjHBoASlBKnIJB9qBRQB7KdITxV8E/CFhp2saHDfWV5eyXMN9qUVu6B3G04dh1Az+Neh2CeC2+Fth4Bn1iGMXMUkbX52tbf2iY4rjd5wbGE3CP8SCfX5XHFddffL8JNFBBG7W74jI64gtKAOScYYgnLA4POf1pP50DtnpQRjNADkA7nHpxnNSRQvM22JCz9gTzV/TbSKWPzVWWURkeYFHI9xxXo3hfww+o3AVobWzAKyC4upgQfxyooA4A+F9TjijkurWeBJPub4myfwxmqV/afYpgmfnbk7XGB/hX1THZ+B9AtBNq+oQ3VwyBJJopd24DtgE/yrz29174QrJOlvot4Qp+WQqR5hz79KAPJtAiBuVkaMCVPug5XJ7fz619vfCqS51DwjazanZ/ZGCYUEYyo6H2r5ctX8M3eobtAtba2hVtwFxLvlYnsqjHNfXPhGBLfwtbxFpVCRAM8h5PGeKANXwQkU+k6pHC8br9tdWKvuGdqf0xxXQjv1yozwDz17+vWuS+F09nc6NrLad9o+zjUZFDSR4LHZHkqO4/nXXmPLqygDjPcYA6fzNADkBZXzgADaMnsPeqV1pyTo5UGLduDqvIOTycDufUcirkT7vl5AU4549Pz4qZMFiQvocg9aAOUmtr2KKWCO3QnHJdycjPADAY544xxVoaVLJEhuWgbpwyM5IPY/N/teg/SuhkQuuO/UH0NI33cZxnIBx096AMu2t3glYv5bqMMmF2kc8j7xwBz2A69a8N8SfCjU59UurbRpZzpV+f9IUXHkxqCSGDcfMAM/njjv8AQcjKv8XT5vw7802RQIxFHgFvQjA/P/DvQB4x4b+H11d6tat4k+3zwwwh4luZt48zJAQjHQBc5HUBc5r2SKJYFCQoAOW46k49f89PagR7JN4b5toQLxhfccZP/wCupWBLLkYGBxjNAHL+LvAvhzxhbQ2viWx+3QQSNPHGbiWPZIc7iCjA856dOOBVvwz4X0fw0sQ0i1+zbbaKzXdM8pESNI6JucngNLJ7nIB6ADZO5EbkLsB6nbk46k9utLg7Duj/AI84BHrwev40AVdG0uy0TTINN0qBobSBSkMQZmEa9QoLZOBk4GcAcDgYq8GJUHoW56HpUSQqSkmCHXcRk54J579Dj8KkJIKqo4xgcADP/wBbFAFFrbUXdHF4AO8aoFGOfYn04yKiksGFnPBdN50c+dwzndnqvPGCBjnj6dtZXyzYyQD6dOB+dNYElgApBA6/Nn6j0oA+c9U+G/iO11F4dL+3nT0G+3lhu1jwMkjbno4AAAIOcmu18I+Erw+IUvNS1PWNQENpi3lvVVBE77fuIXJWQLvDNgYLcZyBXqH2WFJxNtUSbmbcVGVyOcHt/wDrqOK3WK4DxggH5jtAQc98dCeP1oARLdDAIx8g6EoOff3BPIz1/OldASMguxA5yQACT+vJp4zu2EHZgDrkD04z/nil35AOF7sOMDp39KAIZQBHIqlWL7sru56dufy9KhuxIV2q42FMZ7np+Ryc5578DrU+QYmVsjcCuCMj0xx0yP51BMcoqEE9ip75J6fqP/rUASwrjSLoMACVcnByOVrn9Cu7bUoZZ7SZJEWaSAsjZG9GKsPYgqR+FbklxBb6DqE9xIsMEUcjyvIcKihckk5xjHOfSvmzxr8dNC0a2u4fAkcc+pz3AkmnaArCSMAt6uSEAzx1znNZz30FY9u1nX7Tw/ppvNaEsFsJGjMixNJsUOQHcKDhQoBLHjn14rU8N3cOrWCzxSxyjzJVVlIIKrK6A8f7v86+WtT8ceM/FtxHqesaNrUXhCR1U2VhAQtxAzfxSkfPl1jHGAdxAIzz6V4G1CCxtn8Q6FqY/s/UpI49YglGDpkkoJjZVOPlWRyG4wQxI6cS00I92ECb2cqGZ1AOecgZ/wATT44GR2YSPhgBsJ+Vcen17/SmCRdpY5OP0qVZMEDkj+VMYye189JFL/eXZgqCAM8j15789uMVkXcFzdWrS2sytqNu4YrEVBKglkX5gQpKtjJGOT7Y3N+7/DFRwW8Udy8yRgSOqhmHVgM4z69T+dMZjXumm61nSpbmK4uTE5kJZyqwfIewwr5IAxg4yT6VH4m8DaH4mtruDWIJZkubiK4kKysjFoxhACuCAOePc10uN20gsME/j2rO8Q6nJpWhXupQWsl59lQytBFy7qvLBfVsA4Hc8VS0AvxW8UTu8caq7gBnA5bHAye+K8s+MdlH4e0iy12ysrowaZFdRiSxO2axaZD/AKQmCAcuAGznh8jGDm14S+LVl4j8RazYWljJLZ2rotldW5MpvSy5IVQuBt7knAyM4rtPE+s6dpVii6mFkW7ZbdbcgEy7iFIweoAbJ9gaSa6hY4P4HeLdY8XWsk17sTS7K3jsoXfJmvJ0VfNnJPbJXAxn5jmvTrWQXGbiK4WW3dRsC4IGM5II65/pXFfCXQbfQtBFnaxlYIpppreRMNG8Uz7wqt/FtwFJ/wBkHkEZ7mGKK2t44oUWOGJQqIowFUDgAU0BzXxF0OTXNDt1tLKG71C0vILu182UxiN0cEuD/eC7sZBGcZBHFX47uz8N+FLWXV5YNPtrO2jSTL5SPCgbQTyemB3NQa/408N+H4ZZNX1zT7YxjLRtOpk+gQHcT7AV4J4i+IumfFRJNO1O/g8P+E0nWWWWaQC6cRqWYYBI+Y7QoxuOGIztIocl0FsfReka1p2roG068hnYwxXBRWG9EkXchZeo3DkZrQYkD5Rk5HfFeCeHfEWi+B/F7waVZXUmm6lEDZzqsbreIPmVIZV/1hUNwr/MASoJJRT7jpmoWup2cd3YTxzwSdGRgwz3GR3HQikpX0GWunWg8H60UHjk9KYCBQCcDGTk0cZA706m5+YjB4xz2pgOooopgcr8WP8AklnjL/sC3v8A6Ievzz8KTwx3hW5t1lixntkH15+lfoZ8WP8AklnjL/sC3v8A6Ievzw8N2b396kVnGjTD52MrFVA9sUAaOraZa2+oN/aEjx2c5JjkjUZTn+IfT+VYmqaY1kFkjnhubZzhZYmyPoR2Ne4+G/AA1zRpIbmE3MyfwrKCT6nJPr0rzXxv4NuPD9yYII7qMZy0NyQp+o6ZoA4elBweMenSpXtp0TzHhkWP+8UOPzp5spxb+dszF/eByKAK+aKKKAEpaOMH1ooASloNJQAV3HiCLyfhF4OJJPnahqUgB7AC2Xj/AL5riMcZ7V2/iyR/+FY+A4SuEBv5FOc5zMoP0+5QBxFKDzk4+lIOaKAN2xmmuLdY7exBWPkmEMSfqRxXRzeObxdMFlameIr8534bafbj+dZnhvxTLpemyWotrWWJuWMuVIx9Dz1qpq/k6nceZaxrDxnaxIB+nNAGdPcyXRDpCAwOWcMSSe5POOvtWjZ6Os4E+s3S2UOBsZxu3+3Bz0rJjlNs2FChsENt5/CpllxKjIEO35iC23nHufp9aAPVvDcmjeHLSO4sYYZZnK5muIznPouCOte9x/EPSr3RktLe+Sa+eLBjtv4M9ct0BHvXyXpFrquv3qw2DwiUZwUYDb6ck8D8zXunw8+H+rNp8zra2LSSDb57SSbE/AqDn6ZBoA9q+Bsqv4Y1MLdfahHqMibyckfu4zg/nXeHy2lYqCcHJOPT/wCv/L2rz/wH4RufB3gTUtPika7u7q885jEfLyXEaHB9MLn6cV0kV7PJbpJ5d3biaPhXUNJGxOQpwfvYx7Djk0Ab8TLt/dnJXK4GOPw/WljRstuLfeyCev8A9YVgPqEkGwSPK5aQxCXyx8oOfnYZ6DHXvntg4hjuNbmunNvdwLH/AAxS2T8YI+VpAzL03ZPUHHBoA6bcHJUhTkEYxkEf57U/aOcdDXKi91e3vJ1kWxljkjDW5ijfdGzMeZAWAZTnqpz14OafNf8AiK2V5JdOtDCMsSk+Dgdzuxxx3I60AdK6jPy8MBwT0H19ajVcDdIBkDGeOR6GsiHXZlvZoL6xljSNRJ5qlSgUgnHLBi3HZSOep61XfxbaR3DRTo8a+YqRuVLLISeNpAPPfBxj1oA6Bgu8MNpJJIyOpx6/T+tNeRNjbTtG0jpjp/n6c1iPrF0xd/syJa4JWcFpCB3BUhevYg4Hr2qdZ5Ch8pjbrFjLC2fBPfBIAPBPOD1HXGKANNFVWf5idzB/mY8fT0HH0+lBfLgENtJGDn26+3pWLJNrcMsm+fT/ACiQsClXLvz/ABAe2emfXHGKvRy3EbInkvKSMyMpUJuI5A74zgUAXo++Cu7scZ4+n5VJt9XY85/TpWNeXslnHvm2hTjDfKWJwMdSAM4bGT29ucsa7qIiQSRW8bSOQomwvyA4J4ZsnkHHfke5AOriiCZbJ5JOCxI6+nalbK5YAnHOPWsuy1X7RvIsLmMAcO6qVkHquCTj6gH1pE1VwoN5bGJu4QmQjHVhgZIzgfjQBog/MFyRjkjjA/8ArfX/APUM67AWKhcY6Yx/h/8AWrIudeSC4ih+x30iyHaJFjUKGB6ZYjn8Ki/te4ljZmtWsZSSq/aZAMqOc/JnH09PTigDXdd0bLjK5PbOPUd/ft3ppG9uDsUHKsPbPI+vftg/jWHf6jcsVS2txI4+SP7RKEUtg545YgD2yfTGaW2ubpXjRpY90YDu6yBiznghRj7uM8nHPr1IBrSZBIZtvHDFs7epyAfp34/KopOAjDJ3cAEbhye465x+PFQSXt1JLK0AtPLVQWeWVgMEHPAXjGO/19qx9c8QvpdpCl6Fa4bPyW8iYkAODgvjAwCTnHYc5xQBb8aRQ3fw28WW808drBJpt1G9wwyI1MB+dsdQAe3YV8u2/hrwN4ctLnU0t9Uiksbcz29xqM6QpeS7TtjWMjfhshgdv8J5FfRk+pXur/C/xhcXFvaWLfZrtLcTyJJGE8jhpDyuMk57YrwDw18H7ma6n8QanqQ1vV8LdQW9zC0VvcSNyBIzjLLjqABjp9Jl6kswNU+LXirxZNdW1hmHSmhe2a1sIsKsTrg5JGWI4x0x1GK3vhx8Qk0uW80XxELVYE22721xCQZINxBj3dtvmbhuzwCBywrrbP4YeMoSbvTPEOj6DPsWIQabYYjRNxYje3zE5wc9+c9jXJfHbwdJpbtq2qyx313PFhbuCIW7zBApKyKvyMyhTyMZVs/8ssFcq6bk+p79c+NtB8Ni2srvU4/Lt0WKaY5/dMR+5LkDo21hnpkdq7GCcMi5ZAzLu69enT8xzXxRd+O9e1Xw9YwxQMNU0WFIrmWG2WRpLcMskUpPUbWVMt05Uj7zZ9w134taXpXgex1DSdU0bVtQMRj2tKbdsZGVWMDcGAK9dowjHOcAw1YtHrmma7bX1x9nhWeN+dpnhZBJhnB2Zxn7hPHYj1rbQ7uAMV8laN8YvE/ifWgsSwSTLJ5sOnRERtLEeHijk4YSYCspGTkMBnIWvpLwJ4iHiLSFnXBZVUrIHDCeMj5ZBgcZwwK4yrKw7AlrcaOmU5A4I9qXg+9A96CQo5IA6VaA8b+FXgkfDifxZretztb2CXE4tFeXKx2gYMX2ju21Pf5RTfDN03xS8Qald3kSPoVlM1mIgnFyhEgB3dtoZWyPvZ+lQhNY+Ies3Ms0c9v4YnmWNVibBvbGRArZ64w684xwTg5Gas+NfGWg+A9Fh0jSbm4tF014o547CFN9wfLx5IdvlDYCs7clRtHVhU31uI7zxV4i03wVoMMl3c21vDGyRKJnC7U9lHLYVTgAc4+prwa/8deOvildxWWgIuheG725+zQ3ZDK0jAMSu8csflJKoOADk4Brkrd9U8aeJX1DxXY3msandkDS9K84rGinJEjqvzLCoYdMbstz1J9E1vxJH4XuIfCfhy0ufEXjBIvs0s8CtBDaAgFo4I4yvljgZ246fMxI4N99ROXYxr/4B+HpITJaeM7aaeGdYLsTyoqCXqyZGSGJPAPNcT4n8N2eveK9Q0zwxp1/e6NpcMcOnaZpcqu8qnJaeRyGCgsXPzfOd4wMA16DB8GbvX9KeCfV9Dt78OtxeaZp9siESKG2pJMCzBhvIJwQOeCfmr1f4bfDax8JQpLJFbC7WRpEitQywwkgrkbiWkfaSN7knBIUKDiqXM9wt2PkGz0l7Qaho15eT2cUc7y6W7OqvbX64/czr1jLDKlsAblVgdoJr0P4JfEm98JeItUh8UB7fSLi4Zb9NrE2N3kgEoSWCsFIIGfu8Y24r274n/D+y1Vm1Kw0Ozuruc7bwco78YWX5cbymSGXqyM4HO2vnz4x+FNQsIrjU2Zhdt5UWoRMmGliYF7e4f8A2sKYnb/npGxz89JxX9f1/XzGrrc+y7WeK6tori3kWSGVBIjr0ZSMgj8DUuK+EfDPxN8Y6ZElnoutX8ewpDbWKIJ41iweF35IIOB3yD1+UA+yfD/4w6q+trD4jk1G9QSSpNAunrG1vEWXZM2wZIQK24Y/j4zt5L2V2O6PoujvUFld299Zw3dlMk9tMgkjkjOVdSMgg1NiqAWiiimByvxX/wCSW+Mc9P7GvP8A0Q9fBPgjSZb6/KaaYZpSMnLFcA/5/Wvvb4sf8ks8Zf8AYFvf/RD1+e/gjUrnStajurZY2C/eVzwRQB9V+Dvh3PFp8F8bmex1BAGxZzZH0O/Oa7698K2fiKzig8QWMV6IgGEjja2f+A4rO8HeKo7rToX1AW8AKr86ElTx244PTrXXrqtpZRgzSt5UhCK2C+Se3GaAPNvFXw00a3ty/h62givEXKxMwIbPqGz+dfOXxZ0G40q2ga50eSyYscyA7kJ9tvA/GvtXWNP0vxBbqWYuVwyPC5Vvpkda8W+L3hnWNLs5GFt/bmjPwYo4g0yE9M+3bIoA+QKKtagjJdyK8flMGI8vGCnsaq0ALSUtJQAUUUUAKPfOK7Hxi23wX4EhOMixuZSP967mH8lFcbXafERGh03wVBIQJI9CjYpj7oeeeRfzV1P40AcZ2opwVerFguDggZye3ejaSOATjr3oAntI45J41lmEakj5nXK/jzXpfi1dHGiwq1zCJ9gKPE5fPHQ+nWuJ0izSSUfZGJkChjgbz79Old3a6feXL22bVbiI4XiIsxPQdDxQB5/dRTyWiT+QxUdX2jLDGecVq6H4T1bWp0W1WM+aAWaZiqj6kj+VexaL4E02UxSCSeyvUUCXKeeAM/3RjH411uo6lYWj2kNtHd3ksQ8tYkfyA/PUjnqR/wDqoAzPhV8JrbTb4y61dWl1DsykMJDnIPPJ+te5vrkGlW2wKiQRc4XJKr9B06Vm+H/CthPHFez6OllebQQBJnbx6jrXMfF/xVa+FdLhFnNCk8jlGMeCy9wOv40Adla+J7XVvAeoajBFdmGKcQbY4z5h+ZMELkEj5h3HHpVWw8S2+szXEAurzzxEf9GntjHggnO1QS3qDnI47Yrkvhtdx+IPg3rcmqTXskB1IbmhfbMQpgYAMCNpzxnIA6nisrTfhusiBr7XtXvLR5kNpHbfPLGdy8mQqwHQ9PYnkkEA9Zn1BpWVbidYfurB5fyMzEY4LDPOew6dPWpre+c2heZLmSTJchQ33QRkllPI5yMegHArzrT/AA3e2JSHT9RuFtp2aOZtRtfOm8rnmMgDPGBnPTrwKvDwTpsNywtV1WyMzGaNrKWSSJTtxuYMuwHp908Y68CgDsotb0W7D2dvIs1tCELLGN+0MDj5eWG4dBjnt3xduPEWmR26+ZJLGJ1+XzLWQKT05yoBGa8xuNB1ZtEJbULK2uiyiFpvMlWdV4Cu8eAGUD5cdNx46k0LiHxxYXqT6R4ntJbmVAs6mcTjOeirKOAQD34xjOOaAPT117RmkL381tHJG4TzHcRgc/Jgk5Y5HQdCap3niSwWVIbFnnZkeeM79uecfLgZA5JywxkD1BHm8U/j86heNqFjFcv5TGC5s7C3RpWGQAZnJROS3JGfmIwM8aWjTeOL43N5rCaVbrHsSWG2gNxLdICSFDB13MBuPYexoA7qXUwb+xXAnguGIw4ZiEAB+4qHJ6n5iAAOcdC2wu9RNz5SjT4sDOJUk80Lzxtb3OecA54rk49E1TULm9vJNTa0tfsp8nT4lMcm/Iy00idEbBJUEfNjJ4Nc3bz3KWUmmQ+IrCa+KqsFvCJLqMOp6MHfKHPAwCAOo4AAB6r/AMJdDOsyWqXK3CEpsltHTc4wMbgCOR0OcY79cTWeuC586LybyG4EZk/fJvXCkDIIOBznj+VcO17rUOj2891f2uiakZUWb+0BvL/LtJVo3Un/AGRgZz3xmquoy+NHuvJs9a0C2jRwROVmge4BQcNCc7fm+inHIzyADuX1uxSIzXyrFDHgmW4YKuc9QcnPQce496SPxFZXNlCRuliix88KxvEnUZJycAYOMe3FcRZL4jby7rWbzw1cylwrCNpcbcchlTK5PpgDqam1ltWuLSCTw9o1jfWiglbaMERZ6fPhQCRzzn3yM0Aeg/2vbSW77ruVzJvRzGnnKvHK5X7p74Jzx6YqJ7zTxZBbl5QjD7lzlJABkhWzzjnOa8/0671yC7I1Hw94ihvFQtG2lPA1vNnBBD/e2/KOCD1HHBrQ/tzWJoZxf+FPEtxNIv8AqNqDd8uADJuCheuccknoc8gHSLexzSxWNxa+ZLHCSSMYiU/wkbtxZhzgdjVdvE2iIQiSxTBlHmIs0b7Oo+YDnOeO/JGCa4N5fHd3ZxSWPhzQknkKSBZmdZY1B3BtxfllJxye47VraLF4wSW5u7iDw5FOUEMaWsBJkfukzJkqAMAD1PTigDp7bV/JW1igsFjcybVH2gPhSBk8HkknOOc9+tXbzXdPijK33l20sw2iEqBJKCOOOnY+v6V5xfwavqT20iaVE99aShSJ47p49u08pIwUEjGQxPQ/jWnf23iiKdP7EtPDrabMVkX7VcyblA9Qxz+Xv0yRQB3tnqFk9sRFa3MQ3EGMQMSfVzkY289f8aj1rULePykeMQLcHZtkCrI5Oc/KcZB2gnpwM/TznVJPGVnp9udP0G5lnkcGVtP1h2ijG4ZBUr+QyRgY5rH1yy8ZQaZB9vvdH0qe4twtwl/ctJMUJGUWQYWJdpYHbySSPegD2ewurbVvCmpiwcIpSWEsqqdp2cHBG08EEZGMYBFeNaX4Ks4/Femaz4VvLi5uLW7A1aS5unZnjcAFGDHhhndtwOOnYV6n4BWG38Lat5dxBdW6zyMBaK0m0eUhK5yfMbOTleDkACqEukad4l03VILSO/shcwvbNcBGgGXPzuin7zgqPnI6hcEiokxNGZpnhnXNV0C80rxdrF0zTySEyadtgRYSNqxZwTxjdxjryTWn4k8KXHiDwzqGk3v2WRQ+6xZkLbQqKE8zJ5JbeGx1Vsdya19E0w6QthZi+vLpFijtt0xQn5Iz83TJLYJJ5OdvbNSSX7Ti40rTbiWPUbaIxrcTJuUShEI39N2fMU8HnB/GU7O5Nj5Rj0LXoL3TrTR/KtNa05yNDlfEU10gkffbGQ4RnUlgA3TbIp4Kiuc0Lw9q934kuETwLJd6hFKCdP2Sx26NgktKGbkHjA3Kv4cH6L+JXwvbxNq8y6XdXenSvMbuKUEPBHcnGZAAdyBtuH2/xeW2OWrd8FeJ9audJj0PxRjQvEqqkSXl0EZb5g5BMa5wxwADz1YHHaqv1A+dtdubrTNRspZ7Xw3pF9Zu83k6dbDzrC4DZInQlvMjyAe+AeMYIrp/2f8AVr7QfFF/ot7frp95cotxZC5BMFxvKs2T/dZRlSCMEdeSD7Xrvwy8Ha5YzQLZwWmoysZ2voExcGU7suxbJbJ3Eg5zXjWu+AJtLvNO0zWtWsrGa2QmyuppgqNblsmLLYz5TnOOu2QkZxgktdw+HY+ohqdp59lF9stvMu1ZoEDgmXaMkr6gCuU+KcPi26ttOt/B0duf3jT3Ly44MW2SJRk/xMuP8BXgMRbw74q0fV7u4u73R9JmijlvYHBiSTa7NHAWOJFGQDgdc+xre8afHx5tHvtP8N29zHf3Lssd0Su6MNwNgUcnOcE//qV+hV9Df1D4t6R4H0O807SEiumsXFjp9omV+6zbmcnJwvyjgDOeM9RxvgjwYdaA8QfEbTfK00DydMsIomL3szM7nbGDuYkl3OT8xbJO1aseBtC8G6SXtfEGm3/iXxmyJPLZwozCGRjkREKcBhwXLcKa93tNMha/tbqS4LahYRB5FLCUWwfO5Y4x93cF2g4ztGB1ORaBucx8MfAkvhue81N41h8Q6xFNcXMjESLabpAyR7eMnBOcHbmPgYxXo2naRY6fNcz2ltGlzcuZJ5to3yscZLH8Bx0GOKh0HTUso5JjGDd3QWS4nLFnkfHQkjO0dAOw4wK1SM98VaCxFbwRW0QjgjWOPJOFGOT1NSnPakGcnIGO3NLTGAzgZ61xfjjw7eX+l3M2kx2t5qUcckSW98pMVxbyFTJA5yOpT5WyNuB2zntKimjd4XSOUxSH7rhQcH6HrQJq6PmNPh3c+GdftfEXgHSr59VsmLXOlapG58hmUDMciYWQDLD73QZ56UzxJo+v6v4x0y98ewIF1CBC0OglvtcDRbjE4jfJyGZc44AbJHGa+mY7idSY5raQsqrmRNuxyeu3nPHXkfTNZHiHw/Z+K9Mi+2wTWd7Cxe1uRhZ7SQHh0YE46DjOCODU6MVmedfA3VI4b6bTLC+STSZ4jOtnJhZbK8BzPDt6hOdy+xPcGvZ+vTpXzT4wt9P0W9h1X/SoR5/2XUhAPKn0y8DMyXKHP+qdmkYA/KQ7YIJAHR/D/wCNU2q6lBp+qWq3El5fRwQzQfIsayYADDnO1jjI6/XipTtoVfue50UUVoBn+IdKg17QNT0i7eVLbULWW0laIgOqSIVJUkEZwTjINePab+zR4P06XzINV8RMc5Ae4hIB9ceV1r3GigDh9A+Gul6JHNHa3+qSRy/fWaWNgfw2Crum+CLXT08u31TVvLzkI0ykD2Hy11dFAGZDo0EQ+SWcHGM5GT+lM1HQba+XDSzwnIO6IqOn1BFa1FAHjuv/ALPPg3Xbqa5vJtVW4l+88UkSkfT93WF/wyp4H/6CniT/AMCIP/jNe/0UAeAf8MqeCP8AoK+JP/AiD/4zR/wyr4I/6CviX/wIg/8AjNe/0UAeAf8ADKvgj/oK+Jf/AAIg/wDjNH/DKvgj/oK+JP8AwIg/+M17/RQB4B/wyr4H/wCgp4k/8CIP/jNauvfs4+EdbksXutR15Gs7OGxj8uaHlI12qTmI/Njr0HsK9qooA8BH7K3ggMSdT8Rn63EH/wAZqRP2W/BKHjUfEOOuDPAQf/INe9UUAeK6f+zh4R09y9rqOupIV2lvNgz/AOiq7DSfhlpGnlS95qN3tXaPPaIYH/AI1ruqKAOOu/h7pEyOsEt3aFzl2gMYLexyh4puhfDXw3orRSW1o8s8YOJp33t9eeP0rs6KAKb6ejxmNpZdhGMZA4+uK4Dxb8GPDHiiUPfSajEQc/uJlH81Nel0UAcN4U+Gej+GfCF/4csbm/msb25NzI9y0cjhsIMD5NuMRj+HjJx2xJcfDnS7pJUvLq6uEkXYyvFb428ccRDuM/Wu1ooA5aXwVZzLEJru5k8pQkZaG3JRR0A/ddMcYNNi8EwRSh4dX1eMgs21JI1TJ6naEx+ldXRQBg2fhwWs7yrql+xfPmLiFFfJJJISMDPPXr706Xwxp8m0kNuUghmVHIwePvKf8mtyigDFbQXPH9rX4TcWVRHb/KT3B8rOffNC6CY5g8Gp3sKZyY444ArH1P7vJPHXOa2qKAOeuPCsEzQOt9ewyQEeW8XlqVx2+5g/jUq+HIEiZYbiWGRgVM0UMCyYPuI+K3KKAOet/DAhYt/a+oysSWzMsDkE9SMxccEj6Gr8GlmLaTe3UhUBQWWP7o6Lwg471pUUAZP9g2u+Rt8uXOTjbgfp75pJvD9pMgV3m+UEKw2hlz6EDI6D8hWvRQBRttNS1tvItJpYRkncu0nn6gj9KVdPVc4uLj5vvfMMMeOcYxnjsPX1q7RQBmtpELIE8yVVUcbNqkc5zkAHP41Qj8IaVGbto1uEe7/1zpMylznOeOAc9xzXQ0UAYFx4XgnshZyX199lByIgyAYxjHC5I9iaq2PgfSrG5M9s1wjkAEZQjA6DBXpXU0UAct/whGmqZfJluohKpRwCjAgnJxuU4z7Yqqfhp4Za38l7FXTuHVW59cFcZ/wFdnRQBmWOmwaRptxDa7vLO6QDCjb8oGAFAGOKwtMsGsr/AFC4jcutysQ3SySOwZVIOdxwFxtwFA5LE8musuBm3lBwQVI5+lZ8CAHjhSw6cHjHf8KznuJla5WAKs1xEXW23SpiMsyfKQSoAJztJHHPOO9PggjiSJog0hSHywzcsw+XGSeSeO/41LZYuIEaRDDLKiyPGxBMZI6dxkdODj86tbAMAc+47d6V7hYydU0tL4WLie5hltJPNjlgYBlO0rznIZSGbIIPXPUAiS/sbGYpc6mkci2r+fG86qBAQuCynAwMdznvWjICIi0QG7oAf/11W0zTLbTopobYSiN5GlZJJWkGWOTjcTgdeBxQFjmfHGnX5Gk39pBNdCzuFaSK2+R1QyJ86jnJVVyRzuAIwc1ynxI8PWXj/TZbZbS7k1zTbd3tJImCRuzrkHJyNrmMjkDBRlyD19Vs7C3tDc+Ur4uJPMk3uWBbaq9ycDCjgcV5vb2ereEIdQ1u/nsXsrabyFkVSFa23E+ZMRkgqx5YA4zI2ME0NPcLHlXhf4feMrawa58WXUFhomk2Zjji1FBcQrG/+sAjUkpgZBfg9wcc1pabp2jeGPFa33g+Dw9foEK2PkTPeXt3OELeUgLFYyCV3SEcJ6HJrofiN4mOsXVsun61aR6ckyv52l7ryM/KQDeuNqpCQSu3Oedx4WtTwZa6FZ3tjefD/wAJfZbm9nEUt3K7GKO2Co8jruJxkkRjAGSSRkCqTtohWNzQ428IeHlsNH02XVfEtxIDdkARq9zIC8jSStgbRhjgEkDbxyM9D4I0abQobuK5CRLcXTmKGIFwQB/rHcjJd8ZOTtHyqAMc2rzQ49XuIk1i0he1t2S4Ta7AvPghiQpGVCnGDnOTkVsq8wu5VeJFtQissofJZudwIxxgAc5Oc9sU1vqNInFc9q/iiz0rxLa6XezW1vHJZTXsk00wTYqMigAHrncx9ttdAMdRjnv61WvtPstQVFvrS3uVRgyiaJX2kHIIyOtMYzR9Rg1bTIL61DiCcbk3jBxnHI/CrtQWltHao6QjCvI0hHbLHJ/Uk/jUxYAgEgEnA96FtqAtFFFMAooooA4zx/otxcp9ssdPt9QSeP7FqlpJkNcWZyTsP/PRCSV/3m74rn9B8H+C9FOi2OkzW8889zDeW5aTDzhAZY2ZkwGKqHZdw+YBxzyR6ddrM9pMtrIkVwyMI3ddyq2OCRkZAPbIrD0jw3pWjak17Y6ZFFfXgAuJIMiNdqnkKThRkkfKM/N6ZwtbisdDRRRTGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEdxgwSZxjaev0rivBeoeIr+S7l17TrfSrQNttoVlEszjJ+ZiDtXsQMd663WEnfSL5LOVIbpoHEUrpvVH2naxXIyAcHGRms23HlhFY7yFALEAbvU8VnPcTNMMCcHgkZ9RUVzNGkbN5qxR7SzyZxtA6tn2qDzgEIXB4x1wP0pGkUqQ23Yy7SOCCPx+lTcLl9ckbT82PXqacGCn5mXYxwvr/9eqrXC7cj72Oh4/lT2bJVuDtIOSM/l+tO4yxFEYt+Hd9z7sOc7c9h7VR1fSI9Sezd55ozbOTtGGWRWUqyOrAhgQT+OD7G2HJAJJ4OeOac7OzIigEH7zenI4x7jNUgCG1t4Lf7PDBHHBgjy1QBcHqMVyPhr4eaN4Vvpn8NW6WMF2ri7wzvI4/gVGLYRQSx4GemMYrqJ4FmSGMSTQRxnlY2K7wAQBkc46H8KsuQCuQfXg/59adwIrgugt4ktzcRu3lyEsPkXafmOevIAx71Z6UgYHFMgmSeJZYm3Rt0Yd6YCNcRLdR27OBNIjSKncqpUE/gWX86lqFoIWuUnaNTOiMiuRyFYqWH4lV/KpcjNFwFoPIIzj3oo70wCkAO8kn5cDAx0paQDAAJz9aAFAwMUc5znj0opAwPTP4jFAC0jKGKkgEqcj2OMf1NLSfxUgFooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF+zLY3LJncI2IwMnOK5t5JFCMCGOQVIbA5Gce9b+szra6RfXDglIoJJCB3AUmuATxQkd1NHLbDbuKghwSAMglhjjJB9eO9ZzJZ0pSRFL/OzHr8wwDjGP8APrUVxebCI2DmU5AUKTtPbnoBx3rB1XxpBZRN51rO6+R9oJixkLibjr1zA3tyPem3fifT4Y764ZJVMMLO4OCWVJCnHPY5OPQ1AHWRzr5KkDdgcgHj0q3HICvzDb1Ckc1yMXiaxjVHSObJh8z7oxj950zx/wAsm/P3qhrfjRbK3tri2iDwibddMo+ZIQjFmAJHzZC/nRcd+h6Esy4OOg4wR+lKlwSWPReBya4KfxnYRTtbr5iss6Q5wPvO0QHfp++T9fQVRPxBsYYYyZJT5pYL8oxxIY/X+8DRcLnpM14scbtglVBJxj+uKi+1qAegcc/Mevv9K4BvG9iLSKWUzNHPC0uzaD8oJBPXrwat2/i22eIzRnEXll2PGSBKIjwM/wAR/Ki4rnaGaZj+7XfnkBQABgdCSe/0qzHcEx5cFSOvI4rg7Xxta4kmkvWeEKWCpblSu0AnknnrVmz8ZafcpO7eehtt8jAqeAobrjjkAkf5wc1ijuFk+fBbGOcYo3ozKTg46E9K5K28WWEl69t558wKmDsODuUMPx+YVOPEml7yzTZRFLsSjcABskcf7Jp8wHU78ZzgADr2p9c1da9p0cCzS3C7Nx2ho24xtB6A/wB9fzq6de05EjZ7tAJHjjXarHLOQFHTuSKpSA2aaudq7sE9yOKzodZ0+WMMtypGeuD/AM8/M9P7hzS/2tYQwuxuFWONGdic8BV3MenYHNPmQGjRnnFUJtUsoFkklnRQhwxz05X+rr+dI+q2SyIDcRZdxEASfvZXjp/tr+YouBodKRRtAGScevNZcmvaapIa8hVgFbG7qGcxqfxcbfrViLULWaSFElTdISEU9yoBOPoDRzIC9RRRVgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLWrI6lo1/YrL5RuoJIRJt3bNykZxkZxnOMiuNm+HSSXF1MNRCvPzkW/Q8dfn56V39FJxTA4O9+Hou42jk1M4NuLcH7PyB++5B3df35/L3qDUvhwbqz1OGDVEha8tWtwxtSQhMgfdgOM9+Mj616HRRyoVkeczfDu++yrHaa9FBItukKubHeMq8hzgydCJSMewOe1VdR+FUt7aX0D6+4S4h8lR9kUiIbNpI+bJ7nr3r1CilyoXKtzx+8+DU1zfNcDxHsRrgXDRixznDQMBnzPWDr/tn05rv8EJHSNT4l4QPj/Qe7TNLn/We+P84r2iijlQ7Hj83wYea2ggk8RNsiieL5bPG7dnn7/bNakPwt8iDyodadR5ZQ/6MOSZ/Ozw34Y/H2r0yijlQWR5NbfCO4gtbiMeIEM0kUsYkNhnBdcBsGQ5xxxwOO1SSfCCG4S9S71dpkuY2i2mAgKCB2D9mGe3YfX1WijlQWPPbb4cNFqJun1ZXyqqV+zEE4Cjk7yOi9gKevw8aON44dV8tDE8QAt843b8n7/+309veu/oo5UFjirvwO09qsK6lsG9mJ+zg5yY+Pvf9M/19uZbjwX5sMES34WOKaCbBgznymU4+9xnbj2zXYUU+VBZHKWnhFreHyjqG9MY/wBTzn7MIf73tu/HHvRc+EnmtLmD7eB50E0GTDnG+PZnG7nHXFdXRS5UPzOZ1Hwt9thuE+2BDMR8wi5GGjI7/wDTP9fao5fCbyNbt/aGDDcpcf6nO7aYjt+9/wBMuvv7c9VRRyq9wt0OFbwE5kkddTUNJFbxMfs2SfKumnz97uCF9sZ9q29P8PyWtxZSveCQ2zyPgRY3b1C/3jjGM/jW/RQopAFFFFUAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows the short axis view from a two-dimensional echocardiogram recorded at the base of the heart at the level of the aortic valve; the line (M) bisecting the aortic valve represents the plane of the M-mode beam used to generate the M-mode echocardiogram in panel B. The aortic valve opens nearly to the aortic (Ao) walls (panel B) and while opened it has a box-like configuration. The line marks the peak of the R wave on the ECG. There is a brisk anterior systolic motion of the entire Ao root and even faster earlier diastolic relaxation (posterior motion); the posterior movement of the aortic root occurs predominantly in early diastole with very little movement in late diastole. This pattern occurs in young healthy hearts that rely predominantly on early relaxation for filling rather than atrial contraction. The M-mode echocardiogram with simultaneous phonocardiogram is seen in panel C. The vibrations on the posterior moving non-coronary aortic leaflet (down arrows) are similar in timing and frequency with the low intensity, early systolic \"innocent\" murmur recorded on the phonocardiogram (up arrows). These vibrations are common in normal valves with normal or elevated cardiac output.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16228=[""].join("\n");
var outline_f15_54_16228=null;
var title_f15_54_16229="Acetaminophen and pseudoephedrine: Drug information";
var content_f15_54_16229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7861?source=see_link\">",
"    see \"Acetaminophen and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ornex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Ornex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Contac&reg; Cold and Sore Throat, Non Drowsy, Extra Strength;",
"     </li>",
"     <li>",
"      Dristan&reg; N.D.;",
"     </li>",
"     <li>",
"      Dristan&reg; N.D., Extra Strength;",
"     </li>",
"     <li>",
"      Sinutab&reg; Non Drowsy;",
"     </li>",
"     <li>",
"      Sudafed&reg; Head Cold and Sinus Extra Strength;",
"     </li>",
"     <li>",
"      Tylenol&reg; Decongestant;",
"     </li>",
"     <li>",
"      Tylenol&reg; Sinus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Relief of cold, flu or sinusitis symptoms:",
"     </b>",
"     Oral (Ornex&reg;, Ornex&reg; Maximum Strength): Two caplets every 4-6 hours as needed (maximum: 8 caplets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Relief of cold, flu or sinusitis symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years (Ornex&reg;): One caplet every 4-6 hours as needed (maximum: 4 caplets/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ornex&reg;: Acetaminophen 325 mg and pseudoephedrine hydrochloride 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ornex&reg; Maximum Strength: Acetaminophen 500 mg and pseudoephedrine hydrochloride 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion, and minor aches and pains associated with colds, flu, sinusitis, or allergies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ornex&reg; may be confused with Orexin&reg;, Orinase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7714083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MAO inhibitor therapy or within 14 days of therapy; concurrent use with other products containing acetaminophen",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7714084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment; acetaminophen may cause severe hepatic toxicity with acute overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Pediatrics: Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient's age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dosage limit: Limit acetaminophen dose to &lt;4 g/day (adults) or &lt;2.6 g/day (children &lt;12 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients with hypertension, thyroid disease, diabetes mellitus, cardiovascular disease, or prostatic hyperplasia should consult a physician prior to use. Products containing acetaminophen are not recommended in patients consuming &ge;3 alcoholic beverages/day; consult a physician. If symptoms persists &gt;7 days or are accompanied by fever that lasts for &gt;3 days, consult a physician. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ornex Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-500 mg (24): $7.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ornex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-325 mg (24): $6.18",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Day Flu (EC);",
"     </li>",
"     <li>",
"      Panadol Cold (MY);",
"     </li>",
"     <li>",
"      Panadol For Cold Relief (SG);",
"     </li>",
"     <li>",
"      Panadol Sinus (HK);",
"     </li>",
"     <li>",
"      Panadol Sinus Relief Original Formula (AU);",
"     </li>",
"     <li>",
"      Sinumax Ped (ZA);",
"     </li>",
"     <li>",
"      Sinutab (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/54/16229/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9191 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16229=[""].join("\n");
var outline_f15_54_16229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129654\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129666\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129655\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129661\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129656\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129657\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129645\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129636\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129646\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129671\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129664\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7714083\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7714084\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129662\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129642\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129652\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322960\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129650\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129648\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9191|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/43/7861?source=related_link\">",
"      Acetaminophen and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16230="Immune globulin: Patient drug information";
var content_f15_54_16230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Immune globulin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/23/1402?source=see_link\">",
"     see \"Immune globulin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/55/15226?source=see_link\">",
"     see \"Immune globulin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11513233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bivigam&trade;;",
"     </li>",
"     <li>",
"      Carimune&reg; NF;",
"     </li>",
"     <li>",
"      Flebogamma&reg; DIF;",
"     </li>",
"     <li>",
"      GamaSTAN&trade; S/D;",
"     </li>",
"     <li>",
"      Gammagard S/D&reg;;",
"     </li>",
"     <li>",
"      Gammagard&reg; Liquid;",
"     </li>",
"     <li>",
"      Gammaked&trade;;",
"     </li>",
"     <li>",
"      Gammaplex&reg;;",
"     </li>",
"     <li>",
"      Gamunex&reg;-C;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      Octagam&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11513234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gamastan S/D;",
"     </li>",
"     <li>",
"      Gamimune&reg; N;",
"     </li>",
"     <li>",
"      Gammagard Liquid;",
"     </li>",
"     <li>",
"      Gammagard S/D;",
"     </li>",
"     <li>",
"      Gamunex&reg;;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      IGIVnex&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11821754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700695",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney problems in some patients. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is made from human plasma (part of the blood) and may have viruses that may cause disease. This drug is screened, tested, and treated to lower the chance that it carries an infection. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11821756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the harshness of other infections in people with a weak immune system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat idiopathic thrombocytic purpura (ITP).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used treat chronic inflammatory demyelinating polyneuropathy (CIDP).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the harshness of infection by hepatitis A, measles, chickenpox (varicella), and rubella.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4009602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multifocal muscle neuropathy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11821755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A bleeding or blood clotting problem or IgA deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3302593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         I.M.",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low platelet levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3302602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gammaplex&reg;, Hizentra&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2749751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to polysorbate 80.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3302603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Hizentra&reg;, Privigen&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2773299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have too much proline in your blood (hyperprolinemia).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11821760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have fluid loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11821761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11821763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11821758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3302622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         SubQ:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion under the skin over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11821759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11821764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3869942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given in a doctor's office.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2773301",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Hizentra&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3509444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gammagard&reg; Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11821765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16472 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16230=[""].join("\n");
var outline_f15_54_16230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821754\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821756\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821755\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821760\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821761\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821763\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821758\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821759\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821764\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821765\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/23/1402?source=related_link\">",
"      Immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/55/15226?source=related_link\">",
"      Immune globulin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16231="Alaryngeal speech rehabilitation";
var content_f15_54_16231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alaryngeal speech rehabilitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Jan S Lewin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16231/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/54/16231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer face multiple, often severe psychological and functional problems associated with the diagnosis and treatment of their disease. Although organ preservation with functional conservation is a primary goal of therapy in patients with head and neck cancer, particularly laryngeal and hypopharyngeal cancer, this is not always possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The options for alaryngeal voice rehabilitation in the patient with total laryngectomy will be reviewed here. General issues related to speech and swallowing rehabilitation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434151938\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of rehabilitation following total laryngectomy is restoration of voice and speech production as closely as possible to that of the patient's premorbid status. No patient undergoing total laryngectomy should be without some method of functional speech production.",
"   </p>",
"   <p>",
"    There are three major approaches used to restore oral communication, and many patients learn to use all three methods:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The artificial larynx",
"     </li>",
"     <li>",
"      Tracheoesophageal (TE) voice restoration",
"     </li>",
"     <li>",
"      Esophageal speech",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different approaches are not applicable to all laryngectomized individuals. Selection of the mode of alaryngeal communication should be based upon the individual's specific needs, personality, physical capabilities, level of independent functioning, family support, and motivation. The ultimate decision should be the patient&rsquo;s choice and not that of the physician, family, or speech pathologist.",
"   </p>",
"   <p>",
"    Despite significant improvements in speech production using other methods, the artificial larynx remains the most commonly used alternative for a majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a report of 166 laryngectomized patients who participated in the Veterans Administration Cooperative Study, the artificial electrolarynx (55 percent) or tracheoesophageal speech (31 percent) were the primary method of speech production in 55 and 31 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/2\">",
"     2",
"    </a>",
"    ]. Only a few patients developed usable esophageal speech (6 percent) or remained nonvocal (8 percent). &nbsp;",
"    <br/>",
"   </p>",
"   <p>",
"    For many patients, tracheoesophageal (TE)voice restoration, performed as a primary procedure at the time of a total laryngectomy, is the preferred approach for voice rehabilitation in centers with experience. Although the timing of the procedure is important, other factors such as patient motivation and clinician expertise are essential to ultimate successful TE speech production. Total laryngectomy remains a relatively infrequent procedure. In most cases, laryngectomized patients make up a very small percentage of speech pathologists&rsquo; caseloads when compared with other more common rehabilitative populations such as stroke and traumatic brain injury. Thus, many clinicians have general familiarity with alaryngeal speech rehabilitation, but they do not have the necessary expertise in TE voice restoration to thoroughly manage the often complex rehabilitative and prosthetic needs of the TE speaker, particularly the TE speaker with a complicated medical and surgical history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTIFICIAL LARYNX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of artificial larynx is the electrolarynx, which can be used immediately after surgery. It is an electronic, battery-powered device that produces vibration that is transmitted through the external tissues of the neck or cheek or delivered intraorally via a plastic tube into the oral cavity for speech production. The patient shapes the sound for word production via movements of the tongue, jaw, lips and pharynx.",
"   </p>",
"   <p>",
"    There are numerous manufacturers of artificial larynges. Some new devices include mechanisms for pitch variation for more natural and melodious speech [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/4\">",
"     4",
"    </a>",
"    ]. Selection of the appropriate device is dependent upon a variety of factors including adequate sound transmission for optimal speech intelligibility and patient preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The artificial larynx has the advantage of providing immediate postoperative verbal communication with relative ease. The artificial larynx is equal in intelligibility to esophageal speech [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/5\">",
"     5",
"    </a>",
"    ] and is better discriminated in noise than esophageal speech, resulting in improved communication in noisy environments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of the artificial larynx does not affect the acquisition of either esophageal or tracheoesophageal (TE) speech. Thus, it can also be used as an interim means of communication while the patient is learning esophageal speech production or during the immediate postoperative healing period prior to placement of a TE voice prosthesis. It can serve as a backup to the other alaryngeal speech alternatives in the case of an emergency, should esophageal or TE speech production become effortful or fail due to fatigue, upper respiratory tract infection, cancer recurrence, or problems associated with the TE prosthesis. &nbsp;Therefore, all patients who have undergone total laryngectomy should receive an electrolarynx, regardless of its use as the primary method for communication. &nbsp;",
"   </p>",
"   <p>",
"    The artificial larynx may draw unwanted attention to the laryngectomized speaker, a disadvantage that prompts many to seek an alternative form of alaryngeal speech.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary disadvantage of the electrolarynx is the mechanical sound quality, which many patients find unacceptable. In addition, the devices necessitate the use of one hand, a problem for some patients interested in returning to work and for those who want to be able to speak without the use of their hands. Although newer devices offer adaptations for hands-free use, the modified devices are often awkward to use, and therefore have not been embraced by most patients.",
"   </p>",
"   <p>",
"    The artificial larynx also may draw unwanted attention to the laryngectomized speaker, a disadvantage that prompts many to seek an alternative form of alaryngeal speech.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRACHEOESOPHAGEAL VOICE RESTORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheoesophageal (TE) voice restoration offers the laryngectomized individual the potential for spontaneous, effortless speech production.",
"   </p>",
"   <p>",
"    TE voice restoration has often been cited as the alaryngeal speech alternative most comparable to normal laryngeal speech in quality, fluency, and ease of production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. TE speech is superior to esophageal speech in terms of speech quality, longer phonatory duration, and higher maximal vocal intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, patients who use this modality are generally more satisfied with their speech, perceive their speech to be of better quality, have improved ability to communicate over the telephone, and have fewer limitations in their interactions with others compared with those using the electrolarynx or esophageal speech [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small, surgically controlled fistula is created in the tracheoesophageal wall. The opening is maintained by a unidirectional valved prosthesis that protects the airway during swallowing and opens to divert pulmonary air across the pharyngoesophageal mucosa for phonation when the tracheostoma is occluded. TE speakers can shunt air from the trachea into the pharyngoesophagus either by manual occlusion of the stoma with a digit or by the use of a tracheostoma breathing valve. The movement of the structures of the oral cavity then shapes the sound into words for speech production.",
"   </p>",
"   <p>",
"    The tracheostoma breathing valve attaches to the neck via peristomal or intraluminal attachments. It remains open during quiet breathing and automatically closes in response to an increase in expiratory air flow to allow speech production. The device permits hands-free speech and eliminates the inconvenience, unwanted attention, and lack of hygiene associated with digital stomal occlusion.",
"   </p>",
"   <p>",
"    When a tracheostoma valve is used in lieu of digital occlusion of the stoma, the most common problem is maintaining the seal between the valve attachment and the skin. This is particularly true for patients who use the peristomal type attachment, whether it is a standard, commercially available device, or it has been customized to the patient&rsquo;s individual neck contour. Nonsignificant benefit in the duration of seal attachment has been reported when peristomal attachments are customized [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/15\">",
"     15",
"    </a>",
"    ]. A similar problem occurs when the valve cannot be adequately retained in the trachea using the intraluminal attachment. In either case, air leakage and eventual detachment of the valve occurs, which is distracting to the listener and frustrating to the TE speaker.",
"   </p>",
"   <p>",
"    A customized intraluminal attachment may offer some patients who are unable to wear a peristomal or standard intraluminal attachment an additional alternative for attachment of the hands-free tracheostoma valve [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. One study reported a significantly higher success rate with hands-free TE speech using custom Barton buttons as compared with standard Barton buttons and peristomal attachments (85 versus 57 and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/15\">",
"     15",
"    </a>",
"    ]. A step-by-step approach for customizing a new type of laryngectomy button, the Larybutton, has been described to provide assistance to clinicians attempting to modify this device for intraluminal attachment of breathing valves for hands-free speech production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/18\">",
"     18",
"    </a>",
"    ]. When peristomal or intraluminal attachments fail, digital occlusion of the stoma for TE speech production is often preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since its introduction in 1980, the surgical method has become simpler and the occurrence of complications rare. In some instances, TE puncture can be performed as an outpatient procedure, using local anesthesia, with high rates of reported success [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific problems associated with the production of TE speech can be subdivided into two groups: physiologic-anatomic variations in structure and function, and mechanical problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Physiologic-anatomic variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic-anatomic variations may be directly related to the laryngectomy itself, including pharyngeal constrictor hypertonicity or \"spasm,\" hypopharyngeal stricture, flaccidity of the neoglottic segment, enlargement of the TE puncture, and stomal stenosis and irregularity. Some of these problems may be aggravated following laryngectomy, especially in patients with gastroesophageal reflux and Candida colonization within the oropharynx. Some of these problems may be worse in patients who have received radiation therapy either definitively for cure or in combination with surgery.",
"   </p>",
"   <p>",
"    Early results with pharyngeal myotomy, performed primarily or secondarily, significantly reduced the occurrence of pharyngeal constrictor hypertonicity and facilitated vocal rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Currently, the use of botulinum toxin (Botox) injection, a noninvasive treatment for the relief of constrictor hypertonicity, has been equally successful and is preferred over surgical alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Furthermore, improved surgical techniques, greater success with intraluminal devices for breathing valve attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/15\">",
"     15",
"    </a>",
"    ], new medications, and better prosthetic designs have reduced the magnitude of complications and in many cases, eliminated them.",
"   </p>",
"   <p>",
"    Following radiation therapy, some patients may experience problems with their TE voice. Common problems may include difficulty with stomal occlusion and tenderness or pain when removing, cleaning or replacing the voice prosthesis. Placement of a \"dummy\" prosthesis during the course of radiation therapy ensures patency of the fistula and prevents spontaneous closure of the TE tract. Although short-term use of a catheter to stent the TE tract is often helpful in maintaining patency of the TE puncture, extended catheter placement may be contraindicated in irradiated patients. When the catheter remains in place for longer periods of time, the weight of the catheter against the fragile TE mucosa may cause erosion and enlargement of the puncture site resulting in leakage and aspiration around the catheter and later around the TE prosthesis.",
"   </p>",
"   <p>",
"    Patients, particularly those who have been irradiated, may also experience leakage of saliva or food around the TE prosthesis due to an enlarged or irregular TE puncture. Radiation therapy affects tissue elasticity. Leakage around the prosthesis likely occurs because the TE puncture accommodates the dilating effect of the prosthesis, resulting in a circumferential enlargement of the TE puncture.",
"   </p>",
"   <p>",
"    Many conservative treatment options have been proposed for management of leakage around the prosthesis but most have failed to provide long-term resolution of the problem. In some instances, removing the prosthesis and inserting a catheter with a smaller diameter than the prosthesis temporarily alleviates the problem. More often, patients will require modification of the TE voice prosthesis that enlarges the posterior retention flange to provide adequate surface coverage of the fistula within the esophageal lumen. One study reported elimination of aspiration around the prosthesis after placement of a customized TE prosthesis in 99 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of surgical techniques have been proposed to facilitate closure of the enlarged TE puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/26\">",
"     26",
"    </a>",
"    ]. Other investigators have also studied injections of various materials into the TE wall to facilitate stenosis of the enlarged puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. In severe cases, intractable leakage may require surgical closure and repuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a recent systematic review found that less than 20 percent of patients with an enlarged TE puncture require complete closure of the puncture site [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both TE voice production and swallowing are intimately related after total laryngectomy; thus, any intervention that affects one will most certainly affect the other. A thorough examination by a knowledgeable and experienced clinician who can carefully weigh the functional benefits against the potential risks associated with the proposed intervention is extremely important. This will minimize the potential for deterioration or permanent loss of either speech or swallowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mechanical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical problems are most often related to the management and use of the TE prosthesis. They include problems experienced during sizing, fitting, removing, and replacing of the TE voice prosthesis within the puncture tract. Improved prosthetic design, an increased variety of products, and better professional training have significantly reduced the occurrence of these types of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434152534\">",
"    <span class=\"h2\">",
"     Factors associated with successful TE voice restoration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate success using this method depends to a large extent upon clinician expertise. This is particularly important for patients undergoing complex pharyngeal reconstructions that require the use of fasciocutaneous free flaps or visceral transpositions. Superior speech and swallowing outcomes have been reported following fasciocutaneous free flap reconstructions such as those that use the anterior thigh or radial forearm free flap compared with those following visceral transpositions using the jejunum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, visceral transposition as a reconstructive alternative for circumferential defects of the pharynx has become less popular. &nbsp;",
"   </p>",
"   <p>",
"    Several factors have often been cited as being associated with successful TE voice restoration: the age of the patient, history of radiation therapy to the neck, and timing of the TE puncture as a primary or secondary procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/3\">",
"     3",
"    </a>",
"    ]. Age, prior use of radiation therapy, and pre- or postoperative timing are not contraindications to TE voice restoration or the other forms of alaryngeal communication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, in patients who have been heavily irradiated, secondary TE puncture may be preferred.",
"   </p>",
"   <p>",
"    In addition, anecdotal reports have suggested a positive relationship between increased diameter of the TE voice prosthesis and enlargement of the TE puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A systematic review and multivariable analysis of 194 patients, however, failed to identify a statistically significant association between use of a large diameter prosthesis and subsequent enlargement of the TE puncture.&nbsp;Instead, medical and oncologic factors showed an increased risk of developing an enlarged TE puncture. Key risk factors included radiotherapy, advanced nodal disease, recurrent cancer after laryngectomy, postoperative stricture, extended",
"    <span class=\"nowrap\">",
"     resection/reconstruction,",
"    </span>",
"    and nutritional deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the TE puncture is performed as a primary procedure at the time of total laryngectomy or secondarily after the patient has fully healed from surgery seems to be a matter of surgical preference. The psychologic benefits and quick restoration to a quality lifestyle are advantages of primary voice restoration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, this approach has become the standard for voice rehabilitation following total laryngectomy in centers of excellence.",
"   </p>",
"   <p>",
"    Some clinicians perform both TE puncture and placement of the TE prosthesis simultaneously at the time of surgery. This may be particularly true in some places in the United States in which expert speech pathologists are not available, or in places outside the United States in which selection and placement of the TE prosthesis are part of the physician&rsquo;s responsibility. However, in our experience, patient success and optimal voice restoration are best facilitated when the TE puncture is performed and allowed to heal and mature before the prosthesis is placed. In this way, acute edema can resolve, sizing and fitting can accurately be achieved, the best voice prosthesis can be selected to fit the patient&rsquo;s needs, and expensive and unnecessary replacements of an ill-fitting, poorly working voice prosthesis can be avoided.",
"   </p>",
"   <p>",
"    The goal of patient selection for TE speech is to identify those individuals who will achieve useful sound production. In most cases, the contraindications to tracheoesophageal voice restoration are impaired cognitive-mental functioning or continued substance abuse (alcohol, pharmaceuticals) as these conditions prevent reliable, precise, and consistent management of the tracheoesophageal voice prosthesis. When patients present with significant and multiple comorbidities or psychosocial dysfunction, it is often more prudent to consider TE puncture as a secondary procedure to allow for postoperative recovery and adaptation to new anatomic and physiologic changes.",
"   </p>",
"   <p>",
"    When TE puncture is recommended as a secondary procedure following total laryngectomy, proper preoperative evaluation will help determine appropriate candidacy. Preoperative esophageal insufflation testing continues to be useful to predict postoperative TE speech production and allows the patient to hear his or her new voice. In addition, it provides a preoperative functional baseline for postoperative comparison. However, preoperative air insufflation may not be as critical as it once was. Should postoperative TE speech failure occur, the simple procedure of botulinum toxin injection to relieve pharyngeal constrictor spasm has made routine preoperative air insufflation less critical [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Thus, some institutions no longer routinely insufflate the esophagus prior to TE puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434152434\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL SPEECH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, esophageal speech production was the traditional choice for alaryngeal speech rehabilitation. The vibratory source is the pharyngoesophageal (PE) segment. Oral air that is introduced into the esophagus and expelled past the PE segment is the driving force for speech production.",
"   </p>",
"   <p>",
"    There are several methods used to teach esophageal speech [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/40\">",
"     40",
"    </a>",
"    ]. The goal is for the patient to be able to rapidly impound air into the esophagus, and then expel air from the esophagus through the oral cavity in a controlled manner to produce fluent speech.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434152479\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal speech has the advantage of verbal communication that does not require the use of any mechanical or prosthetic device, thereby leaving the hands free while avoiding the maintenance associated with the care of a prosthesis. The voice is produced by the patient with his or her own remaining postoperative anatomy and therefore is often viewed as more normal and desirable.",
"   </p>",
"   <p>",
"    The vibration of the pharyngoesophageal segment more closely approximates the sound of laryngeal vibration even though the pitch (mean 77.1 versus 102.8 Hz) and intensity (median 59.3 versus 69.3 dB) of esophageal voice are lower than that of normal laryngeal speech [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434152486\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary disadvantages of developing esophageal speech are the length of time required to learn the technique and the reduction in quality compared to TE and normal laryngeal speech. Conservative estimates suggest four to six months of daily practice and regular speech therapy sessions may be required to facilitate speech production; for some patients, it may take longer. In addition, although the majority of laryngectomized patients can learn to produce esophageal sound and some phrases, it has been estimated that less than 30 percent of patients are able to develop and use esophageal voice as their primary means of communication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16231/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The scarcity of speech pathologists and fluent esophageal speakers trained to properly teach the method of esophageal speech production further limits its availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434152517\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of rehabilitation following total laryngectomy is restoration of voice and speech as closely as possible to that of the patient's premorbid status. There are three major approaches used to restore oral communication: the artificial larynx, tracheoesophageal voice restoration, and esophageal speech. (See",
"    <a class=\"local\" href=\"#H434151938\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Artificial larynx",
"      </strong>",
"      &ndash; The artificial larynx is a battery-powered device that produces vibration that is transmitted through the external tissues of the neck or cheek or delivered intraorally via a plastic tube into the oral cavity for speech production. The artificial larynx provides immediate postoperative verbal communication, is equal in intelligibility to esophageal speech, and provides improved communication in noisy environments. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Artificial larynx'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The primary disadvantage of the electrolarynx is the mechanical sound quality, which many patients find unacceptable. In addition, the devices necessitate the use of one hand, a problem for some patients interested in returning to work and for those who want to be able to speak without the use of their hands.",
"     </li>",
"     <li>",
"      <strong>",
"       Tracheoesophageal speech",
"      </strong>",
"      &ndash; Tracheoesophageal (TE) voice restoration uses a controlled fistula in the tracheoesophageal wall that diverts pulmonary air across the pharyngoesophageal mucosa for phonation when the tracheostoma is occluded. TE voice restoration is the alaryngeal speech alternative most comparable to normal laryngeal speech in quality, fluency, and ease of production. The ultimate success with TE voice restoration depends to a large extent upon clinician expertise. Most studies report successful TE speech in more than 80 percent of patients who receive primary puncture and more than 70 percent who receive secondary TEP. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tracheoesophageal voice restoration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Esophageal speech",
"      </strong>",
"      &ndash; Esophageal speech production depends upon air that is introduced into the esophagus and is then expelled past the pharyngoesophageal segment, the vibratory source for sound production. The primary disadvantages of developing esophageal speech are the length of time required to learn the technique and the reduction in voice quality compared to tracheoesophageal and normal laryngeal speech compounded by the lack of availability of trained clinicians who can teach it. (See",
"      <a class=\"local\" href=\"#H434152434\">",
"       'Esophageal speech'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/1\">",
"      Culton GL, Gerwin JM. Current trends in laryngectomy rehabilitation: a survey of speech-language pathologists. Otolaryngol Head Neck Surg 1998; 118:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/2\">",
"      Hillman RE, Walsh MJ, Wolf GT, et al. Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998; 172:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/3\">",
"      Mendenhall WM, Morris CG, Stringer SP, et al. Voice rehabilitation after total laryngectomy and postoperative radiation therapy. J Clin Oncol 2002; 20:2500.",
"     </a>",
"    </li>",
"    <li>",
"     Meltzner G, Hillman RE, Heaton JT, et al. Electrolaryngeal speech: the state of the art and future directions for development. In: Contemporary Considerations in the Treatment and Rehabilitation of Head and Neck Cancer, Doyle PC, Keith RL (Eds), Pro-ed, Austin 2005. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/5\">",
"      Kalb MB, Carpenter MA. Individual speaker influence on relative intelligibility of esophageal speech and artificial larynx speech. J Speech Hear Disord 1981; 46:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/6\">",
"      Clark JG, Stemple JC. Assessment of three modes of alaryngeal speech with a synthetic sentence identification (SSI) task in varying message-to-competition ratios. J Speech Hear Res 1982; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/7\">",
"      Robbins J. Acoustic differentiation of laryngeal, esophageal, and tracheoesophageal speech. J Speech Hear Res 1984; 27:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/8\">",
"      Singer MI. Tracheoesophageal speech: vocal rehabilitation after total laryngectomy. Laryngoscope 1983; 93:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/9\">",
"      Williams SE, Scanio TS, Ritterman SI. Temporal and perceptual characteristics of tracheoesophageal voice. Laryngoscope 1989; 99:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/10\">",
"      Yu P, Hanasono MM, Skoracki RJ, et al. Pharyngoesophageal reconstruction with the anterolateral thigh flap after total laryngopharyngectomy. Cancer 2010; 116:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/11\">",
"      Max L, De Bruyn W, Steurs W. Intelligibility of oesophageal and tracheo-oesophageal speech: preliminary observations. Eur J Disord Commun 1997; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/12\">",
"      Debruyne F, Delaere P, Wouters J, Uwents P. Acoustic analysis of tracheo-oesophageal versus oesophageal speech. J Laryngol Otol 1994; 108:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/13\">",
"      Robbins J, Fisher HB, Blom EC, Singer MI. A comparative acoustic study of normal, esophageal, and tracheoesophageal speech production. J Speech Hear Disord 1984; 49:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/14\">",
"      Moukarbel RV, Doyle PC, Yoo JH, et al. Voice-related quality of life (V-RQOL) outcomes in laryngectomees. Head Neck 2011; 33:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/15\">",
"      Lewin JS, Lemon J, Bishop-Leone JK, et al. Experience with Barton button and peristomal breathing valve attachments for hands-free tracheoesophageal speech. Head Neck 2000; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/16\">",
"      Blom ED, Singer MI, Hamaker RC. Tracheostoma valve for postlaryngectomy voice rehabilitation. Ann Otol Rhinol Laryngol 1982; 91:576.",
"     </a>",
"    </li>",
"    <li>",
"     Lewin JS. Maximizing tracheoesophageal voice and speech. In: Tracheoesophageal Voice Restoration following Total Laryngectomy, Blom ED, Singer MI, and Hamaker RC (Eds), Singular Publishing Group, San Diego 1998. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/18\">",
"      Lewin JS, Montgomery PC, Hutcheson KA, Chambers MS. Further experience with modification of an intraluminal button for hands-free tracheoesophageal speech after laryngectomy. J Prosthet Dent 2009; 102:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/19\">",
"      LeBert B, McWhorter AJ, Kunduk M, et al. Secondary tracheoesophageal puncture with in-office transnasal esophagoscopy. Arch Otolaryngol Head Neck Surg 2009; 135:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/20\">",
"      Blom ED, Pauloski BR, Hamaker RC. Functional outcome after surgery for prevention of pharyngospasms in tracheoesophageal speakers. Part I: Speech characteristics. Laryngoscope 1995; 105:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/21\">",
"      Huo J, Klastsky I, Labruna A, Weiss MH. Secondary pharyngeal myotomy for tracheoesophageal speech. Ear Nose Throat J 1995; 74:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/22\">",
"      Hamaker RC, Blom ED. Botulinum neurotoxin for pharyngeal constrictor muscle spasm in tracheoesophageal voice restoration. Laryngoscope 2003; 113:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/23\">",
"      Lewin JS, Bishop-Leone JK, Forman AD, Diaz EM Jr. Further experience with Botox injection for tracheoesophageal speech failure. Head Neck 2001; 23:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/24\">",
"      Krause E, Hempel JM, G&uuml;rkov R. Botulinum toxin A prolongs functional durability of voice prostheses in laryngectomees with pharyngoesophageal spasm. Am J Otolaryngol 2009; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/25\">",
"      Kress P, Sch&auml;fer P, Schwerdtfeger FP. [The custom-fit voice prosthesis, for treatment of periprothetic leakage after tracheoesophageal voice restoration]. Laryngorhinootologie 2006; 85:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/26\">",
"      Op de Coul BM, Hilgers FJ, Balm AJ, et al. A decade of postlaryngectomy vocal rehabilitation in 318 patients: a single Institution's experience with consistent application of provox indwelling voice prostheses. Arch Otolaryngol Head Neck Surg 2000; 126:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/27\">",
"      Ferrer Ram&iacute;rez MJ, Guallart Dom&eacute;nech F, Brotons Durb&aacute;n S, et al. Surgical voice restoration after total laryngectomy: long-term results. Eur Arch Otorhinolaryngol 2001; 258:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/28\">",
"      Trussart C, Lawson G, Remacle M. Voice prostheses: long-term follow-up retrospective study (three- to sixteen-year follow-up of 22 patients). Rev Laryngol Otol Rhinol (Bord) 2003; 124:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/29\">",
"      Lorincz BB, Lichtenberger G, Bihari A, Falvai J. Therapy of periprosthetical leakage with tissue augmentation using Bioplastique around the implanted voice prosthesis. Eur Arch Otorhinolaryngol 2005; 262:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/30\">",
"      P&eacute;ri&eacute; S, Ming X, Dewolf E, St Guily JL. Autologous fat injection to treat leakage around tracheoesophageal puncture. Am J Otolaryngol 2002; 23:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/31\">",
"      Seshamani M, Ruiz C, Kasper Schwartz S, Mirza N. Cymetra injections to treat leakage around a tracheoesophageal puncture. ORL J Otorhinolaryngol Relat Spec 2006; 68:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/32\">",
"      Hutcheson KA, Lewin JS, Sturgis EM, et al. Enlarged tracheoesophageal puncture after total laryngectomy: a systematic review and meta-analysis. Head Neck 2011; 33:20.",
"     </a>",
"    </li>",
"    <li>",
"     Lewin JS. Problems associated with alaryngeal speech. In: Contemporary Considerations in the Treatment of Head and Neck Cancer, Keith RL, Doyle P (Eds), Pro-Ed, Inc, Austin 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/34\">",
"      Lewin JS, Barringer DA, May AH, et al. Functional outcomes after circumferential pharyngoesophageal reconstruction. Laryngoscope 2005; 115:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/35\">",
"      Baugh RF, Lewin JS, Baker SR. Preoperative assessment of tracheoesophageal speech. Laryngoscope 1987; 97:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/36\">",
"      Trudeau MD, Schuller DE, Hall DA. The effects of radiation on tracheoesophageal puncture. A retrospective study. Arch Otolaryngol Head Neck Surg 1989; 115:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/37\">",
"      Acton LM, Ross DA, Sasaki CT, Leder SB. Investigation of tracheoesophageal voice prosthesis leakage patterns: patient's self-report versus clinician's confirmation. Head Neck 2008; 30:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/38\">",
"      Blom ED. Some comments on the escalation of tracheoesophageal voice prosthesis dimensions. Arch Otolaryngol Head Neck Surg 2003; 129:500.",
"     </a>",
"    </li>",
"    <li>",
"     Freeman SB, Hamaker RC. Tracheoesophageal voice restoration at time of laryngectomy. In: Tracheoesophageal Voice Restoration following Total Laryngectomy, Blom ED, Singer MI, Hamaker RC (Eds), Singular Publishing Group, Inc, San Diego 1998. p.19.",
"    </li>",
"    <li>",
"     Lewin JS, Rhys-Evans PH, Blom ED. Functional voice restoration after total laryngectomy. In: Principles and Practice of Head and Neck Surgery and Oncology, 2nd, Informa Healthcare, London 2009. p.598.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16231/abstract/41\">",
"      Gates GA, Ryan W, Cooper JC Jr, et al. Current status of laryngectomee rehabilitation: I. Results of therapy. Am J Otolaryngol 1982; 3:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3394 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16231=[""].join("\n");
var outline_f15_54_16231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H434152517\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H434151938\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTIFICIAL LARYNX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRACHEOESOPHAGEAL VOICE RESTORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Physiologic-anatomic variations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mechanical problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434152534\">",
"      Factors associated with successful TE voice restoration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H434152434\">",
"      ESOPHAGEAL SPEECH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434152479\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434152486\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H434152517\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16232="Histology case 1";
var content_f15_54_16232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Histology case 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Which light micrograph correlates with the clinical presentation?",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16232=[""].join("\n");
var outline_f15_54_16232=null;
var title_f15_54_16233="Pathophysiology and etiology of sudden cardiac arrest";
var content_f15_54_16233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and etiology of sudden cardiac arrest",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Jie Cheng, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16233/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/54/16233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease.",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cardiac diseases that lead to the genesis of the arrhythmia resulting in cardiac collapse and sudden death are varied, and the association with sudden death in some cases is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/1\">",
"     1",
"    </a>",
"    ]. Identification of the patient at risk for sudden death and identification of the factors that precipitate the fatal arrhythmia continue to represent a major challenge. This topic will review the mechanisms and etiology of SCA. Treatment for SCA, the evaluation of survivors, and the outcomes of SCA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARRHYTHMIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of collapse in an individual patient is often impossible to establish since, for the vast majority of patients who die suddenly, cardiac activity is not being monitored at the time of their collapse. As a result, the mechanism can only be inferred, based upon information obtained after the process has been initiated.",
"   </p>",
"   <p>",
"    However, there have been many cases in which the initiating event has been witnessed or recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This has usually occurred in patients being continually monitored in the coronary care unit or with a 24-hour ambulatory ECG recording device or an implantable cardioverter-defibrillator (ICD). Ventricular tachycardia (VT) or ventricular fibrillation (VF) account for the majority of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, a bradyarrhythmia is responsible for some cases of SCD (",
"    <a class=\"graphic graphic_table graphicRef57596 \" href=\"UTD.htm?12/32/12812\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The distribution is different among patients with an ICD. Arrhythmic death accounts for 20 to 35 percent of deaths; post-shock or primary pulseless electrical activity (PEA, also called electromechanical dissociation) is a frequent cause of SCD in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Mechanisms of death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distribution of causes is also different with unmonitored out-of-hospital SCD. VF and pulseless VT appear to be responsible for 25 to 35 percent of episodes, although estimates vary widely. PEA accounts for as many as 25 percent of all cases of SCD.",
"   </p>",
"   <p>",
"    Among patients who collapse in an unmonitored setting in whom the exact time of onset and the etiologic arrhythmia is uncertain, asystole is often the first rhythm observed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/6\">",
"     6",
"    </a>",
"    ]. Asystole correlates with the duration of the arrest and may be the result of VF that has been present for several minutes or longer and then leads to the loss of all electrical activity as a result of hypoxia, acidosis, and death of myocardial tissue (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately 80 percent of patients with",
"    <span class=\"nowrap\">",
"     VT/VF,",
"    </span>",
"    the sustained ventricular arrhythmia is preceded by an increase in ventricular ectopy and the development of repetitive ventricular arrhythmia, particularly runs of nonsustained ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/2\">",
"     2",
"    </a>",
"    ]. These spontaneous arrhythmias are present for a variable period of time prior to the development of",
"    <span class=\"nowrap\">",
"     VT/VF.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained monomorphic VT can accelerate to a rapid rate and then degenerate into ventricular fibrillation (VF). However, the relationship between monomorphic VT and SCD has been debated, with some studies suggesting that this arrhythmia is present in only a minority of patients with SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Thus, sustained monomorphic VT may simply be the company kept by VF or, in the appropriate setting such as recurrent coronary ischemia, it may provide a rapid wavefront that becomes fractionated, leading to VF [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link&amp;anchor=H7#H7\">",
"       \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\", section on 'Relation between SMVT and VF'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A sustained polymorphic VT can degenerate into VF. This is most often the result of underlying ischemia, although it may also result from acquired or congenital QT prolongation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link\">",
"       \"Pathophysiology of the long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular fibrillation can develop as a primary event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In about one-third of cases, the tachyarrhythmia is initiated by an early R on T ventricular premature beat (VPB); in the remaining two-thirds, the arrhythmia is initiated by a late cycle VPB [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A bradyarrhythmia and asystole were, in initial studies, less common causes of SCD, being observed in only about 10 percent of cases documented on an ambulatory monitor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/2\">",
"       2",
"      </a>",
"      ]. A bradyarrhythmia is more often associated with a nonischemic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/10\">",
"       10",
"      </a>",
"      ], while pulseless electrical activity or asystole are the most common rhythms seen with a pulmonary embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .) In some cases, the bradyarrhythmia may result in a ventricular tachyarrhythmia as an escape mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation results from multiple localized areas of microreentry without any organized electrical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/12\">",
"     12",
"    </a>",
"    ]. The most likely mechanism is rotating spiral waves [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/13\">",
"     13",
"    </a>",
"    ]. This almost always occurs in the setting of underlying myocardial disease that is often diffuse, resulting in heterogeneity of depolarization and the dispersion of repolarization. This disparity of electrophysiologic properties is a precondition for reentry. A triggering event is usually necessary to precipitate the arrhythmia in a vulnerable heart [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diversity in conduction and recovery parameters (myocardial heterogeneity) results in fragmentation of the impulse as it travels through the myocardium, producing multiple areas of localized reentry or multiple spiral wavelets of myocardial activation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/12\">",
"     12",
"    </a>",
"    ]. Since there is no organized electrical activity or myocardial depolarization, there is no uniform ventricular contraction resulting in failure of the heart to generate a cardiac output. With the development of global ischemia, the rate of VF decreases because of a reduction in the rotation period of the spiral waves which results from the increase in their core area [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ECG in established VF shows high-frequency undulations or fibrillatory waves that are irregular in amplitude and periodicity, occurring at a rate above",
"    <span class=\"nowrap\">",
"     320/minute;",
"    </span>",
"    QRS complexes are not seen (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/15\">",
"     15",
"    </a>",
"    ]. However, at the very onset of VF, the fibrillatory waves may be coarse with a tall amplitude, and may appear to be regular (",
"    <a class=\"graphic graphic_waveform graphicRef80454 \" href=\"UTD.htm?29/47/30455\">",
"     waveform 2",
"    </a>",
"    ). The QRS complexes in this setting are indistinguishable from the T waves, and they appear to be sinusoidal in configuration. This finding may represent a brief period of an organized ventricular flutter, with a rate exceeding 260 beats per minute. These initial ECG changes are collectively referred to as type I VF, and may be associated with spontaneous defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the duration of VF increases, progressive cellular ischemia and acidosis develop, resulting in an electrophysiologic deterioration, manifested by an increase in fibrillation cycle length and prolonged diastole duration between fibrillation action potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. During this later (type II) VF, the fibrillatory waves rapidly become finer and more irregular in amplitude, duration, and cycle length; spontaneous resolution has not been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Over a period of several minutes, the fibrillatory waves become so fine that there does not appear to be any electrical activity (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many cardiac and noncardiac causes for a sustained ventricular tachyarrhythmia that can result in SCD (",
"    <a class=\"graphic graphic_table graphicRef62184 \" href=\"UTD.htm?16/52/17228\">",
"     table 2",
"    </a>",
"    ). The following approximate frequency of causes of out-of-hospital SCDs have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      65 to 70 percent of all SCDs are attributable to coronary heart disease (CHD) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. However, the frequency of CHD is much lower in SCDs occurring under the age of 30 to 40 (eg, 24 percent under the age of 30 in a review of SCDs in the United States in 1999, and 8 percent in a series of autopsies in military recruits) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/19,21\">",
"       19,21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These observations were largely made from analyses of all reported SCDs in the United States using the diagnosis on the death certificate, which is of uncertain accuracy. A similar frequency of CHD was noted in a study of 84 consecutive survivors of out-of-hospital cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/22\">",
"       22",
"      </a>",
"      ]. Immediate coronary angiography revealed clinically significant coronary disease in 60 (71 percent) of the patients, 40 of whom (48 percent of all patients) had an occluded coronary artery. The absence of an occluded coronary artery in the other 20 patients does not preclude an acute coronary syndrome (or ischemia) since absence of occlusion on early angiography is seen in 60 to 85 percent of patients with a non-ST elevation acute coronary syndrome and in up to 28 percent of patients with an ST elevation MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link&amp;anchor=H10#H10\">",
"       \"Coronary artery patency and outcome after myocardial infarction\", section on 'Spontaneous reperfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      10 percent are due to other types of structural heart disease (eg, congenital coronary artery anomalies, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. The frequency is much higher in subjects under the age of 30 (over 35 percent in a review of SCDs in the United States in 1999, and over 40 percent in a series of autopsies in military recruits) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/19,21\">",
"       19,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      5 to 10 percent are arrhythmic SCDs occurring in the absence of structural heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      15 to 25 percent of cardiac arrests are noncardiac in origin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23,26\">",
"       23,26",
"      </a>",
"      ]. The causes include trauma, bleeding, drug intoxication, intracranial hemorrhage, pulmonary embolism, near-drowning, and central airway obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of SCD increases with age in both men and women; however, at any level of multivariate risk, women are less vulnerable to sudden death than men and a higher fraction of sudden deaths in women occur in the absence of prior overt CHD (",
"    <a class=\"graphic graphic_figure graphicRef59028 \" href=\"UTD.htm?18/4/18509\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/18,27\">",
"     18,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H598833\">",
"    <span class=\"h2\">",
"     Autopsy studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of cardiac causes of SCD varies with age, the population studied, and geography. While coronary heart disease (CHD) is listed as the underlying cause of SCD on 62 percent of death certificates among the general population in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/20\">",
"     20",
"    </a>",
"    ], younger patients, athletes, and those without known prior disease have a different distribution of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23,28,29\">",
"     23,28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an autopsy study of 902 persons with suspected SCD (mean age 38 years), 715 cases (79 percent) occurred in persons with underlying cardiac pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/30\">",
"       30",
"      </a>",
"      ]. CHD was felt to be the primary cause of SCD in 511 patients (57 percent); however, CHD was far more common in persons 35 years of age or older (73 percent versus 23 percent in those &lt;35 years), whereas those under 35 years of age were significantly more likely to die from non-CHD causes such as sudden unexplained death (primary arrhythmic death, 41 versus 11 percent), hypertrophic cardiomyopathy (13 versus 3 percent), or myocarditis (6 versus 2 percent).",
"     </li>",
"     <li>",
"      An autopsy study from Israel evaluated 162 subjects aged 9 to 39 years with SCD; none had previously diagnosed underlying cardiac disease, and death occurred in the absence of trauma within 24 hours of onset of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23\">",
"       23",
"      </a>",
"      ]. Approximately 15 percent of deaths were noncardiac (most often intracranial hemorrhage), and 73 percent were cardiac. Among those 20 to 29 years of age, CHD was found in 24 percent, myocarditis in 22 percent, and hypertrophic cardiomyopathy (HCM) in 13 percent. Among those 30 to 39 years of age, CHD was found in 58 percent, myocarditis in 11 percent, and HCM in 2 percent.",
"     </li>",
"     <li>",
"      An autopsy series from the United States evaluated 286 competitive athletes under age 35 in whom cardiovascular disease was shown to be the cause of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/28\">",
"       28",
"      </a>",
"      ]. The most common underlying disorders were HCM (36 percent, with possible HCM in another 10 percent), an anomalous origin of a coronary artery (13 percent), and myocarditis (7 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"       \"Risk of sudden cardiac death in athletes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A markedly different distribution was noted in a report from northern Italy where arrhythmogenic right ventricular cardiomyopathy (ARVC) is relatively common [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/29\">",
"       29",
"      </a>",
"      ]. Among 49 sudden deaths in young athletes, ARVC was most common (22 percent), followed by coronary atherosclerosis (18 percent), an anomalous origin of a coronary artery (12 percent), and HCM in only 2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myocardial ischemia and infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 65 to 70 percent of SCDs are attributable to CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and it is estimated that SCD accounts for 30 to 50 percent of coronary deaths (",
"    <a class=\"graphic graphic_table graphicRef55696 \" href=\"UTD.htm?8/48/8971\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/18,31\">",
"     18,31",
"    </a>",
"    ]. The incidence of SCD is related to the clinical manifestations of preexisting CHD, being highest in those with a prior myocardial infarction (MI) and intermediate in those who have angina without a prior infarction (",
"    <a class=\"graphic graphic_figure graphicRef52309 \" href=\"UTD.htm?24/42/25261\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/18\">",
"     18",
"    </a>",
"    ]. However, SCD can occur in patients with silent ischemia and can be the initial manifestation of CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology of coronary heart disease\", section on 'Sudden cardiac death'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among SCD episodes that occur without warning, angiography demonstrates an occluded coronary artery in almost one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinical and ECG changes appear to correlate poorly with coronary occlusion. Furthermore, among patients with typical ECG changes or cardiac enzyme elevations after resuscitation, it may be difficult on clinical grounds alone to determine whether an acute MI caused VF, or VF resulted in myocardial injury because of the absence of coronary artery blood flow.",
"   </p>",
"   <p>",
"    Among patients who present with an acute MI rather than SCD, the incidence of VF varies with the type of infarct and time. This topic is discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest experience with acute ST elevation MI comes from the GUSTO-1 trial of 40,895 patients who were treated with thrombolytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/32\">",
"       32",
"      </a>",
"      ]. The overall incidence of VT or VF was 10.2 percent: 3.5 percent developed VT, 4.1 percent VF, and 2.7 percent both VT and VF. Approximately 80 to 85 percent of these arrhythmias occurred in the first 48 hours.",
"     </li>",
"     <li>",
"      The best data in non-ST elevation acute coronary syndrome come from a pooled analysis of four major trials of over 25,000 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/33\">",
"       33",
"      </a>",
"      ]. The overall incidence of VT or VF was 2.1 percent: VT occurred in 0.8 percent, VF in 1 percent, and VT and VF in 0.3 percent. The median time to arrhythmia was 78 hours, with the 25th and 75th percentiles being 16 hours and seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A peak incidence of VF within the first 48 hours after acute MI has also been noted in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. These episodes are presumably due to ischemia, while later onset VF may be related to healing of the infarct with the development of scar (and an increased risk of monomorphic VT) and associated with an increased risk of late SCD. Late SCD most often occurs in the first year, with the majority of events seen within the first few months and being due to a ventricular tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The risk of late",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    appears to be equivalent in patients with ST elevation and non-ST elevation infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data do not include patients with SCD who do not survive until hospitalization. It has been estimated that more than 50 percent of deaths due to acute MI occur out of the hospital, and most episodes occur within one hour of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/38\">",
"     38",
"    </a>",
"    ]. Among patients with out-of-hospital cardiac arrest, the risk is greater in those with acute occlusion of the left anterior descending or left circumflex arteries (odds ratio 4.82 and 4.92, respectively, compared to those with a right coronary artery occlusion).",
"   </p>",
"   <p>",
"    In addition, there are patients who have unstable coronary lesions that may be responsible for acute ischemic events, short of infarction, and that can cause electrical instability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/22,39,40\">",
"     22,39,40",
"    </a>",
"    ]. The potential frequency of this effect was illustrated in a report of 84 resuscitated patients who underwent coronary angiography immediately upon admission: 76 percent had significant coronary disease, spasm, or an unstable lesion, and almost one-half had coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of unstable plaques has been confirmed in a number of autopsy studies of men and women with coronary disease who died suddenly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 113 such men: 59 had an acute coronary thrombus and 54 had severe narrowing of the coronary artery by an atherosclerotic plaque without acute thrombosis (stable plaque) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/40\">",
"       40",
"      </a>",
"      ]. Among those with acute thrombosis, 41 resulted from rupture of a vulnerable plaque (a thin fibrous cap overlying a lipid-rich core) and 18 from erosion of a fibrous plaque rich in smooth-muscle cells and proteoglycans.",
"     </li>",
"     <li>",
"      The likelihood of plaque rupture may vary in different subgroups. In a review of 141 men with SCD associated with coronary artery disease, the 25 patients who died during exertion were significantly more likely to have plaque rupture (72 versus 23 percent in those who died at rest) and hemorrhage into the plaque (72 versus 41 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with SCD associated with unstable angina, the thrombi typically have a layered appearance indicative of episodic growth [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/43\">",
"       43",
"      </a>",
"      ]. Episodic growth may alternate with intermittent fragmentation of the thrombus, leading to distal embolization of both thrombus and platelet aggregates and microinfarction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of severe coronary disease alone in a survivor of SCD does not prove a cause-and-effect relationship. Among patients who are not in the acute phase of a myocardial infarction, an appreciable risk of recurrent",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    may persist despite successful revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of heart failure (HF), regardless of etiology, increases overall mortality and the incidence of SCD in both men and women. This was illustrated in a 38 year follow-up of patients in the Framingham Heart Study: the incidence of SCD in those with HF, compared to those without HF, was increased five-fold in both sexes, although the absolute risk in women was only one-third that of men (",
"    <a class=\"graphic graphic_figure graphicRef58658 \" href=\"UTD.htm?31/17/32029\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/18\">",
"     18",
"    </a>",
"    ]. The SCD death potential in men and women with HF was as great as that noted in patients with overt coronary heart disease (13.7 and 3.8 versus 12.9 and 2.4 per 1000 patients, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Published series suggest a relatively consistent pattern with 30 to 50 percent of all cardiac deaths in patients with HF being categorized as sudden deaths, with or without preceding symptoms. However, it is often difficult to distinguish those dying suddenly and unexpectedly from those experiencing terminal arrhythmias in the setting of progressive hemodynamic deterioration. It has been suggested that progressive pump failure, sudden arrhythmic death, and sudden death during episodes of clinical worsening each account for approximately one-third of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/47\">",
"     47",
"    </a>",
"    ]. In the AIRE trial, for example, only 39 percent of sudden deaths were thought to be due to arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/48\">",
"     48",
"    </a>",
"    ]. VT degenerating into VF is the most common cause of SCD; a bradyarrhythmia or PEA is responsible in 5 to 33 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis of heart failure\", section on 'SCD and progressive HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An acute coronary event appears to be the precipitating factor in some patients with HF. The prevalence of coronary thrombus, ruptured plaque, or myocardial infarction and its relationship to SCD was examined in an autopsy study of 171 patients with HF in the ATLAS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/49\">",
"     49",
"    </a>",
"    ]. In patients with significant coronary artery disease, an acute coronary finding was found in 54 percent who died suddenly and in 32 percent who died of myocardial failure, although an acute coronary event had not been clinically diagnosed before death. In contrast, an acute coronary finding was uncommon in those without coronary disease, occurring in only 5 percent of those who died suddenly and in 10 percent of those who died of myocardial failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension with left ventricular hypertrophy (LVH) appears to increase the risk of SCD. Such patients appear to be less likely to have coronary thrombi than normotensives who had SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/50\">",
"     50",
"    </a>",
"    ]. However, most such patients have severe coronary disease suggesting that the hypertrophied myocardium is more susceptible than normal myocardium to the effects of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCD also occurs more commonly in patients with hypertrophic cardiomyopathy. Among competitive athletes who die from SCD due to proven cardiac cause, hypertrophic cardiomyopathy may be the most common underlying disorder, accounting for 36 percent of 286 cases in an autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Absence of known structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death can occur in patients who have no previous history of heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23,27,51\">",
"     23,27,51",
"    </a>",
"    ]. However, most of these patients have underlying structural heart disease. The frequency with which this occurs was illustrated in an autopsy study that evaluated 162 subjects aged 9 to 39 years with SCD; none had previously diagnosed underlying disease and death occurred in the absence of trauma and within 24 hours of onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23\">",
"     23",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 15 percent of deaths were noncardiac (most often intracranial hemorrhage) and 73 percent were cardiac.",
"     </li>",
"     <li>",
"      The most common causes of heart disease were coronary disease (58 percent in those over age 30 compared to 22 percent in younger subjects), myocarditis (11 and 22 percent in the two age groups), hypertrophic cardiomyopathy (13 percent in younger subjects), sarcoidosis, and arrhythmogenic right ventricular cardiomyopathy.",
"     </li>",
"     <li>",
"      Approximately one-half had some prodromal symptoms, such as chest pain or dizziness.",
"     </li>",
"     <li>",
"      SCD occurred during routine activity in 49 percent, during sleep in 23 percent, and in relation to exercise in 23 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association with exercise has also been described in competitive athletes. In a United States registry of SCD in 286 competitive athletes under age 35 in whom cardiovascular disease was shown to be the cause at autopsy, the most common underlying disorders were hypertrophic cardiomyopathy (36 percent, with possible HCM in another 10 percent), an anomalous coronary artery of wrong sinus origin (13 percent), and myocarditis (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A different distribution of causes was noted in a series of 49 athletes under age 35 with SCD from northern Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/29\">",
"     29",
"    </a>",
"    ]. The most common causes were arrhythmogenic right ventricular cardiomyopathy (22 percent, which occurs more frequently in this region), coronary atherosclerosis (18 percent), anomalous origin of a coronary artery (12 percent), mitral valve prolapse (10 percent), myocarditis (6 percent), and hypertrophic cardiomyopathy (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Absence of structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In different reports, 10 to 12 percent of younger patients have VF in the true absence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/23,52\">",
"     23,52",
"    </a>",
"    ], while a lower value of about 5 percent has been described when older patients are included [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16233/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This can occur in a variety of settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brugada syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Commotio cordis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"       \"Commotio cordis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Idiopathic ventricular fibrillation, also called primary electrical disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic ventricular tachycardia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital or acquired long QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"       \"Diagnosis of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Short QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=see_link\">",
"       \"Short QT syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=see_link\">",
"       \"Patient information: Ventricular fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18475278\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of organized cardiac electrical activity with hemodynamic collapse. The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation, cardioversion, antiarrhythmic drug) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact mechanism of collapse in an individual patient is often impossible to establish since, for the vast majority of patients who die suddenly, cardiac electrical activity is not being monitored at the time of their collapse. However, in studies of patients who were having cardiac electrical activity monitored at the time of their event, ventricular tachycardia (VT) or ventricular fibrillation (VF) accounted for the majority of episodes, with bradycardia or asystole accounting for nearly all of the remainder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Arrhythmic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the majority of patients with",
"      <span class=\"nowrap\">",
"       VT/VF,",
"      </span>",
"      sustained ventricular arrhythmia is preceded by an increase in ventricular ectopy and the development of repetitive ventricular arrhythmia, particularly runs of nonsustained VT. In about one-third of cases, the tachyarrhythmia is initiated by an early R on T ventricular premature beat (VPB); in the remaining two-thirds, the arrhythmia is initiated by a late cycle VPB. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Arrhythmic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many cardiac and noncardiac causes for a sustained ventricular tachyarrhythmia that can result in SCD (",
"      <a class=\"graphic graphic_table graphicRef62184 \" href=\"UTD.htm?16/52/17228\">",
"       table 2",
"      </a>",
"      ). Among all SCD in all age groups, the majority (65 to 70 percent) are related to coronary heart disease, with other structural cardiac disease (approximately 10 percent), arrhythmias in the absence of structural heart disease (5 to 10 percent), and noncardiac causes (15 to 25 percent) responsible for the remaining deaths. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology of SCD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/1\">",
"      Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985; 5:141B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/2\">",
"      Bay&eacute;s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/3\">",
"      Dubner SJ, Pinski S, Palma S, et al. Ambulatory electrocardiographic findings in out-of-hospital cardiac arrest secondary to coronary artery disease. Am J Cardiol 1989; 64:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/4\">",
"      Wood MA, Stambler BS, Damiano RJ, et al. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/5\">",
"      Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/6\">",
"      Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from sudden cardiac arrest: the \"chain of survival\" concept. A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation 1991; 83:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/7\">",
"      Tovar OH, Jones JL. Electrophysiological deterioration during long-duration ventricular fibrillation. Circulation 2000; 102:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/8\">",
"      Weaver WD, Hill D, Fahrenbruch CE, et al. Use of the automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med 1988; 319:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/9\">",
"      Raitt MH, Dolack GL, Kudenchuk PJ, et al. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation. Implications for use of implantable defibrillator. Circulation 1995; 91:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/10\">",
"      Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/11\">",
"      K&uuml;rkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med 2000; 160:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/12\">",
"      Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983; 67:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/13\">",
"      Mandapati R, Asano Y, Baxter WT, et al. Quantification of effects of global ischemia on dynamics of ventricular fibrillation in isolated rabbit heart. Circulation 1998; 98:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/14\">",
"      Kuo CS, Amlie JP, Munakata K, et al. Dispersion of monophasic action potential durations and activation times during atrial pacing, ventricular pacing, and ventricular premature stimulation in canine ventricles. Cardiovasc Res 1983; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     Bardy GH, Olson WH. Clinical characteristics of spontaneous-onset sustained ventricular tachycardia and ventricular fibrillation in survivors of cardiac arrest. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes DP, Jalife J (Eds), WB Saunders, Philadelphia 1990. p.778.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/16\">",
"      Wu TJ, Lin SF, Weiss JN, et al. Two types of ventricular fibrillation in isolated rabbit hearts: importance of excitability and action potential duration restitution. Circulation 2002; 106:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/17\">",
"      Chen PS, Wu TJ, Ting CT, et al. A tale of two fibrillations. Circulation 2003; 108:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/18\">",
"      Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death--United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/20\">",
"      Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/21\">",
"      Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004; 141:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/22\">",
"      Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/23\">",
"      Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/24\">",
"      Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/25\">",
"      Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/26\">",
"      Kuisma M, Alasp&auml;&auml; A. Out-of-hospital cardiac arrests of non-cardiac origin. Epidemiology and outcome. Eur Heart J 1997; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/27\">",
"      Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003; 107:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/28\">",
"      Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/29\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/30\">",
"      Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/31\">",
"      Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989; 79:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/32\">",
"      Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/33\">",
"      Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/34\">",
"      Volpi A, Cavalli A, Santoro L, Negri E. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. Am J Cardiol 1998; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/35\">",
"      Goldberg RJ, Gore JM, Haffajee CI, et al. Outcome after cardiac arrest during acute myocardial infarction. Am J Cardiol 1987; 59:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/36\">",
"      Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/37\">",
"      Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/38\">",
"      Gheeraert PJ, Henriques JP, De Buyzere ML, et al. Out-of-hospital ventricular fibrillation in patients with acute myocardial infarction: coronary angiographic determinants. J Am Coll Cardiol 2000; 35:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/39\">",
"      Stevenson WG, Wiener I, Yeatman L, et al. Complicated atherosclerotic lesions: a potential cause of ischemic ventricular arrhythmias in cardiac arrest survivors who do not have inducible ventricular tachycardia? Am Heart J 1988; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/40\">",
"      Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/41\">",
"      Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/42\">",
"      Burke AP, Farb A, Malcom GT, et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/43\">",
"      Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/44\">",
"      Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/45\">",
"      Natale A, Sra J, Axtell K, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 1994; 5:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/46\">",
"      Daoud EG, Niebauer M, Kou WH, et al. Incidence of implantable defibrillator discharges after coronary revascularization in survivors of ischemic sudden cardiac death. Am Heart J 1995; 130:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/47\">",
"      Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/48\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/49\">",
"      Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/50\">",
"      Burke AP, Farb A, Liang YH, et al. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996; 94:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/51\">",
"      Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990; 120:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16233/abstract/52\">",
"      Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985; 87:476.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 974 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16233=[""].join("\n");
var outline_f15_54_16233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18475278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARRHYTHMIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of VF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY OF SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H598833\">",
"      Autopsy studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Absence of known structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Absence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18475278\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/974|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/4/18509\" title=\"figure 1\">",
"      Incidence of sudden death in men and women increases with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25261\" title=\"figure 2\">",
"      SCD and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/17/32029\" title=\"figure 3\">",
"      Heart failure predicts sudden cardiac death and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/974|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/32/12812\" title=\"table 1\">",
"      Ambulatory ECG in sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/52/17228\" title=\"table 2\">",
"      Major causes of sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/48/8971\" title=\"table 3\">",
"      Proportion CV events SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/974|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/1/26648\" title=\"waveform 1\">",
"      ECG showing changes in VF over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/47/30455\" title=\"waveform 2\">",
"      ECG Ventricular fibrillation tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=related_link\">",
"      Pathophysiology of the long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=related_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16234="Autism spectrum disorders in children and adolescents: Complementary and alternative therapies";
var content_f15_54_16234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Laura Weissman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/54/16234/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/54/16234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) categorizes autism spectrum disorders under \"pervasive developmental disorders\" (PDD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders include autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism); Asperger disorder (also known as Asperger syndrome); pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism; childhood disintegrative disorder; and Rett disorder.",
"   </p>",
"   <p>",
"    The discussion that follows will focus on complementary and alternative therapies for autism, Asperger disorder, and PDD-NOS. Related topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"       \"Clinical features of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"       \"Diagnosis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4122?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=see_link\">",
"       \"Autism spectrum disorders in children and adolescents: Pharmacologic interventions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link\">",
"       \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=see_link\">",
"       \"Asperger disorder: Management and prognosis in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF CAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) therapies, as defined by the National Center for Complementary and Alternative Medicine (NCCAM), are \"a group of diverse medical and healthcare systems, practices, and products that are not generally considered to be part of conventional medicine\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative therapies are those that are used instead of conventional therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"     3",
"    </a>",
"    ]. Complementary therapies are those that are used in conjunction with conventional therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"     3",
"    </a>",
"    ]. The combination of conventional and complementary techniques that have some supportive evidence is often called \"integrative medicine\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"     4",
"    </a>",
"    ]. Some of the interventions originally considered to be complementary may become part of conventional practice when there is scientific evidence to support their use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of complementary and alternative medicine in pediatrics\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of CAM include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whole medical systems (eg, homeopathic medicine, traditional Chinese medicine)",
"     </li>",
"     <li>",
"      Mind-body medicine (eg, meditation, yoga, prayer, mental healing)",
"     </li>",
"     <li>",
"      Biologically based practices (eg, dietary supplements, special diets, immune-modulating agents, etc.)",
"     </li>",
"     <li>",
"      Manipulative and body-based practices (eg, chiropractic manipulation, massage)",
"     </li>",
"     <li>",
"      Energy medicine, which involves the use of energy fields (eg, Reiki, therapeutic touch)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of CAM is slightly different for ASD than for other medical disorders. Many of the behavioral and educational therapies used to treat ASD are not generally considered to be conventional medical therapies, but are commonly accepted practice for the treatment of ASD (eg, intensive behavioral therapy such as applied behavior analysis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4122?source=see_link&amp;anchor=H8#H8\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\", section on 'Intensive behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) is commonly used in children with special healthcare needs. Among 3173 patients in the Autism Speaks Autism Treatment Network with complete information about CAM use, 28 percent reported using CAM (any type) and 17 percent reported using special diets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/5\">",
"     5",
"    </a>",
"    ]. In smaller studies, the prevalence of CAM use ranged from 52 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Rates tend to be higher in children with more severe forms of ASD, those diagnosed at an earlier age, and those with gastrointestinal symptoms or seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/5\">",
"     5",
"    </a>",
"    ]. The types of therapies are diverse (",
"    <a class=\"graphic graphic_table graphicRef81572 \" href=\"UTD.htm?11/21/11613\">",
"     table 1",
"    </a>",
"    ). Those that are \"biologically based\", such as vitamins, supplements, special diets, and body-based practices, tend to be used with higher frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"     4",
"    </a>",
"    ]. Few CAM therapies have been proven effective (or ineffective) in controlled trials. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Biologic-based interventions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonbiologic-based interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rationale for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASD are neurodevelopmental disorders with no known cure, although symptoms can lessen over time with appropriate interventions. The treatment model for ASD differs conceptually from that for other medical disorders: the primary interventions are educational and behavioral, rather than medical or surgical. In addition, the etiology of ASD is incompletely understood. The combination of these factors leads many families to investigate both conventional and CAM therapies as part of the process of understanding and accepting the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=see_link&amp;anchor=H12#H12\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Families choose CAM therapies to treat a variety of symptoms, including the core symptoms of ASD (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 2",
"    </a>",
"    ), inattention, gastrointestinal symptoms, and sleep disturbance, and to promote general health [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"     3",
"    </a>",
"    ]. Some treatments are undertaken to address a biologic condition that the family believes contributes to the pathogenesis of ASD, whether or not there is scientific evidence to support the hypothesis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Underlying hypotheses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When choosing treatments (both conventional and CAM), families of 112 children with ASD rated the following factors to be important [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Safety of prescribed medication (84 percent)",
"     </li>",
"     <li>",
"      Concern about side effects of prescription therapy (83 percent)",
"     </li>",
"     <li>",
"      Experienced unacceptable side effects with prescribed medications (73 percent)",
"     </li>",
"     <li>",
"      Physician recommended (67 percent)",
"     </li>",
"     <li>",
"      Preferred a scientifically proven therapy (66 percent)",
"     </li>",
"     <li>",
"      Wanted more control over treatment (54 percent)",
"     </li>",
"     <li>",
"      Recommended by friends, family, or parents of other patients (53 percent)",
"     </li>",
"     <li>",
"      Hope for a cure (50 percent)",
"     </li>",
"     <li>",
"      Preferred a \"natural\" therapy (39 percent)",
"     </li>",
"     <li>",
"      Read about it in magazine or Web site, or saw it on TV (24 percent)",
"     </li>",
"     <li>",
"      Wanted a holistic approach (14 percent)",
"     </li>",
"     <li>",
"      Cultural",
"      <span class=\"nowrap\">",
"       tradition/family",
"      </span>",
"      tradition (13 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Underlying hypotheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of, or interest in, certain CAM therapies for ASD is based upon various hypotheses about the origins of autism. Although there is little high-quality evidence to support them, these hypotheses propose that the development of ASD is related to [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal abnormalities, such as dysbiosis (abnormalities of microflora) or \"leaky gut\", prompting the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"       secretin",
"      </a>",
"      , antifungal agents, probiotics, etc",
"     </li>",
"     <li>",
"      Food sensitivities and allergies, prompting the use of special diets, such as the gluten-free",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      casein-free (GFCF) diet",
"     </li>",
"     <li>",
"      Autoimmunity, prompting the use of immunotherapy",
"     </li>",
"     <li>",
"      Metabolic abnormalities (eg, in glutathione synthesis, sulfation, folate metabolism), prompting the use of antioxidants",
"     </li>",
"     <li>",
"      Heavy metal toxicity, especially mercury, prompting the use of chelation therapy",
"     </li>",
"     <li>",
"      Nutritional imbalances, prompting the use of nutritional supplements (eg, omega-3 fatty acids, vitamins)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The range of therapies used by families to address these proposed underlying problems is extensive (",
"    <a class=\"graphic graphic_table graphicRef81572 \" href=\"UTD.htm?11/21/11613\">",
"     table 1",
"    </a>",
"    ). The more commonly used CAM interventions are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Biologic-based interventions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonbiologic-based interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICIAN GUIDANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about therapies for children with autism spectrum disorders (ASD) should integrate clinical expertise, patient (or family) values and preferences, and the best evidence of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,8-10\">",
"     4,8-10",
"    </a>",
"    ]. Although complementary and alternative (CAM) therapies are frequently used by families of children with ASD, few such therapies have been proven effective (or ineffective) or safe in controlled trials. Despite the lack of high-quality evidence, families use CAM, and certain CAM therapies are recommended by some clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to ask families of children with ASD specifically about the use of CAM therapies; they may not volunteer this information. A summary of important points when discussing CAM therapies is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef57149 \" href=\"UTD.htm?15/51/16188\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) Committee on Children with Disabilities policy statement on counseling families who chose CAM for their child with chronic illness provides the following recommendations for healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seek information for yourself and be prepared to share it with families",
"     </li>",
"     <li>",
"      Evaluate the scientific merits of specific therapeutic approaches",
"     </li>",
"     <li>",
"      Identify risks or potential harmful effects",
"     </li>",
"     <li>",
"      Provide families with information on a range of treatment options",
"     </li>",
"     <li>",
"      Educate families to evaluate information about all treatment approaches",
"     </li>",
"     <li>",
"      Avoid dismissal of CAM in ways that communicate a lack of sensitivity or concern for the family's perspective",
"     </li>",
"     <li>",
"      Recognize when the family feels threatened and guard against becoming defensive",
"     </li>",
"     <li>",
"      If a CAM approach is endorsed by the family, offer to assist in monitoring and evaluating the response",
"     </li>",
"     <li>",
"      Actively listen to the family and the child with chronic illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluation of evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should evaluate the evidence for all treatments, both conventional and CAM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"     4",
"    </a>",
"    ]. When evaluating the merits of a study, look for a homogeneous case definition, control for potential confounding variables, consistent dosing, appropriate comparison group, appropriate blinding (if applicable), valid outcome measure(s), and adequate sample size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14694?source=see_link\">",
"     \"Evidence-based medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of ASD, effects of other interventions (eg, conventional educational or behavioral interventions), and the placebo effect also must be taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Patients with chronic conditions with unclear pathophysiology, fluctuating courses, subjective symptoms, and few effective evidence-based treatments (such as ASD) are most vulnerable to the placebo effect.",
"   </p>",
"   <p>",
"    In the hierarchy of evidence, randomized, blinded, placebo-controlled studies provide the highest-quality evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is often difficult to perform such studies in children with ASD. Thus, much of the evidence for both conventional and CAM therapies comes from cohort studies, case-control studies, and case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potential harms",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAM therapies may compete with validated treatments for time, effort, and financial resources [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/13\">",
"     13",
"    </a>",
"    ]. There are few data about the adverse effects of CAM therapies. The magnitude of risk for hypersensitivity, systemic toxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical toxicity is not known. Nutritional supplements (eg, omega-3 fatty acids, vitamin B6, magnesium, etc) are classified as foods, rather than drugs. As such, they are subject to different regulations and quality controls. The potential presence of contaminants and interactions of these supplements with prescription drugs have not been studied systematically.",
"   </p>",
"   <p>",
"    Potential adverse effects associated with specific therapies are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Biologic-based interventions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonbiologic-based interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Counseling families",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical practitioners play an essential role in helping families evaluate information regarding CAM for children with ASD. Although families of children with ASD may seek CAM therapies, they also value the recommendations of their healthcare providers. In a survey of families of children with ASD, two-thirds indicated that physician recommendation and scientific proof were important factors in choosing therapies for their children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important for clinicians who care for children with ASD to become knowledgeable about CAM therapies and to provide balanced information and advice about the potential benefits and risks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/13\">",
"     13",
"    </a>",
"    ]. When counseling families who are considering the use of CAM therapies that lack supportive data, the importance of using only one new therapy at a time and collecting objective outcome data should be emphasized.",
"   </p>",
"   <p>",
"    The AAP suggests that the provider encourage families to seek additional information",
"    <span class=\"nowrap\">",
"     if/when",
"    </span>",
"    the CAM treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is based on overly simplified scientific theories",
"     </li>",
"     <li>",
"      Is claimed to be effective for multiple, different, unrelated conditions or symptoms",
"     </li>",
"     <li>",
"      Is claimed to result in a dramatic response or even a cure",
"     </li>",
"     <li>",
"      Is supported by case reports or anecdotal data rather than carefully designed studies",
"     </li>",
"     <li>",
"      Is not supported by peer-reviewed references, or the treatment's supporters deny the need for controlled studies",
"     </li>",
"     <li>",
"      Is said to have no potential or reported adverse events",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BIOLOGIC-BASED INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of biologic-based complementary and alternative (CAM) interventions for autism spectrum disorders (ASD) is ongoing. However, few CAM therapies have been proven",
"    <span class=\"nowrap\">",
"     effective/ineffective",
"    </span>",
"    or safe in controlled trials. The scientific evidence for most interventions is insufficient to make recommendations for or against use. In such cases, the clinician and family must weigh the potential benefits and risks, including competition with validated treatment for time, effort, and financial resources. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Potential harms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin is a hormone produced by the pineal gland that regulates sleep. Some studies suggest that there is abnormal melatonin production in children with autism and other developmental disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits of melatonin for sleep regulation in children with ASD have been suggested by a few scientific studies. The use of melatonin for sleep regulation in children with ASDs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=see_link&amp;anchor=H28#H28\">",
"     \"Autism spectrum disorders in children and adolescents: Pharmacologic interventions\", section on 'Sleep disturbance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Secretin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     Secretin",
"    </a>",
"    is a gastrointestinal hormone. It inhibits intestinal motility and release of gastric acid and stimulates secretion of pancreatic fluid and bicarbonate. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     \"Secretin: Drug information\"",
"    </a>",
"    .) The use of secretin as a potential therapy for children with ASD is based upon the hypothesis that autism is related to gastrointestinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there is little evidence to support this hypothesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=see_link&amp;anchor=H27#H27\">",
"     \"Autism spectrum disorders in children and adolescents: Pharmacologic interventions\", section on 'GI problems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/20\">",
"     20",
"    </a>",
"    ]. Two systematic reviews, the first including 16 randomized controlled trials and the second including seven randomized controlled trials, found no evidence that secretin improves the core features of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. No serious side effects were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) are essential fatty acids with documented cardiovascular benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .) Some studies suggest that plasma omega-3 concentrations in children with ASD are decreased, but no clinical correlation has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether omega-3 supplementation is beneficial for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, the American Heart Association suggests two servings of fish per week for the cardiovascular benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H16#H16\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Meat and protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Omega-3 fatty acid supplementation for children with ASD has been evaluated in two small randomized controlled pilot studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], a systematic review that included one of the randomized trials and five observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/25\">",
"     25",
"    </a>",
"    ], and a meta-analysis of the two randomized- trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/26\">",
"     26",
"    </a>",
"    ]. The pilot studies had inconsistent results. The systematic review and meta-analysis concluded that there is insufficient evidence to endorse the use of omega-3 fatty acids for improvement of ASD symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common side effects of omega-3 supplementation include gastrointestinal distress (eg, nausea, diarrhea). No major side effects were reported in the studies of omega-3 supplementation for ASD. Omega-3 fatty acid supplementation should be used with caution in patients with bleeding disorders or sensitivity to fish. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H24#H24\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H28#H28\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No specific dosing guidelines for omega-3 fatty acids are available. When used for cardiovascular protection in adults, a dose of 250 to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is suggested. The pilot studies in children with ASD used 1.3 and 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. High levels of supplementation should be avoided; although there are no guidelines for children, a maximum dose of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is suggested for adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H27#H27\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Dose and form'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Omega-3 fatty acid supplementation for children with developmental coordination disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/28/13770?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of developmental coordination disorder\", section on 'Dietary therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gluten-free casein-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of the gluten-free",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    casein-free (GFCF) diet for children with ASD is based upon the hypothesis that increased permeability allows gluten and casein peptides to leak from the gut, causing excessive opioid activity and resulting in behaviors observed in ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/7\">",
"     7",
"    </a>",
"    ]. However, children with ASD have neither increased rates of celiac disease nor excessive amounts of opioid-like compounds in their urine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/14,29-32\">",
"     14,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient information about the efficacy and safety of the GFCF diet to make recommendations about its use in children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/20,33\">",
"     20,33",
"    </a>",
"    ]. A 2008 systematic review identified two small randomized controlled trials evaluating GFCF diets in children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/34\">",
"     34",
"    </a>",
"    ]. One found that the combined GFCF diet reduced autistic traits; the other found no difference in outcome measures. Meta-analysis was not possible.",
"   </p>",
"   <p>",
"    A subsequent larger, controlled trial randomly assigned 72 children with ASD to GFCF diet or no dietary intervention for 12 months, after which (based upon a predetermined threshold), the control group was reassigned to the GFCF diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/35\">",
"     35",
"    </a>",
"    ]. The results suggested possible short-term improvement in some core symptoms of autism and",
"    <span class=\"nowrap\">",
"     hyperactivity/inattention,",
"    </span>",
"    but the tools used to assess outcome are more traditionally used for diagnosis, rather than tracking. In addition, effects of other interventions could not be excluded. Eleven children assigned to the GFCF diet withdrew from the study (three children did not want to be on the diet; the families of four children lacked the time and resources to commit to the trial).",
"   </p>",
"   <p>",
"    In an 18-week trial presented at the International Meeting for Autism Research (IMFAR), 21 children with ASD between the ages of 30 and 54 months who were receiving a minimum of 10",
"    <span class=\"nowrap\">",
"     hours/week",
"    </span>",
"    of intensive behavioral intervention were placed on a strict, nutritionally monitored GFCF diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/36\">",
"     36",
"    </a>",
"    ]. After at least four weeks of the GFCF diet, the children underwent weekly randomized double-blind challenges with gluten, casein, both, or neither. Fourteen children successfully completed the study. Three children were excluded for medical reasons (anemia or positive tissue transglutaminase antibody, a marker of celiac disease), and four were unable to establish the diet or dropped out of intensive behavioral intervention. After the gluten and casein challenges, study participants had no change in attention, activity, sleep, or frequency or quality of bowel habits compared with baseline. Although the GFCF diet does not appear to have beneficial effects at the population level, benefits for individuals in certain subgroups (eg, those with significant gastrointestinal disease) cannot be excluded. In the closely monitored study environment, no nutritional adverse effects were noted.",
"   </p>",
"   <p>",
"    None of the other studies reported on adverse outcomes or potential harms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, an observational study suggests that casein restriction is associated with decreased bone mass and increased prevalence of essential acid deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, it is difficult to adhere to a strict gluten-free casein-free diet.",
"   </p>",
"   <p>",
"    Pending more definitive information, providers should counsel families of patients who choose to follow a GFCF diet about the need for adequate vitamin D, calcium, and protein intake. Rice milk, almond milk, and potato milk are not sufficient sources of protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H2#H2\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Nutritional requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     B6-magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a long history of the use of vitamin B6 (pyridoxine) and magnesium for the treatment of mental health disorders (magnesium was added to reduce the side effects of B6) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,38\">",
"     4,38",
"    </a>",
"    ]. However, there has been little research specifically evaluating this intervention for ASD. A 2005 systematic review of three small and methodologically flawed randomized controlled studies (total of 33 patients) of vitamin B6 and magnesium therapy for children with ASD found the data inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Megadoses of vitamin B6 (&gt;100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may result in neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H39#H39\">",
"     \"Overview of water-soluble vitamins\", section on 'Vitamin B6 (pyridoxine)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dimethylglycine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dimethylglycine (DMG), a derivative of the amino acid glycine, is thought to reduce lactic acid build-up during stress, enhance oxygen use during times of hypoxia, and reduce seizure activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/39\">",
"     39",
"    </a>",
"    ]. The use of DMG in children with ASD is based upon the hypothesis that metabolic abnormalities contribute to the development of autism.",
"   </p>",
"   <p>",
"    There is insufficient information about the efficacy and safety of the DMG to make recommendations about its use in children with ASD. Small randomized controlled trials in children with ASD have demonstrated no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Adverse effects have not been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of probiotics as a treatment for autism is based upon the hypothesis that there is an imbalance in intestinal microbes in individuals with ASD. There is insufficient information about the efficacy of probiotics to make recommendations about their use in children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/13,33\">",
"     13,33",
"    </a>",
"    ]. There are no current studies demonstrating harm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/41\">",
"     41",
"    </a>",
"    ]. Probiotics are regulated by the United States Food and Drug Administration (FDA) for impurities and quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antifungal agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) as a treatment for autism is based upon the hypothesis that there is yeast overgrowth secondary to an imbalance in microbes in individuals with ASD. This hypothesis became more popular after a report of two boys with autistic behaviors who had what was interpreted as yeast metabolites in their urine, suggesting candidal overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,42\">",
"     4,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient information about the efficacy and safety of the antifungal agents to make recommendations about their use in children with ASD. No controlled trials have evaluated these therapies in children with ASD. Adverse effects of antifungal agents may include hepatotoxicity, anemia, diarrhea, and exfoliative dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/14,41\">",
"     14,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous immunoglobulin (IVIG) and other immune therapies for children with ASD is based upon the hypothesis that fetal brain development is related to the prenatal immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,43\">",
"     4,43",
"    </a>",
"    ]. However, the data underlying this hypothesis are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not suggest IVIG for the treatment of ASD in the absence of other indications for IVIG (eg, documented immune deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H3#H3\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Indications'",
"    </a>",
"    .) An open trial of IVIG in 10 children with autism suggested subjective improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/46\">",
"     46",
"    </a>",
"    ]. However, subsequent case series failed to replicate this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of IVIG and other immune therapies include transmission of bloodborne pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H30#H30\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Risk of transmission of blood borne pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chelation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chelation is a process of administering a substance (such as ethylene diamine tetra-acetic acid [EDTA], 2,3-dimercaptosuccinic acid [DMSA], 2,3-dimercaptopropane-1-sulfonate [DMPS]), to remove heavy metals from the body. The use of chelation for ASD is based upon the hypothesis that the behaviors observed in children with ASD are secondary to toxicity from mercury or other heavy metals and that children with ASD do not excrete heavy metals effectively. However, there is little evidence to support this hypothesis. The clinical manifestations of mercury toxicity do not resemble those of ASD, and evidence to support a causal relationship between thimerosal and autism is lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and toxicity of mercury\", section on 'General toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not suggest chelation for the treatment of ASD. The safety and efficacy of chelation therapy for ASD, including nonprescription oral or rectal products, has not been studied in controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Chelation agents bind ions nonspecifically and may result in decreased levels of calcium, iron, and magnesium, in addition to toxic heavy metals. When used for documented heavy metal poisoning, chelation requires close monitoring. Death due to hypocalcemia has been reported when sodium EDTA rather than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    was used for chelation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H11#H11\">",
"     \"Childhood lead poisoning: Management\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of hyperbaric oxygen therapy (HBOT) to treat autism is based upon the hypothesis that increasing atmospheric pressure enhances oxygen delivery to the brain to reduce swelling and promote brain recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not suggest the use of HBOT as a treatment for ASD. There is insufficient information about its efficacy. Several uncontrolled trials reported clinical benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. These were followed by a multicenter randomized controlled trial, in which 62 children (aged two to seven years) with autism were randomly assigned to HBOT or slightly pressurized room air (40 treatments over one month). HBOT was associated with improvement in overall functioning, receptive language, social interaction, eye contact, and",
"    <span class=\"nowrap\">",
"     sensory/cognitive",
"    </span>",
"    awareness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/56\">",
"     56",
"    </a>",
"    ]. Subjects were evaluated with the Clinical Global Impression (CGI), Aberrant Behavior Checklist, and Autism Treatment Evaluation Checklist by the treating clinician and the child's",
"    <span class=\"nowrap\">",
"     parent/caregiver",
"    </span>",
"    before the first and immediately following the last treatments (the outcome of the study).",
"   </p>",
"   <p>",
"    The publication of this study has generated much interest. However, there are some important limitations. The outcome measures were evaluated only once, immediately after treatment; it is not known whether meaningful improvement was sustained over time. Children in the control group also improved, sometimes dramatically. Parental assessment on the CGI demonstrated substantially greater improvement than clinician assessment in the control group (increase in overall function of 0.83 versus 0.38).",
"   </p>",
"   <p>",
"    Adverse effects of HBOT may include ear problems (barotrauma) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .) Rare complications of HBOT may include reversible myopia, pulmonary barotrauma, pulmonary oxygen toxicity, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link&amp;anchor=H9#H9\">",
"     \"Hyperbaric oxygen therapy\", section on 'Complications'",
"    </a>",
"    .) In addition, HBOT may compete with validated therapies for time, effort, and financial resources. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4122?source=see_link&amp;anchor=H4#H4\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin C and other oxidative therapies (eg, methylcobalamin and folinic acid) have some evidence of potential benefit for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/58-60\">",
"     58-60",
"    </a>",
"    ], but not sufficiently strong to make a recommendation for or against use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,7,33,61\">",
"     4,7,33,61",
"    </a>",
"    ]. Zinc and digestive enzymes have not been evaluated in controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NONBIOLOGIC-BASED INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of nonbiologic-based complementary and alternative (CAM) interventions for autism spectrum disorders (ASD) is ongoing. However, few of these therapies have been proven",
"    <span class=\"nowrap\">",
"     effective/ineffective",
"    </span>",
"    or safe in controlled trials. The scientific evidence for most interventions is insufficient to make recommendations for or against use. In such cases the clinician and family must weigh the potential benefits and risks, including competition with validated treatment for time, effort, and financial resources. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Potential harms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Music therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of music therapy for children with ASD is based upon the hypothesis that the processes that occur within musical improvisation (sometimes understood to be a kind of nonverbal or preverbal language) may help people with autism to develop communicative skills and capacity for social interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient evidence to make a recommendation about music therapy for children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/20\">",
"     20",
"    </a>",
"    ]. A meta-analysis of three studies (24 participants) of music therapy for children with ASD found improvement in verbal communication skills (standardized mean difference [SMD] 0.36, 95% CI 0.15-0.57) and gestural communication skills (SMD 0.5, 95% CI 0.22-0.79), but not in behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the studies that were included had methodologic limitations and lacked clinically relevant outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Horseback riding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of therapeutic horseback riding (hippotherapy) for children with ASD is based upon the hypothesis that therapeutic horseback riding stimulates multiple domains of functioning (eg, cognitive, social, gross motor) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/63\">",
"     63",
"    </a>",
"    ]. In a nonrandomized study, 19 children with autism who participated in 12 weeks of therapeutic horseback riding (hippotherapy) demonstrated improvements in attention, distractibility, and social motivation compared with 15 wait-list controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/63\">",
"     63",
"    </a>",
"    ]. Additional studies are necessary before this therapy can be recommended. Therapeutic horseback riding is associated with a risk of injury similar to that in other \"limited contact\" recreational activities (eg, baseball, skating). When discussing horseback riding with families who choose to participate, it is important to emphasize the need for appropriate supervision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial magnetic stimulation (TMS) is an energy-based therapy that is proposed to work through electromagnetic induction, which modifies neuroexcitability. It is unrelated to the use of commercially obtained magnets, which are applied topically [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of transcranial magnetic stimulation for children with ASD is based upon the hypothesis that autism is related to a disturbance of cortical modularity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/64\">",
"     64",
"    </a>",
"    ]. Controlled and uncontrolled studies have demonstrated potential benefit in patients with depression, bipolar illness, schizophrenia, epilepsy, and Tourette syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of resistant depression in adults\", section on 'Repetitive transcranial magnetic stimulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and management of drug-resistant epilepsy\", section on 'Other stimulation approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link&amp;anchor=H16#H16\">",
"     \"Tourette syndrome\", section on 'Transcranial magnetic stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not suggest TMS for children with ASD. Additional study is necessary before TMS can be recommended for children with ASD. In an observational study, it was associated with reductions in repetitive-ritualistic behavior in 13 patients with high-functioning autism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/64\">",
"     64",
"    </a>",
"    ]. Improvements in social awareness and irritability were not noted. However, adverse effects may include neurocardiogenic syncope in adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Facilitated communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facilitated communication is a technique in which a facilitator physically guides the hand of a nonverbal child in using an output device (eg, keyboard, mouse, etc) for communication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/41\">",
"     41",
"    </a>",
"    ]. Reviews of published studies of facilitated communication found no evidence to support its use for individuals with communication impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/65\">",
"     65",
"    </a>",
"    ]. Controlled studies revealed that the facilitator, rather than the child, was providing information [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/66\">",
"     66",
"    </a>",
"    ]. We do not recommend facilitated communication as a means of communicating with children with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/20,67\">",
"     20,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facilitated communication must be distinguished from augmentative communication, a method of nonverbal communication in which manual sign, picture exchange, switches, or voice output devices are used without the aid of a facilitator. Augmentative communication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4122?source=see_link&amp;anchor=H15#H15\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\", section on 'Communication interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Auditory integration training",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of auditory integration training (AIT) in children with ASD is based upon the hypothesis that repeated exposure to altered sound via headphones functionally modifies central auditory processing, impacting language and behavior.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics considers AIT to be an investigational therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The Technical Expert Panel (a large multidisciplinary group consisting of experts in psychology, developmental pediatrics, child psychiatry, and education, and parents of children with autism) recommends against it [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/70\">",
"     70",
"    </a>",
"    ]. A systematic review of six randomized controlled trials of AIT in children with ASD found inconsistent results: three studies showed no benefit, and three showed some improvements in the Aberrant Behavior Checklist with uncertain clinical relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/71\">",
"     71",
"    </a>",
"    ]. Another systematic review found that AIT was ineffective in four out of five trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other nonbiologic-based intervention therapies that have some evidence of potential benefit for children with ASD, but not sufficiently strong to make a recommendation for or against use, include yoga, qigong massage, acupuncture, and neurofeedback [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,7,72-78\">",
"     4,7,72-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonbiologic-based interventions that have not been evaluated in controlled trials include craniosacral therapy, chiropractic care, therapeutic touch, healing touch, and Reiki [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pediatric healthcare providers seeking more information about complementary and alternative (CAM) therapies or current trials of CAM therapies in children with ASD, the following Web sites might be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/54/16234/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical trials registry of federally and privately supported clinical trials:",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"       clinicaltrials.gov",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www2.aap.org/sections/chim/default.cfm\">",
"       American Academy of Pediatrics Section on Integrative Medicine",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://nccam.nih.gov/\">",
"       National Center for Complementary and Alternative Medicine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.asatonline.org/\">",
"       Association for Science in Autism Treatment",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://autism.healingthresholds.com/\">",
"       Healing Thresholds",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.autism-society.org/\">",
"       Autism Society of America",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autism spectrum disorders (ASD) are neurodevelopmental disorders with an incompletely understood etiology and no known cure. Many families of children with ASD seek both conventional and complementary and alternative (CAM) therapies as part of the process of understanding and accepting the diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Rationale for use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to ask families of children with ASD specifically about the use of CAM therapies and to work with them in a sensitive manner (",
"      <a class=\"graphic graphic_table graphicRef57149 \" href=\"UTD.htm?15/51/16188\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical practitioners play an essential role in helping families evaluate information regarding CAM for children with ASD. It is important for clinicians to become knowledgeable about CAM therapies and to provide balanced information and advice about the potential benefits and risks. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Counseling families'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"       Secretin",
"      </a>",
"      and facilitated communication are ineffective. We recommend against their use in children with ASD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Secretin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Facilitated communication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Few of the remaining CAM therapies have been proven",
"      <span class=\"nowrap\">",
"       effective/ineffective",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       safe/unsafe",
"      </span>",
"      in controlled trials. In such cases, the clinician and family must weigh the unknown benefit against the potential risks, which include competition with validated treatment for time, effort, and financial resources. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Biologic-based interventions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Nonbiologic-based interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of more definitive evidence of benefit, based upon the increased risk of serious adverse effects, we suggest against the use of intravenous immunoglobulin, chelation therapy, hyperbaric oxygen therapy, and transcranial magnetic stimulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Intravenous immunoglobulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Chelation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Hyperbaric oxygen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Transcranial magnetic stimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is no scientific evidence of a benefit for the following therapies, they are unlikely to be harmful: music therapy, yoga, acupuncture, qigong massage, therapeutic touch, healing touch, Reiki, and neurofeedback. Therapeutic horseback riding is associated with a risk of injury similar to that in other \"limited contact\" recreational activities; appropriate supervision is necessary for children who participate in therapeutic horseback riding. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Nonbiologic-based interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Pervasive Developmental Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR&reg;)., American Psychiatric Association, Washington, DC  p.70.",
"    </li>",
"    <li>",
"     National Center for Complementary and Alternative Medicine. Expanding horizons of healthcare: five year strategic plan 2001-2005. US Department of Health and Human Services, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/3\">",
"      Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007; 37:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/4\">",
"      Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/5\">",
"      Perrin JM, Coury DL, Hyman SL, et al. Complementary and alternative medicine use in a large pediatric autism sample. Pediatrics 2012; 130 Suppl 2:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/6\">",
"      Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006; 36:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/7\">",
"      Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007; 54:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/8\">",
"      Kazdin AE. Evidence-based assessment for children and adolescents: issues in measurement development and clinical application. J Clin Child Adolesc Psychol 2005; 34:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/9\">",
"      Lilienfeld SO. Scientifically unsupported and supported interventions for childhood psychopathology: a summary. Pediatrics 2005; 115:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/10\">",
"      Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. 1996. Clin Orthop Relat Res 2007; 455:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/11\">",
"      Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord 2009; 39:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/12\">",
"      Committee on Children with Disabilities. American Academy of Pediatrics: Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics 2001; 107:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/13\">",
"      Myers SM, Johnson CP, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/14\">",
"      Barbaresi WJ, Katusic SK, Voigt RG. Autism: a review of the state of the science for pediatric primary health care clinicians. Arch Pediatr Adolesc Med 2006; 160:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/15\">",
"      Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 2005; 11:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/16\">",
"      Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998; 129:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/17\">",
"      Nickel R. Controversial therapies for young children with developmental disabilities. Infants Young Child 1996; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/18\">",
"      Johnson KP, Giannotti F, Cortesi F. Sleep patterns in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2009; 18:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/19\">",
"      Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh 2007. www.sign.ac.uk/guidelines/fulltext/98/index.html (Accessed on November 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/21\">",
"      Krishnaswami S, McPheeters ML, Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders. Pediatrics 2011; 127:e1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/22\">",
"      Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 4:CD003495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/23\">",
"      Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism? Neuro Endocrinol Lett 2006; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/24\">",
"      Vancassel S, Durand G, Barth&eacute;l&eacute;my C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/25\">",
"      Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord 2009; 39:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/26\">",
"      James S, Montgomery P, Williams K. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011; :CD007992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/27\">",
"      Amminger GP, Berger GE, Sch&auml;fer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007; 61:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/28\">",
"      Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 2011; 41:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/29\">",
"      Pavone L, Fiumara A, Bottaro G, et al. Autism and celiac disease: failure to validate the hypothesis that a link might exist. Biol Psychiatry 1997; 42:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/30\">",
"      Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002; 325:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/31\">",
"      Hunter LC, O'Hare A, Herron WJ, et al. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 2003; 45:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/32\">",
"      Le Couteur A, Trygstad O, Evered C, et al. Infantile autism and urinary excretion of peptides and protein-associated peptide complexes. J Autism Dev Disord 1988; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     Parr J. Autism. In: Clinical Evidence Handbook, BMJ Publishing Group, London 2008. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/34\">",
"      Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008; :CD003498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/35\">",
"      Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 2010; 13:87.",
"     </a>",
"    </li>",
"    <li>",
"     Hyman, S, Stewart, PA, Smith, T, et al. The gluten free and casein free (GFCF) diet: A double-blind, placebo-controlled challenge study. International Meeting for Autism Research (IMFAR) 2010. imfar.confex.com/imfar/2010/webprogram/Paper6183.html (Accessed on November 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/37\">",
"      Hediger ML, England LJ, Molloy CA, et al. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 2008; 38:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/38\">",
"      Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2005; :CD003497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/39\">",
"      Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol 2001; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/40\">",
"      Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord 1999; 29:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/41\">",
"      Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/42\">",
"      Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem 1995; 41:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/43\">",
"      Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000; 30:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/44\">",
"      Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/45\">",
"      Krause I, He XS, Gershwin ME, Shoenfeld Y. Brief report: immune factors in autism: a critical review. J Autism Dev Disord 2002; 32:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/46\">",
"      Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996; 26:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/47\">",
"      DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 1999; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/48\">",
"      Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1998; 13:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/49\">",
"      Voelker R. FDA warning targets OTC chelation products. JAMA 2010; 304:2112.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Chelation products: Unapproved over-the-counter drugs -- consumer warning. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm229454.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/51\">",
"      Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008; 46:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/53\">",
"      Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses 2007; 68:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/54\">",
"      Rossignol DA, Rossignol LW, James SJ, et al. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr 2007; 7:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/55\">",
"      Chungpaibulpatana J, Sumpatanarax T, Thadakul N, et al. Hyperbaric oxygen therapy in Thai autistic children. J Med Assoc Thai 2008; 91:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/56\">",
"      Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr 2009; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/57\">",
"      Collet JP, Vanasse M, Marois P, et al. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet 2001; 357:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/58\">",
"      Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/59\">",
"      Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009; 42:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/60\">",
"      James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/61\">",
"      Main PA, Angley MT, Thomas P, et al. Folate and methionine metabolism in autism: a systematic review. Am J Clin Nutr 2010; 91:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/62\">",
"      Gold C, Wigram T, Elefant C. Music therapy for autistic spectrum disorder. Cochrane Database Syst Rev 2006; :CD004381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/63\">",
"      Bass MM, Duchowny CA, Llabre MM. The effect of therapeutic horseback riding on social functioning in children with autism. J Autism Dev Disord 2009; 39:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/64\">",
"      Sokhadze EM, El-Baz A, Baruth J, et al. Effects of low frequency repetitive transcranial magnetic stimulation (rTMS) on gamma frequency oscillations and event-related potentials during processing of illusory figures in autism. J Autism Dev Disord 2009; 39:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/65\">",
"      Mostert MP. Facilitated communication since 1995: a review of published studies. J Autism Dev Disord 2001; 31:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/66\">",
"      Smith MD, Haas PJ, Belcher RG. Facilitated communication: the effects of facilitator knowledge and level of assistance on output. J Autism Dev Disord 1994; 24:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/67\">",
"      Jacobson JW, Mulick JA, Schwartz AA. A history of facilitated communication: Science, pseudoscience, and anti-science: Science working group on facilitated communication. Am Psychol 1995; 50:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/68\">",
"      Auditory integration training and facilitated communication for autism. American Academy of Pediatrics. Committee on Children with Disabilities. Pediatrics 1998; 102:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/69\">",
"      Section On Complementary And Integrative Medicine, Council on Children with Disabilities, American Academy of Pediatrics, et al. Sensory integration therapies for children with developmental and behavioral disorders. Pediatrics 2012; 129:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/70\">",
"      Maglione MA, Gans D, Das L, et al. Nonmedical interventions for children with ASD: recommended guidelines and further research needs. Pediatrics 2012; 130 Suppl 2:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/71\">",
"      Sinha Y, Silove N, Hayen A, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011; :CD003681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/72\">",
"      Silva LM, Schalock M, Ayres R, et al. Qigong massage treatment for sensory and self-regulation problems in young children with autism: a randomized controlled trial. Am J Occup Ther 2009; 63:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/73\">",
"      Silva LM, Cignolini A, Warren R, et al. Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med 2007; 35:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/74\">",
"      Lee MS, Kim JI, Ernst E. Massage therapy for children with autism spectrum disorders: a systematic review. J Clin Psychiatry 2011; 72:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/75\">",
"      Holtmann M, Steiner S, Hohmann S, et al. Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 2011; 53:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/76\">",
"      Cheuk DK, Wong V, Chen WX. Acupuncture for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011; :CD007849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/77\">",
"      Lee MS, Choi TY, Shin BC, Ernst E. Acupuncture for children with autism spectrum disorders: a systematic review of randomized clinical trials. J Autism Dev Disord 2012; 42:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/78\">",
"      Ming X, Chen X, Wang XT, et al. Acupuncture for treatment of autism spectrum disorders. Evid Based Complement Alternat Med 2012; 2012:679845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/54/16234/abstract/79\">",
"      Carbone PS, Farley M, Davis T. Primary care for children with autism. Am Fam Physician 2010; 81:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 605 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-02329B04FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16234=[""].join("\n");
var outline_f15_54_16234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF CAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rationale for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Underlying hypotheses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICIAN GUIDANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluation of evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potential harms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Counseling families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BIOLOGIC-BASED INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Melatonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Secretin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gluten-free casein-free diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      B6-magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dimethylglycine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chelation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NONBIOLOGIC-BASED INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Music therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Horseback riding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Facilitated communication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Auditory integration training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/21/11613\" title=\"table 1\">",
"      ASD CAM therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/6/29804\" title=\"table 2\">",
"      DSM IV criteria autism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/51/16188\" title=\"table 3\">",
"      CAM discussion points",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41801?source=related_link\">",
"      Asperger disorder: Management and prognosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4122?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35562?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14694?source=related_link\">",
"      Evidence-based medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/28/13770?source=related_link\">",
"      Overview of developmental coordination disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=related_link\">",
"      Secretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_54_16235="Coefficient for calculating volume for fetal transfusion";
var content_f15_54_16235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transfusion coefficient for calculating transfusion volume for fetal transfusion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Target hematocrit minus beginning hematocrit = Desired increment in hematocrit",
"      </td>",
"      <td class=\"subtitle1\">",
"       Transfusion coefficient",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       0.02",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       0.04",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       0.05",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    As an example, to increase the hematocrit of a 1000 gram fetus from 20 percent to 40 percent, one multiplies 0.04 (coefficient for raising the hematocrit by 20) and 1000 (the estimated fetal weight in grams) to yield 40 mL (the volume that needs to be transfused).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Moise, KJ, Whitecar, PW. Antenatal therapy for hemolytic disease. In: Alloimmune Disorders of Pregnancy. Anemia, thrombocytopenia and neutropenia in the fetus and newborn. Hadley, A, Soothill, P (Eds), Cambridge University Press, Cambridge, UK 2002. p.182.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16235=[""].join("\n");
var outline_f15_54_16235=null;
var title_f15_54_16236="Formula selection II";
var content_f15_54_16236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Formula selection for children and adults (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formula description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples (listed alphabetically, not comprehensive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Hyper-metabolism",
"       </td>",
"       <td>",
"        <p>",
"         1-1.5 cal/mL",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         May have higher osmolalities",
"        </p>",
"        <p>",
"         May be low-fat",
"        </p>",
"        <p>",
"         May contain MCT",
"        </p>",
"        <p>",
"         May contain increased protein",
"        </p>",
"        <p>",
"         May contain some amino acids thought to be conditionally essential (eg, glutamine, arginine)",
"        </p>",
"        <p>",
"         May contain fish oil",
"        </p>",
"        <p>",
"         Lactose free",
"        </p>",
"        <p>",
"         May contain fiber",
"        </p>",
"       </td>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Impact, Impact with fiber, Impact 1.5, TraumaCal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         1.0-1.5 cal/mL",
"        </p>",
"        <p>",
"         Hydrolyzed protein source",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Pepdite Jr, Peptamen Jr, Peptamen Jr 1.5, Vital Jr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Crucial, Perative, Vital HN, Pivot 1.5, Optimental, Peptamen, Peptamen 1.5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Impaired digestion or impaired gut perfusion",
"       </td>",
"       <td>",
"        <p>",
"         0.8-1.0 cal/mL",
"        </p>",
"        <p>",
"         Free amino acids (\"elemental\")",
"        </p>",
"        <p>",
"         May have higher osmolalities",
"        </p>",
"        <p>",
"         May contain MCT oil",
"        </p>",
"        <p>",
"         May be low fat",
"        </p>",
"        <p>",
"         May contain increased protein",
"        </p>",
"        <p>",
"         Lactose-free",
"        </p>",
"        <p>",
"         Most are fiber-free",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Elecare, Neocate Jr, Vivonex Pediatric, EO28 Splash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 cal/mL",
"       </td>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Tolerex, Vivonex Plus, Vivonex TEN, Vivonex RTF",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCT: medium-chain triglycerides.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16236=[""].join("\n");
var outline_f15_54_16236=null;
var title_f15_54_16237="Raccoon eyes";
var content_f15_54_16237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Raccoon eyes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 149px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral periorbital ecchymoses in a child with a basilar skull fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joan E Shook, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16237=[""].join("\n");
var outline_f15_54_16237=null;
var title_f15_54_16238="Contents: Urinary tract infections";
var content_f15_54_16238=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urinary tract infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urinary tract infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asymptomatic bacteriuria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/10999\">",
"           Acute complicated cystitis and pyelonephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15479\">",
"           Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39777\">",
"           Clinical microbiology review: Genitourinary infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/49/15128\">",
"           Candida infections of the bladder and kidneys",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/51/14134\">",
"           Renal and perinephric abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/46/16102\">",
"           Bacterial adherence and other virulence factors for urinary tract infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pyelonephritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/36/12868\">",
"           Asymptomatic bacteriuria in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16804\">",
"           Xanthogranulomatous pyelonephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal and systemic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4807\">",
"           Urinary tract infection in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/6/20579\">",
"           Urinary tract infection in renal transplant recipients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-8042122A27-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_54_16238=[""].join("\n");
var outline_f15_54_16238=null;
var title_f15_54_16239="Common cold treatments in pregnancy 1";
var content_f15_54_16239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62846%7EOBGYN%2F75622%7EOBGYN%2F51533%7EOBGYN%2F77865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62846%7EOBGYN%2F75622%7EOBGYN%2F51533%7EOBGYN%2F77865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, efficacy and safety in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Rhinorrhea, sneezing, throat pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ipratropium bromide 0.06 percent nasal spray",
"       </td>",
"       <td>",
"        Mild improvement in rhinorrhea and sneezing",
"       </td>",
"       <td>",
"        <p>",
"         FDA pregnancy category B.",
"        </p>",
"        It is presumed that the agent can be used nasally in pregnancy because of the small systemic absorption and reassuring animal data.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Cromolyn sodium* aqueous nasal spray (5.2 mg per spray)",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cromolyn sodium* as dry powder (20 mg per inhalation in spincaps). Note: not available in US.",
"        </p>",
"        Other cromolyn inhalation preparations*: solution for nebulization 20 mg/2 mL (available in US) and metered dose inhaler (MDI) 5 mg/puff (not available in US)",
"       </td>",
"       <td>",
"        Mildly shortens the duration and severity of cold symptoms including sneezing and sore throat",
"       </td>",
"       <td>",
"        <p>",
"         FDA pregnancy category B.",
"        </p>",
"        <p>",
"         Less than 10 percent of an inhaled dose of cromolyn is believed to be absorbed systemically.",
"        </p>",
"        <p>",
"         Animal data reassuring.",
"        </p>",
"        The published data with respect to the use of this agent to treat asthma in pregnancy is very reassuring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saline nasal irrigation or spray",
"       </td>",
"       <td>",
"        <p>",
"         Buffered normal and hypertonic saline irrigation or spray modestly improve symptoms of rhinitis and chronic rhinosinusitis",
"        </p>",
"        Benefit in acute URI not established",
"       </td>",
"       <td>",
"        <p>",
"         Nasal saline (OTC): no FDA pregnancy category.",
"        </p>",
"        <p>",
"         Systemic absorption is expected to be low with proper use.",
"        </p>",
"        The published data with respect to the use of this agent to treat chronic rhinosinusitis and pregnancy rhinitis is very reassuring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anesthetic lozenges or sprays",
"       </td>",
"       <td>",
"        <p>",
"         Small studies of benzocaine or lidocaine lozenges and sprays demonstrate benefit in relief of sore throat pain",
"        </p>",
"        Data are lacking for most other OTC preparations such as dyclonine and phenol lozenges and sprays",
"       </td>",
"       <td>",
"        <p>",
"         Topical lidocaine: FDA pregnancy category B; topical benzocaine: FDA pregnancy category C.",
"        </p>",
"        <p>",
"         Systemic absorption of lidocaine and benzocaine occurs via mucous membranes of oral cavity.",
"        </p>",
"        OTC anesthetic lozenges and sprays (dyclonine, phenol): no FDA pregnancy category. Fetal harm appears to be unlikely when used appropriately. Limited data from a study in rats and two epidemiologic studies in humans did not show an increased risk of teratogenesis from use of throat lozenges made from cetylpyridinium chloride (eg, Cepacol). Since human and animal data are lacking for most agents, we prefer acetaminophen based upon availability of pregnancy safety data.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antipyretics and simple analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen",
"       </td>",
"       <td>",
"        Antipyretic and symptomatic relief of associated myalgias, headaches and sore throat",
"       </td>",
"       <td>",
"        <p>",
"         FDA pregnancy category B.",
"        </p>",
"        Extensive animal data and population-based studies are very reassuring regarding the safety of this agent in pregnancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsteroidal anti-inflammatory drugs (NSAIDs)",
"       </td>",
"       <td>",
"        Reductions in headache, malaise, myalgia with a 29 percent reduction in the total (5-day) symptom score. Has no effect on nasal symptoms.",
"       </td>",
"       <td>",
"        <p>",
"         Most NSAIDs are FDA pregnancy category C/D in the third trimester.",
"        </p>",
"        NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies, cleft palate, and gastroschisis have been observed following NSAID exposure in some studies. The absolute risk appears to be low. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. NSAIDs have been associated with oligohydramnios, pulmonary hypertension, intracranial hemorrhage, and necrotizing enterocolitis in infants born prematurely. Their use in pregnancy is not appropriate for the treatment of common cold symptoms. Acetaminophen will offer similar relief in this setting without placing the fetus at increased risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Cromolyn (sodium chromoglycate) inhalation may cause transient bronchospasm, throat irritation, or cough.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Zinc gluconate",
"       </td>",
"       <td rowspan=\"5\">",
"        The evidence of zinc efficacy for treating the common cold is inconclusive at best, and any beneficial effect is minor.",
"       </td>",
"       <td>",
"        The use of zinc for the treatment of the common cold is probably not justified in pregnancy. The noxious taste of zinc lozenges limit their usefulness particularly in pregnant patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal experiments have produced variable but frequently concerning results regarding the safety of high dose zinc supplementation in pregnancy (including increased skeletal defects in mice, exencephaly in hamsters, and an increased incidence of congenital malformations in rats).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated zinc levels in the fetus have been associated with anencephaly and meningomyelocele in some studies but not in others. It is unclear whether this finding simply reflects physiologic abnormalities associated with these defects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One recent report found one infant with a heart defect and one with microcephaly among 26 infants born to 19 mothers treated with zinc for Wilson's disease. This population is too small to estimate whether zinc exposure played any role in the observed defects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc deficiency is associated with impaired fertility and low birth weight but is rare in the western world.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin C",
"       </td>",
"       <td>",
"        Current extensive literature does not appear to support the use of vitamin C therapy for the common cold.",
"       </td>",
"       <td>",
"        Little pregnancy data available however, there is concern that large doses of this vitamin may be harmful during pregnancy. Ascorbic acid appears in the fetus in concentrations higher than those in the mother and pregnant guinea pigs fed large doses of ascorbic acid gave birth to offspring with increased rates of ascorbic acid catabolism. A human parallel to this was seen in two reported cases of mothers who ingested daily high doses of vitamin C and after birth the infants developed scurvy due to an excessively rapid metabolism of vitamin C presumably induced in utero.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinacea",
"       </td>",
"       <td>",
"        No evidence to support efficacy.",
"       </td>",
"       <td>",
"        Recent data reporting on 206 exposed pregnancies found no increased incidence of anomalies compared with controls.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Diphenhydramine",
"        </p>",
"        <p>",
"         Chlorpheniramine",
"        </p>",
"        <p>",
"         Fexofenadine",
"        </p>",
"        <p>",
"         Loratidine",
"        </p>",
"        <p>",
"         Clemastine",
"        </p>",
"        Brompheniramine",
"       </td>",
"       <td>",
"        Clemastine and brompheniramine (and loratadine in conjunction with pseuedoephedrine) decrease sneezing and nasal discharge but have no effect on sore throat, cough, headache and malaise. No antihistamine effects total symptom score or duration for the common cold.",
"       </td>",
"       <td>",
"        <p>",
"         FDA pregnancy classification B and C.",
"        </p>",
"        <p>",
"         Chlorpheniramine and diphenhydramine have mostly reassuring pregnancy data and should be considered the preferred antihistamines in pregnancy.",
"        </p>",
"        <p>",
"         Most of the older antihistamines are not considered to increase the incidence of congenital malformations in humans. Although some antihistamines have been associated with oral clefts in retrospective studies others have found no significant increase in the incidence of major or minor malformations and one study even found that significantly fewer infants with malformations were exposed to antihistamines while in utero than were controls.",
"        </p>",
"        <p>",
"         There are limited human pregnancy data on the newer antihistamines fexofenadine, cetirizine, and loratadine. Therefore, they should not be used as first line agents in pregnancy.",
"        </p>",
"        Use of antihistamine with women in pre-term labor was associated in one study with an increased risk of retrolental fibroplasias and should be avoided in this setting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Cough medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Codeine",
"        </p>",
"        <p>",
"         Dextromethorphan",
"        </p>",
"        <p>",
"         Guaifenisin",
"        </p>",
"        <p>",
"         Benzonatate",
"        </p>",
"        Hydrocodone",
"       </td>",
"       <td>",
"        Uniformly ineffective in the setting of cough from common cold.",
"       </td>",
"       <td>",
"        <p>",
"         All FDA pregnancy classification C.",
"        </p>",
"        <p>",
"         Animal data for codeine, dextromethorphan and hydrocodone conflicting.",
"        </p>",
"        <p>",
"         Human data for all these agents are poor. Guaifenisin was associated with inguinal hernias in one study only. A large case-control study observed an association between first trimester use of opioids and various congenital anomalies.",
"        </p>",
"        <p>",
"         Neonatal withdrawal has been reported in babies born both to addicted and non-addicted women who took codeine in the days prior to delivery. Codeine ingestion near the time of labor can produce respiratory depression in the newborn.",
"        </p>",
"        The lack of efficacy of these agents suggests their use is not justifiable in pregnancy for the common cold especially given questions about the safety of some of these agents in pregnancy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Decongestants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Intranasal:",
"        </p>",
"        <p>",
"         Oxymetazoline",
"        </p>",
"        <p>",
"         Xylometazoline",
"        </p>",
"        Pheniramine",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Short lived mild relief of obstruction with single use. No evidence of sustained effects.",
"        </p>",
"        Spray decongestants associated with rebound effects upon withdrawal.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         All FDA pregnancy classification C.",
"        </p>",
"        <p>",
"         Most commonly used decongestants are in need of further study before they can be definitively considered safe in pregnancy. Present data is variable but these agents probably represent a low risk.",
"        </p>",
"        <p>",
"         Oxymetazoline is the preferred intranasal agent but use for mild symptoms should be discouraged in pregnancy. No clear human teratogenic effect and no effect on uterine blood flow in the setting of normal nasal mucosa but concerns exist about its possible effects on uterine blood flow in the setting of overuse, inflamed nasal mucosa and in cases were poor placental perfusion is already suspected.",
"        </p>",
"        <p>",
"         Pseudoephedrine should be avoided in the first trimester. Two studies have suggested an increased risk of gastroschisis. Later in pregnancy, it is probably the preferred oral agent among the oral decongestants. This agent is less likely to raise blood pressure than the other oral decongestants.",
"        </p>",
"        <p>",
"         Ephedrine is teratogenic in chicks even at small doses. No evidence of human teratogenesis but data are limited.",
"        </p>",
"        Phenylephrine has been associated with a wide range of congenital anomalies in humans and dramatic effects on uterine blood flow in sheep. This agent should be avoided at all stages of pregnancy. The uterine vessels are maximally dilated and have only alpha-adrenergic receptors. The alpha-adrenergic stimulant phenylephrine will cause constriction of these vessels, resulting in reduced uterine blood flow, fetal hypoxia, and subsequent bradycardia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Oral:",
"        </p>",
"        <p>",
"         Pseudoephedrine",
"        </p>",
"        <p>",
"         Ephedrine",
"        </p>",
"        Phenylephrine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_54_16239=[""].join("\n");
var outline_f15_54_16239=null;
